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ABSTRACT 
 
Small molecules perform an extraordinary range of important functions. Major advances 
have been achieved in the laboratory synthesis of small molecules, yet most synthetic efforts are 
specialized for each target, making synthesis a complex and time-intensive process reserved for 
specialists. Instead, a general and automated synthesis strategy could provide the broader 
scientific community rapid access to small molecules for functional studies. To achieve this goal, 
this dissertation describes the advances toward expanding and automating the iterative cross-
coupling (ICC) strategy with N-methyliminodiacetic acid (MIDA) boronate building blocks, an 
analogous approach to how Nature makes small molecules by iterative assembly of bifunctional 
building blocks.  
 With the ultimate goal of understanding and optimizing the promising antilipoperoxidant 
activity of carotenoid natural products, the first total synthesis of synechoxanthin was 
accomplished. The synthesis was enabled by the development of a new methodology for small 
molecule synthesis termed reversed-polarity iterative cross-coupling (RP-ICC), in which the 
polarity of the building blocks is reversed to match the preferred polarity for Suzuki-Miyaura 
cross-coupling. This strategy expanded the scope and flexibility of ICC by increasing the number 
of building blocks that can be utilized in the same platform. With an efficient method to access 
this small molecule, the antilipoperoxidant activity of synechoxanthin was investigated in a 
chemically-defined liposome system. Preliminary studies indicated that synechoxanthin is an 
antilipoperoxidant with similar activity to the carotenoid gold standard astaxanthin. 
 To further simplify and generalize the synthesis of small molecules, the ICC strategy was 
automated through the development of a small molecule synthesizer. Key to this advance was the 
discovery that MIDA boronates can be purified via a novel type of catch-and-release 
chromatography. Many different types of small molecules, including materials, pharmaceuticals, 
and a range of complex natural products and their derivatives were prepared via the fully 
automated iterative assembly of MIDA boronate building blocks. Contemporaneously with the 
development of the synthesizer, the ICC platform was expanded to include C-N and Csp3-Csp2 
bond formations. Collectively, these advances seek to establish the foundation for a general and 
automated platform for small molecule synthesis to ultimately help shift the rate-limiting step in 
small molecule science from synthesis to functional studies.  
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CHAPTER 1 
INTRODUCTION 
 
Small molecules perform an extraordinary range of important functions in science, 
medicine, and technology. Small molecules include, but are not limited to: materials components, 
pharmaceuticals, natural products, and biological probes (Figure 1-1). In fact, more than 238,000 
natural products have been isolated to date,1 yet many of their functions are still unknown 
because of limited access to these isolates from its natural source. If the ultimate goal is to 
understand and optimize the function of these small molecules for the study of biological 
systems, for application as drugs, and/or role as materials, small molecule science can be 
represented in three distinct stages: target identification, synthesis, and functional studies. 
Functional discovery studies require rapid access to a range of different small molecules and 
derivatives. However, there are two major challenges that limit small molecule access. First, 
perhaps due to the diversity present in small molecules, target-oriented synthesis is highly 
complex and specific. This fact alone has significantly limited the access of small molecules to 
the general scientific community because of the prerequisite knowledge and training needed to 
be a synthetic chemist. Second, laboratory synthesis is inevitably a labor- and time-intensive 
process. Due to these reasons, synthesis can take months to even years and represents the slow 
step in small molecule science. Thus, a unified, ideal synthesis platform capable of rapidly 
accessing a wide range of different small molecules for functional discoveries must address both 
of these challenges. This can be achieved by the development of a general synthesis strategy to 
be used across different classes of small molecules and minimization of the labor- and time-
intensive nature of synthesis by automation of this general strategy. 
This chapter will provide background on the advent of general and automated synthesis 
platforms for biomolecules that have enabled functional studies of these molecules. These 
advances as well as the inherent modularity that is present in small molecules became the 
inspiration for the development of a similarly general and automated synthesis platform for small 
molecules. Toward this goal, iterative cross-coupling (ICC) of MIDA boronate building blocks 
show promise as a general strategy to construct many different types of small molecules in an 
automated fashion. Background for the work described in subsequent Chapters, specifically the 
expansion of the MIDA boronate platform to complete a total synthesis of the carotenoid natural 
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product synechoxanthin (Chapter 2) and the development of a small molecule synthesizer 
(Chapter 3), will be summarized in this introductory Chapter. Such advances have the potential 
to broaden the access of small molecules and help shift the rate-limiting step in small molecule 
science from synthesizing these molecules to understanding their functional potential.  
 
 
Figure 1-1. Small molecules are structurally and functionally diverse class of compounds. 
 
1-1 GENERAL AND AUTOMATED SYNTHESIS OF BIOMOLECULES FACILITATES 
FUNCTIONAL STUDIES 
In contrast to small molecules, many biomolecules including peptides, oligonucleotides, 
and oligosaccharides are now routinely prepared via strategies that are general and automated. 
These synthesis platforms have enabled practical approaches toward understanding the structure-
function relationships that underlie the remarkable functional properties of proteins, DNA, and 
carbohydrates.  
Nature’s common strategy of iterative coupling of bifunctional building blocks has been 
translated into the laboratory synthesis of these biomolecules. Even though at first glance these 
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molecules are structurally complex, biomolecules are inherently modular; their linear sequence is 
made from small monomer units that are joined together in an iterative fashion.2 For example, 
polypeptides are made from amino acid building blocks, oligonucleotides from nucleosides, and 
oligosaccharides from individual sugar units (Figure 1-2).  
Mirroring the simple way Nature makes these complex biomolecules, all of these 
platforms iteratively employ one type of reaction to assemble common sets of readily accessible 
units. These processes involve a bifunctional building block where one end is protected, but the 
other is capable of coupling to a growing oligomer attached to a solid support. Following the key 
bond formation, the protecting group is deprotected to allow another iteration of this same 
process in a highly controlled manner. The key to the efficiency of these processes is the simple, 
yet effective solid-phase purification technique, which allows the growing oligomer, linked to a 
solid support, to be purified from excess reagents by washing and filtering. As stated above, due 
to the inherent modularity in the constitution of these biomolecules, they contain common 
functional groups for attachment to a solid support, which make this purification technique 
generally applicable to the entire class of molecules, despite other structural differences. 
 
 
Figure 1-2. Polypeptides, oligonucleotides, and oligosaccharides are inherently modular and all are 
biosynthetically derived from the iterative coupling of bifunctional building blocks. 
 
1-1-1 GENERAL AND AUTOMATED PEPTIDE SYNTHESIS 
The pioneering example of a general synthesis platform is demonstrated by the solid 
phase peptide synthesis (SPPS) strategy conceptualized by Bruce Merrifield in 1963.3 Before 
SPPS, assembling amino acids together to form even small peptide chains was a laborious 
procedure. SPPS revolutionized peptide synthesis by providing a general strategy for this class of 
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biomolecules. Specifically, SPPS is enabled by the use of an amino acid bifunctional building 
block that is orthogonally protected at the N-terminus, frequently as the 
fluorenylmethoxycarbonyl (Fmoc) or tert-butyloxycarbonyl (Boc) derivative, to prevent random 
oligomerization during the coupling event (Scheme 1-1). The C-terminus of a growing 
polypeptide chain is covalently linked to a polystyrene solid support through the presence of a 
common functional group, in this case, a carboxylic acid. After each C-N bond formation event, 
a deprotection sequence reveals a free N-terminus capable of undergoing another C-N bond 
formation. Once the construction process is completed, the peptide can be released from the 
support. This approach is flexible and modular since any protected amino acid can be introduced 
during the coupling reactions. 
 
 
Scheme 1-1. General and automated synthesis strategy for peptides. Growing oligomer (m = n + 1) is 
attached to a soild support for simple purification. [C] = coupling, [D] = deprotection. 
 
Only two years after the development of SPPS, this general strategy was transformed into 
an automated platform and successfully applied to synthesize bradykinin, a polypeptide 
consisting of 9 amino acids.4 Less than 20 years later, fully automated peptide synthesizers 
became available as commercial units, extending the power of synthesis to non-specialists.5 This 
impact was further exemplified in the automated synthesis of interleukin-3 (IL-3), a protein of 
140 amino acids, which had been a difficult protein to isolate, thus its functional studies had been 
hindered by the lack of its availability.6 Enabled by the modular approach, analogues of IL-3 
were prepared by systematically modifying the primary structure of the protein, i.e. by changing 
the amino acid building blocks incorporated into the iterative sequence. Efficient access to IL-3 
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and its analogs led to the understanding that the protein’s tertiary structure is required for its 
activity. This work established the applicability of peptide synthesizers to study large peptides 
and demonstrated to the scientific community the power of such a rapid, fully-automated, 
readily-accessible, and reproducible synthesis platform in understanding functions of biological 
significance.  
Several decades later, a variety of linear peptides can now be synthesized using one 
synthesis platform demonstrating a high level of generality making automation highly practical. 
Cyclic peptides can also be efficiently synthesized simply by folding linear peptides that have 
been synthesized in an automated fashion. The combination of a general and automated synthesis 
platform has had a profound effect on accelerating the ease in which peptides can be accessed 
thereby facilitating functional studies especially in the areas of molecular biology and 
biotechnology. 
 
1-1-2 GENERAL AND AUTOMATED OLIGONUCLEOTIDE SYNTHESIS 
 The above pioneering work and fundamental concepts of SPPS have been applied to the 
automated synthesis of oligonucleotides by Ogilvie and co-workers7 as well as Caruthers and co-
workers. 8  In automated oligonucleotide synthesis, an O-protected nucleotide serves as a 
bifunctional building block to prevent random oligomerization during the coupling event 
(Scheme 1-2). Deprotection of the dimethoxytrityl (DMT) protecting group using dichloroacetic 
acid reveals a free hydroxyl group capable for a subsequent cycle of coupling and deprotection. 
Similarly to SPPS, the key to the success and generality of this platform is the use of a solid-
support, where the growing oligomer can be purified by simple wash and filtration.  
Before the development of such a common and automated platform, it would have taken 
a highly trained and skilled chemist three months of person time to synthesize a 12-unit DNA,7 
but now DNA synthesis can be conducted in a matter of hours by non-specialists with no 
previous experience in nucleotide synthesis. Furthermore, as a testament to the DNA 
synthesizer’s impact on the scientific community, DNA fragments are now commercially 
available and can be purchased on-demand.9 The significant decrease in person time required to 
access such biomolecules has had tremendous impact on facilitating the functional understanding 
and applications of genes in synthetic biology as well as other areas of science. 
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Scheme 1-2. General and automated synthesis of oligonucleotides. Growing oligomer (m = n + 1) is 
attached to a soild support for simple purification. [C] = coupling, [D] = deprotection. 
 
1-1-3 GENERAL AND AUTOMATED OLIGOSACCHARIDE SYNTHESIS 
Recently, Seeberger and co-workers advanced the synthesis of oligosaccharides by 
developing a fully automated platform (Scheme 1-3). 10  Similarly to peptides and 
oligonucleotides, oligosaccharide synthesis involve a saccharide bifunctional building block that 
is orthogonally protected as the levulinoyl (Lev) ester in the presence of other protecting groups 
such as benzyl ethers and pivaloyl esters. This protecting group can be selectively cleaved by 
addition of hydrazine to the reaction mixture to allow another iteration. The growing oligomer 
undergoes the same facile solid-phase purification process as the other biomolecule automated 
platforms that helps turn over the cycle. Since its invention in 2001, this automated synthesis 
platform for oligosaccharides has been optimized and expanded.11 Similar to how the automated 
peptide and oligonucleotide synthesis platforms impacted the scientific community, this platform 
already shows promise to accelerate the understanding of oligosaccharide function in biology 
and drug discovery.12   
Although synthesis of some specialty building blocks and the optimization of reaction 
conditions for more challenging couplings are sometimes necessary, all three of these platforms 
have dramatically increased the efficiency with which these compounds can be prepared, and 
extended the access of these biomolecules to non-specialists. As a result, the focus of research 
has shifted from synthesis of these biomolecules to identification of targets and understanding 
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function. This leads us to question whether a similar type of transformation in small molecule 
science would be possible by a general and automated synthesis platform.  
 
 
Scheme 1-3. General and automated synthesis of oligosaccharides. Growing oligomer (m = n + 1) is 
attached to a soild support for simple purification. [C] = coupling, [D] = deprotection. 
 
1-2 CHALLENGES IN DEVELOPING A GENERAL AND AUTOMATED SMALL 
MOLECULE SYNTHESIS PLATFORM 
The key to the efficiency and practicality of automated peptide, oligonucleotide, and 
oligosaccharide syntheses is the general solid-phase purification of intermediates. Solid-phase 
synthesis strategy has also been applied to the synthesis of small molecules with the goal of 
achieving a general strategy amenable for automation. The first report of solid-phase small 
molecule synthesis was by Clifford Leznoff in 1976, which was accomplished by attachment of a 
solid support to a diol functionality that was present in a specific class of insect pheromones.13 
Since then, the hydroxyl groups present in certain small molecules have attracted interest in 
expanding the field of solid-phase organic synthesis,14 but the applicability of this approach has 
been hindered by the customized conditions used to link each type of small molecule and the fact 
that only a portion of small molecules contain this functional group for attachment to a solid 
support.  
To overcome the challenge of applying solid-supported methods to small molecule 
synthesis, recent advances have focused on addressing the labor- and time-intensive nature of the 
synthesis process through automating the process in solution-phase. For example, the Takahashi 
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group has focused their efforts to access complex natural products,15 including (±) baccatin III, a 
taxol precursor, via automation of solution-phase synthesis. They reasoned that if synthesis of 
key intermediates can be accomplished using an automated synthesizer, this will provide the 
researcher with greater time to focus on the more challenging and down-stream steps of the 
synthesis (Scheme 1-3). With this goal, they showed that solution-phase automated synthesizers 
Sol-capa and ChemKonzert16 was capable of constructing the A and C rings of (±) baccatin III 
through formation of three C-C bonds, 10 oxidations and reductions, 16 protection and 
deprotection steps, and 7 other functional group manipulations on 100 mg - 300 g scale (Scheme 
1-4). Subsequently, the B-ring was synthesized in a semi-automated fashion, which afforded the 
key intermediate. From this point forward, one PhD student carried out the post-automated 
synthesis to (±) baccatin III in 12 steps.17  While this example demonstrated how automated 
synthesizers could minimize the burden of repetitive, routine operations that are inevitable in 
organic chemistry research, this multi-step synthetic sequence had to be manually interrupted to 
execute custom purifications for each intermediate.  
 
 
 
Scheme 1-4. Takahashi group’s strategy to automate the synthesis of key intermediates toward total 
synthesis of taxol derivative, (±) baccatin III. 
 
In efforts to make automated systems more practical, continuous flow multi-step 
synthesis methods have recently been developed.18 Compared to traditional multi-step synthesis 
where each reaction requires purification and isolation of intermediates, one-flow multi-step 
synthesis does not require purification of intermediates. Specifically, the Ley group has 
pioneered the use of immobilized reagents, catalysts, and scavengers to facilitate organic 
synthesis and has applied this concept to flow multi-step processes for the synthesis of natural 
products and pharmaceutical compounds.19 The first multi-step natural product synthesis using 
flow chemistry was accomplished in 2006, which impressively required no manual interventions 
and purifications of intermediates in the 7-step route toward oxomaritidine in 40% overall yield 
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(Scheme 1-5). This complex alkaloid was synthesized in 6 h to afford 20 mg of the target small 
molecule. If conducted in manual batch mode, this synthesis would have taken 4 days of person 
time.20 
 
 
 
Scheme 1-5. Multi-step flow synthesis of (±) oxamaritidine via the use of immobilized reagents, catalysts, 
scavengers, and catch-and-release agents.  
 
The same multi-step flow strategy was applied to the synthesis of Gleevec®, a drug 
marketed by Novartis for the treatment of chronic leukemia, and its structural derivatives.21 
Employing a sulfonic acid-functionalized silica (QuadraSil-SA, SS-SA) for catch-and-release 
purification helped address the problematic precipitation that occurred during the reaction, and 
afforded this drug in 32% yield (>95% purity) over a 3-step procedure with minimal manual 
interventions (Scheme 1-6). However, this catch-and-release purification strategy did not fully 
translate to all of the Gleevec® derivatives. As shown in Scheme 1-6, the nitrogen of the R2 
group must remain basic enough to allow the product to be captured on the SS-SA resin for 
purification. This example demonstrated some of the advantages of flow chemistry employing 
immobilized reagents, namely minimized manual handling of intermediates and increased 
efficiency, but the purification technology limits the type of small molecules to only those 
containing basic nitrogen atoms.  
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Scheme 1-6. Synthesis of Gleevec® and its analogues via three-step flow synthesis. 
 
Developments in methods to automate small molecule synthesis have been impressive,22 
yet the main disadvantage that all of these advances have in common is their customized 
approaches toward each small molecule target that require a high degree of specialist expertise 
for planning, execution, and optimization for each small molecule target. Automating a 
customized approach only reduces person-time required for that target alone, and does not 
represent a general synthesis platform.  
 
1-3 SMALL MOLECULES ARE DIVERSE YET INHERENTLY MODULAR 
Due to the target-oriented nature of synthesis, most efforts have focused on optimizing 
the automation of a specific set of reactions to enable the preparation of a single product. 
However, perhaps it is not beyond our imagination to envision a platform where only one 
strategy and a few reactions can be used to build most small molecules. This will certainly lend 
itself well to automation, and serve as a platform on which to build. The success of automated 
biomolecule synthesis can be attributed to the modular structure. In fact, many natural products 
are inherently modular because they are biosynthesized via iterative assembly of common 
building blocks in the same way peptides, oligonucleotides, and oligosaccharides are made. For 
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example, polyketide natural products are constructed from malonyl-CoA and methylmalonyl-
CoA units,23 polyterpenes from isopentyl and dimethylallyl pyrophosphates,24 and fatty acids 
from malonyl-CoA25 (Figure 1-3). Other classes of small molecules such as nonribosomal 
peptides come from amino acids26 and polyphenylpropanoids are derived from shikimic acid27. 
Even many typologically complex macrocyclic and polycyclic natural products are 
biosynthetically derived from relatively simple and modular linear precursors that are cyclized 
into the final framework.28 Furthermore, reoccurring motifs are found across many materials, 
pharmaceuticals, and biological probes that represent oligomers of aryl or heteroaryl fragments 
(Figure 1-1).   
 
 
Figure 1-3. Modularity in natural products. 
 
Nature has shown us a simple solution to a complex problem. The question becomes 
whether we can learn from Nature and apply this approach in the laboratory. As a step in this 
direction, Moore and co-workers have developed a simple and general synthesis strategy for 
conjugated oligomers via the iterative assembly of phenylacetylene building blocks.29 Analogous 
to how peptides are made, phenylacetylene bifunctional building block protected at one end with 
a trimethylsilyl (TMS) group and an aryl iodide at the other is coupled to a growing oligomer 
containing a free alkyne orthogonally linked to a solid support through a triazene linker. After C-
C bond formation using Pd-catalyzed Sonogashira coupling, addition of TBAF conveniently 
transforms the TMS protecting group to its corresponding free alkyne for another iteration of 
cross-coupling (Scheme 1-7). This method was initially developed as a solution-phase process 
and further developed into a solid-supported synthesis strategy, which simplified workup and 
purification by allowing filtration and washing of insoluble intermediates.30 This method was 
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successfully applied to the iterative synthesis of a wide range of linear phenylacetylene 
oligomers and macrocycles, which helped dramatically advance the understanding of functional 
properties of these polymeric materials.31  
 
 
Scheme 1-7. Solid-phase synthesis strategy for conjugated oligomers that involves iterative assembly of 
bifunctional phenylacetylene building blocks. The rectangle represents an aryl functional group. Growing 
oligomer (m = n + 1) is attached to a soild support for simple purification. [C] = cross-coupling, [D] = 
deprotection. 
 
1-4 BUILDING BLOCK APPROACH TO SMALL MOLECULE SYNTHESIS: ITERATIVE 
CROSS-COUPLING (ICC) STRATEGY ENABLED BY MIDA BORONATES 
      A building block approach for conjugated oligomer synthesis inspired the development of 
a general synthesis strategy for small molecules, with the goal of ultimately transforming this 
strategy into an automated platform. Harnessing the inherent modularity present in a wide range 
of small molecules, we questioned whether we could access most small molecules, including 
materials, pharmaceuticals, and natural products, via a single bond-forming reaction. Since all 
small molecules contain carbon atoms in their backbones, a flexible and modular strategy for 
making small molecules would incorporate a general way to form such C-C bonds in a controlled, 
iterative fashion (Figure 1-4).  
 
 13 
structurally diverse? inherently modular?
C-C bond 
formation?
S
S
S
S
Me
O
H
Me
N
O
N
MeO
N
MeMe Me
Me
Me H
O
materials pharmaceuticals natural products
 
Figure 1-4. Small molecules, including materials, pharmaceuticals, and natural products, are modular in 
their constitution and can be viewed as a collection of building blocks connected by C-C bonds. 
 
As a step in this direction, Dr. Eric Gillis developed a synthesis strategy analogous to 
peptide synthesis termed iterative cross-coupling (ICC) (Scheme 1-8).32 In this ICC approach, 
small molecules are viewed as a collection of building blocks connected by C-C bonds. The 
Suzuki-Miyaura cross-coupling, a metal-mediated coupling reaction between a boronic acid or 
boronic ester to a halide or pseudohalide, was selected to form such bonds for its generality and 
functional group compatibility.22 In Suzuki-Miyaura cross-coupling, it is hypothesized that a 
vacant and Lewis acidic boron p-orbital is required for transmetalation of a boronic acid33 to the 
reactive Pd-OR complexes which have been postulated as the reactive intermediates during 
transmetalation.34 In order to reversibly attenuate the reactivity of the boronic acid and prevent 
random oligomerization for successful iteration, methods to decrease the Lewis acidity of the 
boron p-orbital was investigated by surveying various trivalent heteroatomic ligands capable of 
lone pair electron donation and rehybridization of the boron atom from sp2 to sp3. Through this 
exploration, it was discovered that N-methyliminodiacetic acid (MIDA) can reversibly attenuate 
the reactivity of a boronic acid, similar to the way a Fmoc group protects an amine. This enables 
iterative C–C bond formation between a free boronic acid and the halide terminus of a MIDA 
protected haloboronic acid building block using Suzuki-Miyaura cross-coupling.  
 
 14 
 
Scheme 1-8. Iterative cross-coupling (ICC) strategy for making small molecules. The rectangle 
represents building blocks containing a wide range of functional groups including: aryl, heteroaryl, vinyl, 
acetyl, and alkyl motifs. Growing oligomer is represented as (m = n + 1). [C] = Suzuki-Miyaura cross-
coupling, [D] = deprotection to boronic acid (1 N aqueous NaOH/THF, 23 oC, 10 min). 
 
This strategy is general and can be used to protect a wide range of haloboronic acid 
building blocks with aryl, heteroaryl, alkynyl, alkenyl, and alkyl moieties. Moreover, the MIDA 
boronate functional group is inert to anhydrous cross-coupling conditions, yet can be readily 
hydrolyzed under mild aqueous conditions compatible with many other functional groups to 
generate the corresponding free boronic acid or boronic ester. Advances have been made to 
control the release of boronic acid slowly over the course of the reaction (K3PO4 in 5:1 
dioxane/water at 60 oC) in order to avoid the isolation of unstable boronic acids before and 
during the cross-coupling event.35 Moreover, MIDA boronates are shelf-stable building blocks 
that can be readily accessed via many different methods (Scheme 1-9).36 In addition, the MIDA 
ligand is nontoxic, biodegradable37, and commercially available, therefore MIDA boronates can 
be synthesized conveniently and inexpensively on large scale from the commodity chemical 
iminodiacetic acid. Encompassing all of these advantageous features, more than 160 MIDA 
boronates are already commercially available to date, making this technology readily accessible 
to the scientific community. In addition to these MIDA boronates, thousands of commercially 
available boronic acids and halides serve as MIDA boronate precursors (Scheme 1-9) and 
constitute a formidable pool of off-the-shelf building blocks that are readily available for ICC.  
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Scheme 1-9. Examples of known methods for the synthesis of MIDA boronate building blocks. A. 
Condensation of MIDA boronates to boronic acids under Dean-Stark conditions. B. The use of 
haloborane and disodium salt of MIDA. C. Transesterification of boronic esters to MIDA boronates. D. 
Trapping of the Grignard or lithium reagent with trimethyl borate followed by transligation with MIDA 
affords corresponding MIDA boronates. 
 
1-5 SMALL MOLECULE SYNTHESIS VIA ICC 
 Employing this ICC approach, small molecules are first retrosynthesized into building 
blocks, via disconnections at C-C bonds, where all but the last building block contains a MIDA 
boronate motif. With the exception of the first and last building blocks, all others are bifunctional 
haloboronic acid building blocks where the boronic acid is protected as MIDA, and the halide 
terminus is available for coupling. With building blocks in hand, the first step in ICC begins with 
deprotection of the unreactive Bsp3 MIDA boronate to the corresponding reactive Bsp2 boronic 
acid. This boronic acid can be coupled to the halide terminus of a bifunctional MIDA boronate 
building block, and the resulting MIDA boronate-containing product can be purified by standard 
silica gel chromatography to be ready for another cycle. These bifunctional building blocks are 
assembled in an iterative fashion similar to how peptides and other biomolecules are now 
synthesized in an automated fashion (Scheme 1-10).  
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Scheme 1-10. ICC strategy for the synthesis of small molecules. 
 
Since its initial report in 2007, MIDA boronate building blocks have been used in the 
manual synthesis of many different types of small molecules including natural products 
[ratanhine,32a crocacin C,38 all-trans-retinal,39 !-parinaric acid,39 peridinin,36a (-)-myxalamide A40, 
methyl (5Z, 8Z, 10E, 12E, 14Z)-eicosapentaenoate,41 and synechoxanthin (further discussed in 
Chapter 2)42] and natural product derivatives [C35-deoxy amphotericin B43, the polyene core of 
vacidin A44] (Figure 1-5). As shown in Figure 1-5, wide range of different types of building 
blocks have been incorporated into ICC, majority of them consisting of aryl, heteroaryl, and 
vinyl fragments. 
 
 
Figure 1-5. Small molecules synthesized via ICC via Csp2-Csp2 bond formations.  
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 As illustrated in Figure 1-5, polyene motifs are prevalent across many different types of 
natural product classes. In fact, many of these repeating polyene units are modular; for example, 
the tri-substitued olefin motif is present in all-trans retinal, synechoxanthin, and peridinin. To 
further explore the potential for a systematized and modular building-block approach to small 
molecule synthesis, Dr. Eric Woerly and Jahnabi Roy questioned how many building blocks it 
would take to access most natural products of a single class. Specifically, they asked: if 
restricting the bond-forming reactions to only the Suzuki-Miyaura reaction, how many 
bifunctional MIDA boronate building blocks would be required to make most polyene natural 
product motifs?  
 They addressed this question by devising an algorithm for systematically retrosynthesizing 
polyene core motifs into bifunctional building blocks. A polyene motif was defined as three or 
more carbon-carbon double bonds in conjugation, none of which are contained in a <12-
membered ring. This analysis returned 2,839 compounds, or 1.2% of all known natural products 
as polyene natural products. Further analysis showed that polyene motifs found in >75% of all 
polyene natural products isolated to date represent all major biosynthetic classes (polyterpenes, 
polyketides, hybrid peptide/polyketides, fatty acids, and polyphenylpropanoids), and can be 
prepared using only 12 MIDA boronate building blocks (Figure 1-6). Assembly of these building 
blocks was performed under a general set of cross-coupling and deprotection conditions.45 
Furthermore, these building blocks and general conditions were applied to the first total synthesis 
of several polyene natural products such as !-parinaric acid. 
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Figure 1-6. Synthesis of >75% polyene natural product motifs using just 12 building blocks and 1 reaction. 
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This example further illustrates the diversity of natural products, but more importantly it 
demonstrates the modularity as well. Even though there are over 238,000 natural products 
isolated and characterized to date, it is encouraging to know that there is a bounded number of 
building blocks needed to access a large portion of a certain structural class of natural products. 
While polyene natural products only represent 1.2% of all natural products, it is possible to 
envision the same concept would translate to other small molecule classes due to the modular 
nature. Furthermore, if this general strategy can be automated, it will greatly simplify the 
synthesis process by eliminating the need to isolate intermediates, minimizing person time spent 
on synthesis, and elevating the access of these molecules to specialists as well as non-specialists. 
Chapter 3 will build on this recent advance and address challenges that are associated with 
translating the ICC platform into a synthesizer capable of automatically coupling together MIDA 
boronate building blocks. 
 
1-6 RECENT ADVANCES IN THE MIDA BORONATE TECHNOLOGY 
It is intriguing to consider how many building blocks would be required to access most of 
the structural motifs found in small molecules by applying this concept to other classes of small 
molecule natural products, pharmaceuticals, and materials. The polyene example demonstrates 
that this may be attainable. This concept seeks to promote a systematic approach that has the 
potential to enable the efficient, flexible, and even fully automated access to many classes of 
small molecules. In order for this general strategy to be realized, current limitations of the ICC 
platform must be addressed.  
First, increasing the diversity of building blocks available for coupling and developing 
general and robust methods to couple them would increase the generality and flexibility of this 
strategy. In the ICC approach, starting building blocks have been limited to boronic acid or 
boronic esters capable of coupling to the halide terminus of a bifunctional MIDA boronate 
building block. Chapter 2 will cover the development of a reversed-polarity ICC approach that 
complements the established ICC approach, with an emphasis on increasing the flexibility in 
which small molecules are constructed by expansion of building blocks that can be utilized in a 
single synthetic platform.   
Second, initial reports applying the ICC strategy to the synthesis of small molecules 
mostly consisted of forming Csp2-Csp2 bonds with aryl, heteroaryl, or vinyl MIDA boronate 
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building blocks (Figure 1-5). Many small molecules not only contain C-C, but C-heteroatom 
bonds (such as O, N, S) in their backbones. Due to the masked reactivity of MIDA boronates and 
its broad tolerance to many different types of reaction conditions and reagents, the ICC platform 
can be expanded to include increased variety of building blocks that can undergo different 
reactions beyond Suzuki cross-coupling.46 
Additionally, progress has been made in the area of developing efficient ways to 
synthesize heterocycles incorporating MIDA boronates, because of the importance of these 
structures in drug targets and natural products.47 For example, Hamann and co-workers have 
demonstrated that MIDA boronate-functionalized isoxazoles and triazoles can be prepared 
through cycloaddition reactions (Scheme 1-11A).48 Also, Toste and co-workers have prepared 
heterocyclic MIDA boronates through a tandem gold-catalyzed cycloisomerization reaction 
followed by Suzuki-Miyaura cross-coupling from substituted alkynyl MIDA boronates (Scheme 
1-11B).49  
 
 
 
Scheme 1-11. A. Isoxazole synthesis via MIDA boronate chemistry. B. Benzofuran and indole synthesis 
via MIDA boronate building blocks. 
 
In addition, palladium-catalyzed bond formations of MIDA boronates with heteroatoms 
and challenging heterocycles have recently shown promise. 50  Natural products and 
pharmaceutical agents have been prepared via C-N bond formations using MIDA chemistry.51 
One recent example by Hamman and co-workers demonstrates a method to couple a wide range 
of aliphatic and aromatic amines to haloarene MIDA boronates via Buchwald-Hartwing cross-
coupling to form N-Csp2 bonds. Employing this method, histamine H3 antagonist was 
synthesized in 63% yield via a two-step, one-pot cross-coupling sequence via N-C/C-C bond 
formations via formation of an enolized MIDA boronate in situ (Scheme 1-12).52  
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Scheme 1-12. Synthesis of histamine H3 antagonist via N-C followed by C-C bond formations through an 
enolized MIDA boronate intermediate. 
 
Finally, it would be advantageous to apply MIDA boronates to cross-coupling of Csp3-
hybridized building blocks. However, this field of synthetic chemistry has many challenges and 
unsolved problems. Cyclic natural products, such as steroids, are biosynthesized via cyclization 
of linear precursors that contain increased levels of saturation in their backbones due to the 
presence of Csp3-hybridized atoms that allow predisposed flexibility for cyclization. If we 
wanted to use the same strategy Nature uses to make even these complex architectures, we need 
efficient ways to make such Csp3-Csp3 or Csp3-Csp2 bonds. While significant advances have 
been made to couple Csp3 atoms, the scope of Suzuki-Miyaura cross-coupling methods are still 
limited to a particular set of substrates or conditions that are not compatible with a wide range of 
functional groups (Scheme 1-13).53 The challenges with unstable boronic acid resurface again as 
B-alkyl boronic acids are known to be susceptible to protodeborylation and !-hydride 
elimination. 
 
 
Scheme 1-13. Recent advances in Suzuki-Miyaura cross-coupling of Csp3-hybrized atoms utilizing alkyl 
boronates. 
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Recently, two reports in the literature have utilized MIDA boronates as precursors for 
Csp3 cross-coupling. Junqi Li has pioneered the development of iterative Csp3 coupling via a 
chiral PIDA (pinene-derived iminodiacetic acid) boronate bifunctional building block. 54 
Specifically, glucagon receptor antagonist under evaluation for treatment of type-II diabetes was 
synthesized in a stereocontrolled manner by iterative Csp3-Csp2 Negishi cross-coupling followed 
by Csp3-Csp2 Suzuki-Miyaura cross-coupling (Scheme 1-14). Furthermore, Yudin and co-
workers developed a direct method to couple B-alkyl MIDA boronates and alkyl bromides 
(Scheme 1-15).55 Collectively, these results show that new methods can be incorporated with the 
ICC platform. Chapter 3 describes our latest efforts to address the latter two challenges by 
building on these recent advances to achieve a small molecule synthesis platform that can 
synthesize a wide range of small molecules.  
 
 
Scheme 1-14. Synthesis of glucagon receptor inhibitor via Csp3-Csp2 Negishi cross-coupling followed by 
Csp3-Csp2 Suzuki-Miyaura cross-coupling enabled by the bifunctional PIDA boronate building block.  
 
 
Scheme 1-15. Csp3-Csp2 Suzuki-Miyaura cross-coupling with alkyl MIDA boronates. 
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1-7 THE PROSPECT OF A GENERAL APPROACH TO SMALL MOLECULE SYNTHESIS 
Over the last century, impressive number of advances has been made in the development 
of synthetic methods that nearly any small molecule can now be made by a specialist with 
enough time and effort.56 Several perspectives have been written on the topic of an ideal 
synthesis and have focused on the aspects of atom-economy,57 step-economy,58 and redox 
economy.56 These concepts translate well for a process-level synthesis of a small molecule with 
already known functional interest. The collective limitation to these concepts is that it focuses on 
one small molecule synthesis pathway. While one synthetic path may be ideal to make one small 
molecule, these concepts may require much time and effort to be translated to another target, 
which does not enable rapid and systematized access to many different small molecules using 
one general strategy. 
Small molecules represent 85% of new drug approvals in 2013.59 The increased demands 
for small but diverse libraries in the drug discovery process within the past decade have led to a 
demand for automated synthesis platforms.60 In this context, a remote-controlled medicinal 
chemistry lab was built at Eli Lilly & Co. that is capable of running more than 60 different types 
of reactions. The senior director of discovery research and technology at Eli Lilly was recently 
quoted in C&EN stating, “We measure the value of automation not by the number of compounds 
it turns out but by the diversity of the compounds.”61  
Developing a general strategy to synthesize most small molecules is an ambitious goal, 
yet the establishment of this automated synthesis lab suggests that this goal might be achievable. 
Of the total 16,349 reactions run in this remote chemistry lab from late 2008 through 2011, 
amide coupling and Suzuki-Miyaura cross-coupling were the two most popular methods 
employed, totalling ~6500 reactions. In addition, another ~4500 reactions represent chemistry 
that has been shown to be compatible with the MIDA boronate technology. In fact, the ICC 
strategy could potentially incorporate close to 70% of the total number of procedures employed 
by the remote-controlled synthesis lab at Eli Lilly, suggesting the possibility that a range of 
different small molecules can be accessed through one common strategy. Expansion and 
automation of the ICC strategy with the MIDA boronate platform could simplify the synthesis 
process and provide access to small molecule targets relevant not only to the pharmaceutical 
industry, but many other sectors of the scientific community such as biotechnology and 
functional materials.  
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CHAPTER 2 
TOTAL SYNTHESIS OF SYNECHOXANTHIN VIA REVERSED-POLARITY  
ITERATIVE CROSS-COUPLING 
 
ABSTRACT 
     Deficiencies of human proteins that protect cells from lipid peroxidation have been linked 
to many prevalent diseases, including atherosclerosis, neurodegenerative disorders, and cancer. 
Remarkably, some species of bacteria have the ability to thrive in environments of extreme 
oxidative stress, which has been attributed to the presence of specialized carotenoids in their 
membranes. These natural products might therefore serve as valuable prototypes for 
understanding and optimizing the capacity for small molecules to serve as antilipoperoxidants in 
human cells. In this vein, a structurally unique aromatic dicarboxylate carotenoid, 
synechoxanthin, was isolated in 2008 from the exceptionally reactive oxygen species 
(ROS)-resistant cyanobacterium Synechococcus. With the ultimate goal of understanding and 
optimizing the promising antioxidant activity of this natural product, we herein report its first 
total synthesis. This synthesis was achieved using only one reaction iteratively to assemble three 
simple and readily accessible building blocks in a completely stereocontrolled fashion. This 
route was enabled by a novel Reversed-Polarity Iterative Cross-Coupling (RP-ICC) strategy, in 
which the polarity of the bifunctional building blocks is reversed to match the preferred polarity 
for Suzuki-Miyaura cross-coupling. Moreover, a final one-pot two-directional double 
cross-coupling sequence enabled rapid assembly of the C2-symmetric carotenoid core. This 
convergent approach also enabled a total synthesis of renierapurpurin, a biosynthetic precursor to 
synechoxanthin. With synechoxanthin in hand, the antilipoperoxidant activity of synechoxanthin 
was evaluated in comparison to !-carotene and the carotenoid gold standard astaxanthin. 
Synechoxanthin demonstrated equally effective antilipoperoxidant activity compared to 
astaxanthin in an in vitro chemically defined liposome system. This preliminary result 
demonstrates the potential for synechoxanthin to serve as an antilipoperoxidant and as a probe to 
interrogate the still poorly understood mechanism of lipid peroxidation. The efficient, completely 
stereocontrolled, and inherently flexible nature of this building block-based pathway has opened 
the door to systematic studies of the antioxidant functions of synechoxanthin and its derivatives. 
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     Stephanie Y. Chang contributed to the total synthesis of synechoxanthin, specifically by 
assisting with the synthesis and characterization of building blocks 2.17, 2.32, and 2.26. Hannah 
M. S. Haley contributed to the optimization of the chemically-defined TBARS assay, originally 
developed by Dr. Eric M. Woerly, and control experiments with !-carotene and astaxanthin, in 
addition to completing the total synthesis of renierapurpurin. 
 
Portions of this chapter are adapted from Fujii, S.; Chang, S. Y.; Burke, M. D. Angew. Chem. Int. 
Ed. 2011, 50, 7862-7864. 
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2-1 CAROTENOID NATURAL PRODUCTS ARE PROMISING ANTILIPOPEROXIDANTS 
     Lipid peroxidation is a naturally occurring physiological process that plays an important 
role in aerobic metabolism.1 However, lipids containing polyunsaturated fatty acids (PUFAs) are 
primary targets for attack by reactive oxygen species (ROS), and this autooxidation process can 
cause or exacerbate diseases of inflammation.2 Although the underlying connection between 
lipid peroxidation and the development of human diseases is still not well understood, it is 
known that lipid peroxidation affords several toxic electrophiles that can alkylate DNA or 
proteins.3 Fortunately, there are a number of proteins in the body that protect humans from the 
deleterious effects of lipid peroxidation.4 As further evidence indicating the importance of 
attenuating lipid peroxidation, deficiencies of such proteins have been linked to the molecular 
pathophysiology of many prevalent diseases such as atherosclerosis,5 cancer,6 rheumatoid 
arthritis,7 and may also contribute to an accelerated aging process.8 Given the deleterious impact 
these diseases have on human health, the potential health benefit of small molecule 
antilipoperoxidants is exceptional. Small molecules that can safely and effectively replicate this 
antilipoperoxidant function can, in theory, serve as substitutes for these missing or dysfunctional 
proteins, thereby operating as prostheses on a molecular scale.  
     In recent years, carotenoid natural products have received tremendous attention as one of 
the most promising classes of small molecule antilipoperoxidants. 9  Carotenoids are 
tetraterpenoid molecules that are naturally produced in chloroplasts and chromoplasts of plants 
and photosynthetic organisms such as plants, protists, bacteria, and fungi. The highly conjugated 
polyene core of a carotenoid is mainly responsible for the bright colors present in many fruits, 
vegetables, and fish. Among these carotenoid natural products, !-carotene (2.1, Figure 2-1) is 
perhaps one of the most well studied, yet in vitro as well as in vivo studies demonstrate that its 
antioxidant activity remain unclear and controversial.10 In fact, one clinical trial was interrupted 
because the study showed that large doses of !-carotene in combination with vitamin A increased 
the incidence of lung cancer in smokers by 28%.11 In contrast, astaxanthin (2.2, Figure 2-1) is 
considered the “gold standard” antilipoperoxidant,12 and is available as a dietary supplement, 
generating $200 million in sales per year.13  In addition, an astaxanthin derivative has shown 
promise as a cardioprotective agent in preclinical trials for the treatment of ischemia and 
reperfusion injuries14 and atherosclerosis.15  
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     However, due to the proposed stoichiometric reactivity of typical carotenoids through free 
radical scavenging,16 the protective capability of astaxanthin is inherently limited.17 Free radical 
scavenging is initially effective because carotenoids can react in a stoichiometric fashion with 
ROS and thereby eliminate these potential peroxidants from the lipid membrane.18 Eventally, 
however, the carotenoid is consumed to form breakdown products that may even promote 
lipoperoxidation.19 In fact, it has been shown that high molar ratios of astaxanthin (>5% of total 
lipid content) are generally required to achieve substantial antilipoperoxidant activity in an in 
vitro assay.17  
 
Figure 2-1. Carotenoid natural products !-carotene and astaxanthin.  
     Alternate mechanisms for antilipoperoxidation such as catalytic ROS quenching20 or 
modulation of membrane dynamics 21  have been proposed. These mechanisms have an 
advantage over stoichiometric antilipoperoxidation of carotenoids because it does not result in 
the consumption of the carotenoid. However, the lack of direct evidence regarding these 
mechanisms and limited access to non-commerial carotenoids have precluded the rational 
optimization of the antilipoperoxidant activity of common carotenoids, including astaxanthin.  
 
2-2 AROMATIC CAROTENOIDS SHOW PROMISE AS ANTILIPOPEROXIDANTS 
     These studies suggest that one possible approach to increase the antilipoperoxidant activity 
and lifetime of a carotenoid would be to diminish the stoichiometric reactivity of the carotenoid 
toward reactions with electrophilic oxidants by increasing its stability. Thus, in order to guide 
our search for small molecules that possess exceptional stability yet maintain the capacity for 
antilipoperoxidant activity via catalytic quenching, we became intrigued by atypical carotenoids 
with aromatic functionality.  
     Carotenoids with aromatic termini have shown exceptional stability, such as isorenieratene 
(2.3, Fig 2-2), which was found intact in carbonates of the 1.6 billion year old Barney Creek 
Formation in Australia.22 In addition, 3,3’-dihydroxyisorenieratene (3,3’-DHIR) (2.4, Fig 2-2), 
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also an aromatic carotenoid, was shown to have superior antilipoperoxidant activity compared to 
non-aromatic carotenoids.23 A recent study showed that both of these aromatic carotenoids 
prevented UV-induced DNA damage in human skin fibroblast cells and showed reduced levels 
of lipid peroxidation in a liposome-based assay.24 Although it has been demonstrated that 
aromatic polyenes have increased chemical stability over their non-aryl-substituted counterparts 
in solution-phase experiments,25 the stabilizing effect of an aromatic terminus on the overall 
reactivity of the carotenoid has not yet been directly tested in a lipoperoxidation assay.  
     In addition to the aromatic functionality of some carotenoids, we also questioned whether 
polarity has an effect on antilipoperoxidant activity of the carotenoid. A leading model suggests 
that non-polar carotenoids align perpendicular to the bilayer normal, thus disrupting the 
membrane alignment and promoting lipoperoxidation.26  In contrast, polar carotenoids are 
predicted to favor a parallel alignment in the lipid bilayer, thereby stabilizing the membrane and 
decreasing its permeability to ROS.26 With this logic, 3,3’-DHIR shows promise as an 
exceptional antilipoperoxidant. However, 3,3’-DHIR has been shown to oxidize to the quinone 
leading to the destruction of the carotenoid in a cumene hydroperoxide inhibition assay.23 Thus, 
although these studies are promising, they suggest that an ideal carotenoid antilipoperoxidant 
would possess polar termini that cannot be further oxidized.  
 
 
Figure 2-2. Apolar aromatic carotenoid natural products isorenieratene and 3,3’-dihydroxyisorenieratene.  
 
2-3 SYNECHOXANTHIN: A CAROTENOID NATURAL PRODUCT PRODUCED IN AN 
ORGANISM THAT THRIVES IN ENVIRONMENTS OF HIGH OXIDATIVE STRESS  
     We therefore turned our attention to carotenoids produced by organisms that thrive in 
environments of extreme oxidative stress27 that ideally possess aromatic termini with polar 
functional group appendages that cannot be easily oxidized. We hypothesized that these natural 
products might serve as valuable prototypes for understanding and optimizing the capacity for 
small molecules to serve as powerful antilipoperoxidants in human cells.  
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     In this vein, a structurally unique aromatic dicarboxylate carotenoid, synechoxanthin (2.6, 
Scheme 2-1), was isolated in 2008 from the exceptionally ROS-resistant cyanobacterium 
Synechococcus sp. strain PCC 7002.28 This strain of cyanobacteria is known to be remarkably 
tolerant to light-intense environments,29 and a higher level of synechoxanthin was isolated from 
this strain compared to other cyanobacteria. We were intrigued by the unique chemical features 
of synechoxanthin, specifically its aromatic termini and biscarboxylic acid appendages. 
Specifically, we hypothesized that the carboxylic acid appendages might perform the dual 
functions of 1) reinforcing parallel alignment of synechoxanthin to the bilayer normal and 2) 
decreasing the nucleophilicity of the polyene toward stoichiometric reactions with electrophillic 
oxidants. In fact, studies have shown that electron-withdrawing groups in close proximity to the 
double bond decreases the reactivity of the olefin toward peroxy acids.30  
     Moreover, a recent study reported that knocking out synechoxanthin via genetic 
manipulation of the cyanobacterial biosynthetic machinery diminished the ROS resistance, 
indicating that this natural product may help protect the cyanobacterium from oxidative stress.31 
Furthermore, it was recently reported that a series of enzyme-mediated modifications of the 
terminal rings of !-carotene transform this typical carotenoid into synechoxanthin (Scheme 
2-1).32 It is proposed that the cruE gene encodes !-ring desaturase/methyltransferase enzymes to 
afford renierapurpurin (2.5), and the cruH gene is involved in the initial oxidation of 
renierapurpurin at the C-18 and C-18’ positions.32 This proposed biosynthesis outlines a unique 
transformation from an apolar non-aromatic carotenoid, to renierapurpurin, an apolar aromatic 
carotenoid, to synechoxanthin, a polar aromatic carotenoid (Scheme 2-1). As described earlier in 
this Chapter, the antiliperoxidant activity of !-carotene has been controversial, and the 
antilipoperoxidant activities of the latter two carotenoids have not been systematically 
investigated to date. Thus, these carotenoids serve as excellent probes to interrogate the impact 
of these tailoring enzyme modifications on carotenoid antilipoperoxidant activities.  
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Scheme 2-1. Proposed biosynthetic pathway from !-carotene to synechoxanthin.  
 
2-4 TOTAL SYNTHESIS OF C2-SYMMETRIC CAROTENOIDS 
     In order to systematically compare the antilipoperoxidant activity of synechoxanthin to its 
biosynthetic precursors as well as to the gold standard astaxanthin, we sought for an efficient and 
modular approach to access synechoxanthin. In general, isolation of carotenoids from natural 
sources is inefficient, and does not readily allow derivatization for systematic testing of the 
above hypotheses. Perhaps due to these reasons, the biological function of synechoxanthin has 
been minimally explored to date. Obviating the challenges associated with isolating 
synechoxanthin from the producing organism, we sought to gain access via a fully 
stereocontrolled total synthesis.  
     The highly complex nonaene framework found in synechoxanthin and many other 
C2-symmetric carotenoids represents a substantial structural and stereochemical challenge. One 
of the most commonly employed strategies to access this motif involves carbonyl condensation 
reactions. For example, retrosynthesis of the polyene core via a double Wittig olefination to a 
C10-trienedialdehyde and two C15-polyenylphosphonate salts is a common method (Scheme 
2-2).33  
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Scheme 2-2. Commonly employed double Wittig olefination approach toward C2-symmetric carotenoids. 
 
     Two advantages of this route include the utilization of carotenoid symmetry in which only 
two building blocks are required, and high yields that are achieved on the key Wittig olefination 
step. However, one of the main challenges of this approach is the lack of stereocontrol, which 
results in a mixture of cis and trans isomers that must be thermally isomerized followed by 
tedious and carotenoid-specific crystallizations to form the all-E isomer.33 In some cases, 
unprotected polar functional groups are not compatible with this approach; thus a different 
protecting group strategy may be needed for each polar carotenoid. Although this strategy has 
been extensively applied to the industrial synthesis of several C2-symmetric carotenoids, this 
approach is not ideal when the goal is to prepare many polar derivatives as single 
stereoisomers.33  
     Another convergent approach that has been applied to the synthesis of C2-symmetric 
carotenoids is through a homodimerization reaction. McMurry carbonyl coupling has been used 
to synthesize !-carotene and isorenieratene (Scheme 2-3).34 In addition, olefin metathesis has 
been employed in the construction of several carotenoids, including !-carotene, zeaxanthin, and 
violaxanthin (Scheme 2-3). 35  These methods offer the advantage of only requiring one 
functionalized fragment that can be transformed to the target in one step. However, since a 
stereoselective bond-forming reaction is used, carefully optimized conditions are necessary, 
especially for the olefin metathesis method, to avoid the formation of several side products 
resulting from competitive metathesis side reactions.35  
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Scheme 2-3. Homodimerization approach toward C2-symmetric carotenoids. 
      
     Recently, palladium-catalyzed cross-coupling reactions have received much attention for 
their utility in constructing polyenes because the key C-C bonds can be constructed in a 
stereospecific manner. Several notable examples include the iterative 
carbometalation/metal-exchange/Negishi approach and the two-fold Stille method.36 Negishi 
and co-workers have reported the synthesis of both symmetrical and unsymmetrical carotenoids, 
!-carotene and "-carotene, using the former method.37 Specifically, dienyne 2.8, a bifunctional 
building block containing a vinyl bromide and a protected alkyne, is coupled to an organozinc 
intermediate (that is synthesized from 2.7) using a stereospecific palladium-catalyzed 
cross-coupling reaction. Removal of the alkyne protecting group reveals a terminal alkyne 2.9, 
regenerating the functionality needed for another carboalumination/cross-coupling cycle 
(Scheme 2-4).37 (E)-1-bromo-2-iodoethene (2.10) was used as a key two-carbon synthon to 
couple the organozinc reagents to complete the synthesis of !-carotene in 41% overall yield. 
While this method provided all-E carotenoids without the need for cystallizations or 
isomerizations, the functional group compatibility of the carboalumination reaction has limited 
the application of this method to apolar carotenoids.37 
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Scheme 2-4. Synthesis of !-carotene by an iterative carbometalation/metal exchange/Negishi reaction. 
 
     The two-fold Stille coupling approach, developed by de Lera and co-workers, was applied 
to the synthesis of !-carotene and zeaxanthin (Scheme 2-5).38 This methodology provides an 
efficient preparation of these carotenoids by constructing the polyene core using a double Stille 
coupling to a central pentenyl bisstannane building block 2.11. However, the synthesis of 2.11 
utilized a Julia olefination reaction and resulted in a mixture of isomers.38 As a result, this 
strategy does not provide a completely stereocontrolled synthesis of these carotenoids. 
 
 
Scheme 2-5. Two-fold Stille coupling approach toward the synthesis of zeaxanthin and synechoxanthin 
methyl ester. 
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     As an extension to this approach, de Lera and co-workers recently employed a C18 
diiodoheptaene 2.15 to synthesize several C2-symmetric carotenoids, including !-carotene, 
lycopene, and synechoxanthin methyl ester either through Suzuki-Miyaura or Stille 
cross-coupling reactions (Scheme 2-5).39 For example, synechoxanthin methyl ester 2.16 was 
synthesized in 79% from vinyl stannane 2.14 and diiodoheptaene 2.15 via a two-fold Stille 
coupling. The advantage of this approach is the rapid construction of the carotenoid skeleton 
utilizing a common polyene core. For this reason, this strategy is most beneficial for accessing 
carotenoids that have greater than nine conjugated double bonds. However, this comes with a 
major limitation in that key building block 2.15 readily isomerizes to the di-cis-isomer upon 
exposure to light or heat, making it an unstable fragment incompatible for long-term storage. 
 
2-5 RETROSYNTHESIS OF SYNECHOXANTHIN VIA ITERATIVE CROSS-COUPLING 
     In contrast to these common methods, the use of only stereospecific cross-coupling 
reactions to assemble stable, stereochemically defined polyene building blocks represents a very 
attractive alternative. Ideally, these building blocks would be readily accessible, non-toxic, and 
very stable to long-term storage. We thus aimed to synthesize carotenoid natural products using 
an efficient, modular, and flexible synthetic strategy using only stable building blocks and 
stereospecific reactions to construct the polyene core. Iterative cross-coupling (ICC) 40 
introduced in Chapter 1 offers an attractive, alternate approach towards the construction of small 
molecules in this manner. In this ICC approach, polar functional groups are tolerated, modularity 
and flexibility for derivatization are introduced, and the issue of stereocontrol is addressed by the 
stereospecific Suzuki-Miyaura cross-coupling of bifunctional haloboronic acid building blocks 
protected as the corresponding N-methyliminodiacetic acid (MIDA) boronate esters.41 Because 
these building blocks contain preinstalled functionality and stereochemistry required in the target 
molecule, this approach requires no post-coupling modifications aside from global deprotections. 
Prior to this work, ICC has enabled the construction of many polyene-containing small 
molecules including the following: one-half of the polyene macrolide amphotericin B,25 all 
trans-retinal,25 ?-paranaric acid,42 and the polyene core of vacidin A.43 Furthermore, a total 
synthesis of carotenoid natural product (-)-peridinin was achieved in a fully stereocontrolled 
manner via ICC one year prior to the completion of this work.44  
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     Taking advantage of the C2-symmetry of synechoxanthin, we envisioned this natural 
product could be synthesized using a convergent building block approach and the ICC 
methodology. Synechoxanthin was retrosynthesized in a manner that would be maximally 
amenable to derivative synthesis (Scheme 2-6). One retrosynthesis suggested that 
synechoxanthin can come from three different building blocks that can be assembled via an 
“outside-in” or an “inside-out” approach (Scheme 2-6). A method that allows assembly of the 
polyene core later in the route, i.e. the outside-in approach, is attractive because this avoids the 
need to purify, isolate, and carry forward the sensitive polyene functionality through multiple 
reactions.45 The longest polyene intermediate formed via this outside-in strategy would be a 
tetraene, which is less susceptible to decomposition or isomerization than the longest polyene 
intermediate that would be formed via an inside-out approach (Scheme 2-6).45 
 
 
Scheme 2-6. A. “Outside-in” approach toward the synthesis of C2-symmertric small molecules. B. 
“Inside-out” approach toward the synthesis of C2-symmertric small molecules. 
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     Guided by this established ICC strategy, we applied only Suzuki-Miyaura transforms to 
retrosynthesize synechoxanthin into three readily accessible building blocks (2.17, 2.18, and 
2.10) having all of the required functionality preinstalled in the correct oxidation states and with 
the desired stereochemical relationships (Scheme 2-7). In the final step, we anticipated a 
convergent two-directional Suzuki-Miyaura coupling with lynchpin building block 2.10 to 
complete the assembly of the polyene core. 
 
Scheme 2-7. Retrosynthetic analysis of synechoxanthin via ICC (m = n + 1). [C] = coupling, [D] = 
deprotection. 
     The synthesis of building block 2.17 commenced with electrophilic aromatic substitution 
on commercially available phenol 2.19 using N-bromosuccinimide to afford aryl bromide 2.20 
(Scheme 2-8).46 MOM protection of phenol 2.20 afforded aryl bromide 2.21 in 85% yield. Aryl 
bromide 2.21 was then lithiated and trapped with carbon dioxide to afford benzoic acid 2.22 in 
moderate yield. Benzoic acid 2.22 was protected as the methyl ester, and the MOM group was 
deprotected in one pot to afford benzoate 2.23 in 89% yield. Methylation of the acid facilitated 
the purification and handling of subsequent intermediates, and later allowed a direct comparison 
2.18
BrI
2.10
RO
B(OR)2
HO2C CO2H
N(MIDA)
iterative cross-coupling
Me
Me Me
Me Me
Me
Me
Me
Me
OH
HO
O
O synechoxanthin 2.6
B
Me
Me
O
MeO
O
O
Me Me
Me
Me
2.17
MeN
O
OB
O
O
Me
I
MeN
O
OB
O
O
B-protected
haloboronic acid
C
D
X
MeN
O
OB
O
O
m n
 40 
of synechoxanthin methyl ester 2.16 to the structural data reported in the literature. Notably, 
these reactions required minimal to no purifications and were scalable on gram scale. Triflation 
of benzoate 2.23 afforded aryl triflate 2.24 in 89% yield. Finally, Miyaura borylation of 2.24 
using bispinacolatodiboron achieved the synthesis of building block 2.17 in 90% yield (Scheme 
2-8). 
 
 
Scheme 2-8. Synthesis of building block 2.17. 
 
     Synthesis of bifunctional building block 2.18 was accomplished by applying the 
methodology recently developed in our laboratories for the metal-selective coupling of 
bismetalated olefin 2.27.23 First, vinyl stannane 2.25 underwent highly regio- and 
stereocontrolled iododestannylation to afford vinyl iodide 2.26 in 75% yield. The trans 
relationship of the iodine to the MIDA boronate was confirmed by X-ray crystallography 
(Scheme 2-9). Vinyl iodide 2.26 was coupled to 2.27 under standard Stille coupling conditions to 
afford dienyl germane 2.28 in 86% yield. Iododegermylation of 2.28 afforded building block 
2.18 in 83% yield.  
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Scheme 2-9. Synthesis of building block 2.18. 
   
     With the first two building blocks in hand, we targeted the synthesis of tetraenyl MIDA 
boronate 2.31. Suzuki-Miyaura cross-coupling of 2.17 with halodienyl MIDA boronate 2.18 
produced dienyl MIDA boronate 2.29 in 60% yield as a single stereoisomer under optimized 
conditions (Scheme 2-10). Subsequent transesterification of MIDA boronate 2.29 with pinacol44 
revealed the sp2-hybridized pinacol boronic ester 2.30 in 92% yield. Pinacol boronic ester 2.30 
was subsequently coupled to another equivalent of bifunctional building block 2.18 to provide 
the key tetraene MIDA boronate 2.31 in a modest 50% yield, but again with complete 
stereocontrol. In addition to providing very modular and completely stereocontrolled access to 
key intermediate 2.31, this route revealed that polyenyl MIDA boronates 2.18, 2.29, 2.30 and 
2.31 are crystalline solids that are fully compatible with silica gel chromatography and long-term 
storage. However, the overall yield of 2.31 over this three-step sequence was only 28%, despite 
extensive optimization of these conditions. We therefore sought to retain the highly favorable 
features of this ICC-based pathway, but gain more efficient access to this key tetraenyl MIDA 
boronate intermediate. 
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Scheme 2-10. Synthesis of tetraene MIDA boronate intermediate 2.31. 
 
2-6 RETROSYNTHESIS OF SYNECHOXANTHIN VIA RP-ICC 
     We hypothesized that these modest yields observed in the ICC pathway may be 
attributable to a polarity mismatch between the building blocks and the inherent polarity 
preference for Suzuki-Miyaura cross-coupling.47 In cross-coupling, the organoboron species 
generally serves as the nucleophile and the halide represents the electrophile (Scheme 2-11A).48 
Therefore, electron-donating functional groups that enhance the nucleophilicity of the 
organoboron species and electron-withdrawing functional groups that enhance the 
electrophilicity of the halide both increase the reactivity between the two coupling partners. In 
fact, Monteiro and co-workers conducted competitive Suzuki-Miyaura cross-coupling 
experiments surveying a variety of aryl halides with electronically different para-substituents 
and observed that electron-withdrawing substituents on the aryl halide increase the rate of 
oxidative addition through a Hammett analysis (! = 2.3).49 On the other hand, electron-donating 
para-substituents on the arylboronic acid was correlated to the increase in the rate of the reaction 
with bromobenzene (! = -0.68).49  
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Scheme 2-11. A. Electronic preference in Suzuki-Miyaura cross-coupling. B. Example catalytic cycle of 
Suzuki-Miyaura cross-coupling. EDG = electron-donating group, EWG = electron-withdrawing group. 
 
     In the case for building blocks retrosynthesized for synechoxanthin via ICC (Scheme 2-7), 
due to conjugation with the electron-withdrawing methyl ester substituent at the para-position of 
the aryl ring, 2.17 and 2.30 represent electron-deficient boronic esters that are poor 
cross-coupling substrates in Suzuki-Miyaura cross-coupling. 50  Specifically, electron-poor 
arylboronic acids are less nucleophilic and undergo transmetalation at a slower rate than 
electron-neutral and -rich arylboronic acids, and are more susceptible to base and 
metal-catalyzed protodeboronation51 and homocoupling (Scheme 2-11B).52 In contrast, aryl 
halides and alkenyl halides with proximal electron-withdrawing groups are more activated 
toward oxidative addition than those with donating groups, making electron-deficient halides 
superior substrates, often cross-coupling under milder conditions and/or in higher yields than 
their electron-neutral and -rich counterparts (Scheme 2-11B).53   
LnPd(0)
oxidative 
addition
transmetalation
reductive
elimination
OHB(OH)3
Br
OMe
O
B(OH)2 +
Pd catalyst
base
OMe
O
II
II
LnPd
OMe
O
Br
Pd
Ln
OMe
O
MeO MeO
Br
OMe
O
OMe
O
MeO
B(OH)2
MeO
Pd
OMe
O
OB
MeO
Ln
HO OH
MeO
EWG activates C-Br bond
for oxidative addition
(hydroxo)Pd intermediate
coordinates to the empty p oribtal
of the boronic acid
electrophilenucleophile
electron-donating 
groups preferred
electron-withdrawing
 groups preferred
A.
B.
EDG enhances the
nucleophilicity of the
Cipso to the boronic acid
 44 
     In this vein, we were interested in probing whether the MIDA boronate functional group 
serves as an electron-donor or an electron-acceptor. To test this, we performed a simple NMR 
experiment surveying a range of monosubstituted benzenes along with phenyl MIDA boronate to 
determine the chemical shift at the para position, since 13C chemical shifts at the para position of 
mono-substituted benzenes have been correlated with chemical reactivity parameters.54 The 
following 13C chemical shifts suggested that the MIDA boronate group is neither 
electron-withdrawing or donating (Figure 2-3).  
 
 
 
Figure 2-3. 13C chemical shifts suggest that the MIDA boronate functional group is neither 
electron-withdrawing or donating. 
 
     Stimulated by this logic, the inherent electronic preference in Suzuki-Miyaura 
cross-coupling guided us to alternatively start with an activated organohalide. This switch in 
polarity required us to also reverse the polarity of the bifunctional building block employed in 
the ICC sequence. This retrosynthesis led to the following three building blocks: 2.32, 2.33, and 
2.10 (Scheme 2-12). The next challenge focused on the synthesis of a new type of bifunctional 
building block, 2.33, containing a nucleophilic boron terminus and a protected electrophilic 
halide. However, it was important to first determine the feasibility of this approach on whether 
the MIDA protecting group can be deprotected under mild conditions to reveal the masked 
iodide.  
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Scheme 2-12. Retrosynthesis of synechoxanthin via polarity reversal of building blocks. 
 
     Mild and general methods for halide masking are scarce, but several notable approaches 
have been developed for iterative synthesis. Moore and co-workers discovered that 
1-aryl-3,3-dialkyltriazenes can be employed as a masking group for aryl iodides in the iterative 
assembly of phenylacetylene oligomers (Scheme 2-13).55 Oligomer assembly is accomplished 
using Sonogashira cross-coupling to form Csp2-Csp bonds. Addition of methyl iodide 
conveniently transforms the diethyltriazene (N3Et2) protecting group to its corresponding iodide 
for another iteration of Sonogashira cross-coupling (Scheme 2-13).56 
 
 
Scheme 2-13. A strategy for the iterative synthesis of phenylacetylene oligomers (m = n + 1) using 
diethyltriazene protecting group for aryl iodides. [C] = coupling, [D] = deprotection. 
     In the context of iterative polyene synthesis, Dr. Suk Joong Lee developed a novel strategy 
for making iodopolyenyl MIDA boronate building blocks by employing triethylgermane (GeEt3) 
as a protecting group for vinyl iodides (Scheme 2-14).43 This approach involves a metal-selective 
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Stille coupling of the bifunctional building block to afford polyenylgermanium intermediates 
followed by iododegermylation to reveal another polyenyl iodide for a subsequent Stille 
cross-coupling cycle. 43 
 
 
Scheme 2-14. A metal-selective cross-coupling cycle for polyene synthesis (m = n + 1) employing 
triethylgermane as an iodide protecting group. [C] = coupling, [D] = deprotection. 
     One example from the literature that was particularly relevant to this work was the report 
by H. C. Brown and co-workers in which nucleophilic vinylboronic acids were transformed into 
electrophilic iodides with retention of stereochemistry upon treatment with base and iodine 
(Scheme 2-15A).57 Given that MIDA boronates can be hydrolyzed to boronic acids under 
similar basic conditions, we sought to employ the direct transformation of a MIDA boronate into 
a halide in one step.  
 
 
Scheme 2-15. A. Report by H. C. Brown and co-workers showed the transformation of vinyl boronic acids 
to vinyl iodides can be achieved in one-step. B. Dr. Kaitlyn Gray showed that a dienyl MIDA boronate 2.34 
can also undergo a one-step transformation to its corresponding dienyl iodide with complete retention of 
stereochemistry.  
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     In fact, Dr. Kaitlyn Gray showed that vinyl MIDA boronate 2.34 can undergo a one-step, 
one-pot transformation to its corresponding vinyl iodide 2.35 with retention of stereochemistry 
using 3M NaOH and I2 during the synthesis towards the western half of amphotericin B (Scheme 
2-15B).58 Encouraged by this preliminary result, we predicted that the transformation of MIDA 
boronate 2.33 into a halide intermediate can be readily achieved in a single-pot operation upon 
treatment with base and iodine.  
     The capacity of the MIDA boronate to serve as a masked iodide enabled the development 
of a novel ICC platform termed Reversed-Polarity (RP)-ICC, where an optimal set of building 
blocks that match the inherent electronic preference present in the target molecule can be used to 
construct complex small molecules (Scheme 2-16). Specifically, a boron selective 
Suzuki-Miyaura cross-coupling forms a Csp2-Csp2 bond between a halide and a bifunctional 
building block containing a nucleophilic boron terminus and a masked halide. Although the 
polarity of the building blocks in RP-ICC are reversed from the original ICC strategy, this 
approach affords the same MIDA boronate intermediate that would be accessed via the original 
ICC approach, allowing incorporation of this strategy into the same synthesis platform. Addition 
of base and iodine reveals another dienyl iodide capable for a subsequent Suzuki-Miyaura 
cross-coupling.  
 
Scheme 2-16. RP-ICC strategy for small molecule synthesis (m = n + 1) employing a bifunctional building 
block that contains a nucleophilic boronate terminus and a halide terminus masked as the MIDA boronate. 
[C] = coupling, [D] = deprotection. 
     Complementary to the original ICC approach where the MIDA boronate masks a reactive 
boronic acid or a pinacol boronic ester, both nucleophilic reagents, this approach utilizes the 
MIDA boronate as a halide surrogate, an electrophilic reagent, introducing exceptional flexibility 
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in synthesis design and providing an opportunity to mix and match appropriate strategies 
depending on the target small molecule. Furthermore, this strategy expands the scope of ICC to 
include a larger variety of building blocks. As demonstrated further in section 2-8 and Chapter 3, 
this strategy can also be beneficial when certain starting materials are more easily accessible than 
others, not limiting this strategy to be used only to match the inherent electronic preference 
present in target molecules.  
 
2-7 TOTAL SYNTHESIS OF SYNECHOXANTHIN VIA RP-ICC 
     The capacity to carry MIDA boronates through multiple chemical transformations59 
enabled facile preparation of key building block 2.33 (Scheme 2-17). Transesterification44 of 
MIDA boronate 2.3660 afforded bismetalated bifunctional building block 2.37 in quantitative 
yield. Vinyl iodide 2.26 underwent Stille coupling with stannane 2.37 to achieve the synthesis of 
2.33 in 80% yield. 11B NMR analysis was consistent with distinct hybridization states of the two 
terminal boron atoms (sp2 and sp3) in 2.33, which was confirmed unambiguously via single 
crystal X-ray analysis (Scheme 2-17). Building block 2.33 proved to be a remarkably stable, 
crystalline solid that has been stored under air, ambient temperature, and light on the bench top 
for more than a year without any noticeable decomposition analyzed via a bench-top stability 
test.61 This building block, along with vinyl iodide 2.26 are now commercially available from 
Sigma Aldrich. 
 
Scheme 2-17. Synthesis of 2.33, a building block that consists of a nucleophilic Bsp2 pinacol boronic ester 
terminus and Bsp3 MIDA boronate terminus as a masked halide. 
  
     Building block 2.32, now an activated electron-deficient halide, was synthesized in two 
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steps from aryl triflate intermediate 2.24 synthesized in the previous ICC synthesis pathway 
(Scheme 2-8). Miyaura borylation of 2.24 afforded neopentylglycol boronic ester 2.38 in 66% 
yield, and this boronic ester was converted to its corresponding iodide in one-step using 
choloramine-T and NaI in 76% yield (Scheme 2-18).62 Building block 2.10 was synthesized in 
one step using known literature conditions (Scheme 2-19).63   
 
 
Scheme 2-18. Synthesis of building block 2.32. 
 
 
Scheme 2-19. Synthesis of building block 2.10 according to literature procedure. 
 
     With this RP-ICC strategy and necessary building blocks in hand, we targeted the iterative 
Suzuki-Miyaura cross-coupling of the novel bifunctional building block 2.33. Key to the 
execution of this plan was the predicted capacity to selectively couple the Bsp2-hybridized 
pinacol ester terminus of bisborylated diene 2.33 in the presence of the alternatively 
Bsp3-hybridized MIDA boronate unit.64 Subsequent halodeborylation at the MIDA boronate 
terminus was anticipated to regenerate a new electron-deficient iodide intermediate, which could 
undergo another Bsp2-selective coupling with 2.33 to efficiently build the required tetraene motif 
2.31. As planned, all the cross-couplings required for this pathway involve activated, 
electron-deficient iodide intermediates. 
     As expected, Suzuki-Miyaura cross-coupling of activated, electron-deficient aryl iodide 
2.32 with the Bsp2-hybridized terminus of bisborylated building block 2.33 afforded 2.29 in 70% 
yield as a single stereoisomer (Scheme 2-20). MIDA boronate 2.29 was then halodeborylated in 
a single-pot operation using NaOMe and I2 to afford 2.39 in quantitative yield and with complete 
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retention of stereochemistry, thereby unmasking a new electron-deficient halide for a second 
iteration of Suzuki-Miyaura cross-coupling. Activated dienyl iodide 2.39 was coupled with 
another equivalent of 2.33 to afford stereochemically pure tetraenyl MIDA boronate 2.31 in 65% 
yield. Over this three-step sequence under the same exact cross-coupling conditions, key 
intermediate 2.31 was synthesized in 45% via the RP-ICC strategy compared to only 28% using 
the original ICC approach, highlighting the advantage of this strategy.  
 
 
Scheme 2-20. Synthesis of tetraenyl MIDA boronate 2.31 via RP-ICC. 
 
     Finally, harnessing the capacity of the versatile MIDA boronate motif to also represent a 
masked boronic acid which can be released and coupled in situ and thereby obviate the isolation 
of unstable intermediates,45 a highly convergent and stereospecific assembly of the complete 
polyene framework of 2.16 was achieved (Scheme 2-21). Although 
(trans)-1-bromo-2-iodoethylene, 2.10, has been utilized extensively as a versatile two-carbon 
synthon in the synthesis of polyene frameworks,65 to the best of our knowledge, this type of 
two-directional, one-pot Suzuki-Miyaura coupling represents an unprecedented transformation. 
The goal for this final coupling was to enable fast-release of the potentially unstable tetraenyl 
boronic acid from the stable MIDA boronate building block.61 Specifically, an in situ MIDA 
boronate hydrolysis followed by two-directional double cross-coupling sequence between two 
equivalents of 2.31 and electronically activated 2.10 yielded synechoxanthin bismethylester 2.16 
with complete stereoretention in an overall very efficient one-pot operation (Scheme 2-21). To 
the best of our knowledge, 2.16 represented the longest contiguous polyene prepared at the time 
of the synthesis using Suzuki-Miyaura cross-coupling.  
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Scheme 2-21. Convergent assembly of synechoxanthin methylester 2.16 followed by global deprotection 
completed the first total synthesis of synechoxanthin 2.6. 
 
     One final challenge that surfaced during this final C-C bond formation was the 
identification of byproduct 2.40 resulting from an unproductive homocoupling of two polyenyl 
boronic acids 2.31, which could not be separated from 2.16 by silica gel chromatography or 
reverse-phase HPLC purification (both C-18 and C-8 columns were investigated). We 
anticipated that carrying forward this mixture to the global deprotection might result in a better 
separation of the two products. After surveying a variety of methylester deprotection conditions, 
KOSiMe3 provided clean and rapid conversion to the anhydrous acid salts of synechoxanthin 2.6 
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and its octaene derivative 2.41 (Scheme 2-21).66 Encouragingly, HPLC purification in NH4OAc 
buffer achieved a clean separation of these two polyenes to afford 2.6 in 28% over two steps (or 
53% in the deprotection step). To confirm that the byproduct produced in the previous step was 
indeed 2.40, octaene 2.41 was subjected to methylation using TMS-diazomethane, which 
unambiguously afforded 2.40 in 64% yield and the characterization of this product matched that 
of 2.40 (Scheme 2-21). This concluded, to the best of our knowledge, the first total synthesis of 
synechoxanthin 2.6. In one run, >15 mg of synechoxanthin was synthesized, providing a 
roadmap to study the antilipoperoxidant activity of this unique natural product.  
 
2-8 TOTAL SYNTHESIS OF RENIERAPURPURIN 
     The current route to synechoxanthin allows modification of the core and/or the terminal 
rings for derivative synthesis simply by substituting modified building blocks into the synthetic 
pathway. As discussed earlier in this Chapter, in order to understand the impact of the tailoring 
enzyme modifications on !-carotene to afford synechoxanthin (Scheme 2-1),28 we next targeted 
the preparation of the apolar intermediate renierapurpurin 2.5. This was accomplished by 
replacing building block 2.32 with building block 2.42, which now contains a methyl group 
instead of a methyl ester at the para position (Scheme 2-22). The reason for choosing the first 
building block as a halide instead of a boronic ester was governed by the quick accessibility of 
this building block, which was synthesized in one step using a literature procedure.67  
 
 
Scheme 2-22. Retrosynthesis of renierapurpurin 2.5 via both RP-ICC and ICC where only the terminal 
building block 2.42 required development.  
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     The synthesis commenced with the coupling of the capping aryl iodide 2.42 to the reactive 
pinacol boronic ester terminus of building block 2.33, which encouragingly afforded dienyl 
MIDA boronate 2.43 in 70% yield (Scheme 2-23). Mirroring the synthesis of synechoxanthin, 
halodeborylation of MIDA boronate 2.43 was attempted to unmask a new electrophilic halide for 
a second iteration of Suzuki-Miyaura cross-coupling to 2.33. Unexpectedly, exposure of 2.43 to 
I2 and base (NaOH or NaOMe) consistently resulted in an inseparable mixture of byproducts. 
Fortunately, because this retrosynthesis is flexible, we turned our attention to converting MIDA 
boronate 2.43 to a pinacol boronic ester to form intermediate 2.44 (Scheme 2-23). Simply 
switching the bifunctional building block to 2.18, pinacol boronic ester 2.44 was coupled to the 
halide terminus of 2.18 to afford tetraenyl MIDA boronate 2.45 as a single stereoisomer in an 
unoptimized 39% yield. The final bidirectional coupling proceeded with the in situ release of two 
equivalents of boronic acid derived from tetraenyl MIDA boronate 2.45 and double 
cross-coupling with 2.10 to afford renierapurpurin 2.5 in ~20% semi-purified yield as confirmed 
by 1H NMR and HRMS.68 
 
 
Scheme 2-23. Total synthesis of renierapurpurin 2.5 via incorporating both RP-ICC and ICC strategies.  
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2-9 SYNECHOXANTHIN IS AN ANTILIPOPEROXIDANT IN A LIPOSOME-BASED 
TBARS ASSAY 
     We aimed to compare the antilipoperoxidant activity of these carotenoid natural products 
first in an in vitro antilipoperoxidation assay by replicating the lipoperoxidation process in large 
unilamellar vesicles (LUVs).69 Pre-existing lipid hydroperoxides, when exposed to either Cu70 
or Fe71 salts, are broken down to generate LOO•. Following this initiation event, radical chain 
propagation can proceed, leading to the progressive formation of malondialdehyde (MDA). The 
thiobarbituric acid reactive substances (TBARS) assay72 is a well-established method for 
monitoring lipid peroxidation by quantification of this reactive byproduct formed as a result of 
lipoperoxidation. One molecule of MDA reacts with two molecules of TBA to produce a 
TBA-MDA adduct that can be detected at 535 nm (Figure 2-4).73  
     To monitor lipoperoxidation in a controlled-manner, Dr. Eric Woerly developed a 
LUV-based lipid peroxidation assay system comprised completely of synthetic lipid components 
[POPC (16:0-18:1, 75 mol%) and PUFA (18:0-20:4, 25 mol%)] that retains biological 
relevance.74 For this assay, carotenoids are dissolved in an organic solvent, such as THF, and 
incorporated into the LUV solution via external addition, followed by size exclusion 
chromatography to remove unincorporated carotenoids and non-LUV liposomes.  
     In this assay, carotenoid-incorporated liposome solutions were incubated under air at 37 oC 
in the presence of a CuCl2 initiator and absorbance was measured via HPLC coupled to 
ultraviolet-visible (UV-Vis) spectrometry. Preliminary studies in our laboratory have 
demonstrated this method to be reproducible, but control experiments had to be pursued to 
validate several parameters before applying this method to test the antilipoperoxidant activity of 
synechoxanthin. After confirming the optimal heating time to produce the MDA-TBA adduct, 
and determining that the number of size-exclusion columns do not affect the percent 
incorporation of carotenoids, 75  we started by probing the antilipoperoxidant activity of 
well-studied carotenoids astaxanthin and !-carotene. 
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Figure 2-4. TBARS assay with a chemically-defined liposome system. 
 
     Based on the key structural features of these carotenoids and previous findings, we 
expected to observe increased levels of MDA formation in the presence of !-carotene compared 
to the control with no carotenoids added. In contrast, we expected to observe significantly 
decreased levels of MDA formation in the presence of the gold standard astaxanthin. Consistent 
with our hypothesis, we reproducibly found that !-carotene is a prolipoperoxidant and 
astaxanthin is an antilipoperoxidant under these assay conditions (Figure 2-5).  
 
 
Figure 2-5. TBA-MDA adduct formation over time was evaluated with !-carotene- and 
astaxanthin-incorporated liposomes. Each sample was run in triplicate (plotted as average ± 1 standard 
deviation). 
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     With established benchmarks for carotenoid prolipoperoxidant and antilipoperoxidant 
activities, the antilipoperoxidant activity of synechoxanthin was investigated in a liposome 
system. In this assay, we expected to observe decreased levels of MDA formation in the presence 
of synechoxanthin compared to the control. However, initial attempts to incorporate 
synechoxanthin into liposomes were complicated by the insolubility of this natural product in 
common organic solvents such as THF and MeOH, which hindered carotenoid addition to 
liposomes via external addition. Dissolving synechoxanthin (2-3 mg) in DMSO (3 mL) at 30 oC 
still afforded undissolved synechoanthin as an aggregate, and adding large amounts of DMSO 
(>1 mL) to the lipid film led to disruption of the lipid membrane.  
     This led us to investigate alternate solvent systems that will allow sufficient solubility of 
synechoxanthin so that the external addition protocol can be pursued. We hypothesized that the 
unique polar appendages and the hydrophobic polyene core of synechoxanthin was contributing 
to the insolubility of this natural product in both organic solvents as well as aqueous media, 
favoring aggregation through !-stacking, hydrogen-bonding, and/or the hydrophobic effect. We 
thus tested pH dependence of buffers used as well as the addition of acids and bases to DMSO. 
Employing octaene 2.41 as a control, we saw no effect with surveying pH of the buffer, but we 
were encouraged to see that addition of 5% Et3N in DMSO (v/v) visibly increased the solubility 
of this polyene.  
     With this solvent system, we discovered that octaene 2.41, a derivative of synechoxanthin, 
is an antilipoperoxidant under this assay condition, with equal potency compared to astaxanthin 
over the course of 10 hours.76 Encouraged by this result, the antilipoperoxidant activity of 
synechoxanthin was evaluated under the same assay conditions. Encouragingly, supporting our 
hypothesis, we discovered that synechoxanthin indeed functions as an antilipoperoxidant in this 
lipoperoxidation assay and protects lipids from oxidation at similar levels compared to the gold 
standard astaxanthin (Figure 2-6). 
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Figure 2-6. Antilipoperoxidant activity of synechoxanthin was evaluated against !-carotene and 
astaxanthin. DMSO + 5% Et3N control had no effect compared to the blank liposome. Each sample was 
run in triplicate (plotted as average ±1 standard deviation). 
 
2-10 SUMMARY AND CONCLUSIONS 
     Stimulated by the potential for carotenoid natural products to serve as antilipoperoxidants, 
an efficient, modular, and flexible synthetic approach was developed to access small molecules. 
Through this process, a novel RP-ICC strategy was developed, substantially expanding the scope 
of ICC by introducing new types of building blocks into the same platform. This RP-ICC 
strategy was key to the completion of the first total synthesis of synechoxanthin, as well as its 
biosynthetic precursor renierapurpurin, in a convergent and flexible manner. Although the 
RP-ICC strategy was developed in the context of the synechoxanthin total synthesis, further 
expansion of this strategy beyond polyene natural products can be envisioned by incorporating 
MIDA boronates as halide or pseudo-halide masks for aryl and alkyl building blocks.    
     Enabled by the efficient access to synechoxanthin, preliminary in vitro liposome studies 
indicate that synechoxanthin is an antilipoperoxidant. This encouraging data serves as a starting 
point to systematically investigate the antilipoperoxidant activity of other carotenoid natural 
products including renierapurpurin. It would also be informative to probe the effect of various 
carotenoid lengths on the antilipoperoxidant activity, given that an octaene derivative 
demonstrated similar antilipoperoxidant activity compared to synechoxanthin. Moreover, 
because this building block-based synthesis is highly amenable for derivative synthesis, it stands 
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to enable rationally guided systematic dissection of the structure/function relationships that 
underlie the very promising activities of carotenoid natural products.  
      
2-11 REFERENCES  
                                            
1 Meerson, F. Z.; Kagan, V. E.; Kozov, Yu. P.; Belkina, L. M.; Arkhipenko, Yu. V. Basic Res. 
Cardiol. 1982, 77, 465-485. 
2 Berliner, J. A.; Watson, A. D. N. Eng. J. Med. 2005, 353, 9-11. 
3 Williams, M. V.; Wishnok, J. S.; Tannenbaum, S. R. Chem. Res. Toxicol. 2007, 20, 767-775. 
4 Holm, J. P.; Bhakat, P.; Jegerschold, C.; Gyobu, N.; Mitsuoka, K.; Fujitoshi, Y.; Morgenstern, 
R.; Herbert, H. J. Mol. Biol. 2006, 360, 934-945. 
5 (a) de Waart, F. G.; Kok, F. J.; Smilde, T. J.; Hijmans, A.; Wollersheim, H.; Stalenhoef, A. F. 
H. Atherosclerosis 2001, 158, 227-231. (b) Lewis, P.; Stefanovic, N.; Pete, J.; Calkin, A. C.; 
Giunti, S.; Thallas-Bonke, V.; Jandeleit-Dahn, K. A.; Allen, T. J.; Cooper, M. E.; de Haan, J. B.  
Circulation 2007, 115, 2178–2187. 
6 Saadat, M. Cancer Sci. 2006, 97, 505-509. 
7 Seven, A.; Güzel, S.; Aslan, M.; Hamuryudan, V. Clin. Biochem. 2008, 41, 538-543. 
8 Hulbert, A. J.; Pamplona, R.; Buffenstein, R.; Buttemer, W. A. Physiol. Rev. 2007, 87, 
1175-1213. 
9 Krinsky, N. I.; Johnson, E. J. Mol. Aspects Med. 2005, 26, 459-516. 
10 (a) Bosio, G. N.; Breitenbach, T.; Parisi, J.; Reigosa, M.; Blaikie, F. H.; Pedersen, B. W.; 
Silva, E. F. F.; Mártire, D. O.; Ogilby, P. R. J. Am. Chem. Soc. 2013, 135, 272-279. (b) 
Druesne-Pecollo, N.; Latino-Martel, P.; Norat, T.; Barrandon, E.; Bertrais, S.; Galan, P.; 
Hercberg, S. Int. J. Cancer 2010, 127, 172-184. (c) Jeon, Y.-J.; Myung, S.-K.; Lee, E.-H.; Kim, 
Y.; Chang, Y. J.; Ju, W.; Cho, H.-J.; Seo, H. G.; Huh, B. Y. Nutr. Cancer 2011, 63, 1196-1207. 
11 Heinonen, O. P.; Albanes, D. N. Engl. J. Med. 1994, 330, 1029-1035. 
12 (a) Shen, H.; Kuo, C.; Chou, J.; Delvolve, A.; Jackson, S. N.; Post, J.; Woods, A.; Hoffer, B. 
J.; Wang, Y.; Harvey, B. K. FASEB J. 2009, 23, 1958-1968. (b) Fassett, R. G.; Coombes, J. S. 
Mar. Drugs 2011, 9, 447-475. (c) Hussein, G.; Sankawa, U.; Goto, H.; Matsumoto, K.; 
Watanabe, H., J. Nat. Prod. 2006, 69, 443-449. (d) Miki, W. Pure Appl. Chem. 1991, 63, 
141-146. 
 59 
                                                                                                                                             
13 www.astafactor.com 
14 (a) Lauver, D. A.; Lockwood, S. F.; Lucchesi, B. R. J. Pharm. Exp. Ther. 2005, 314, 686-692. 
(b) Gross, G. J.; Hazen, S. L.; Lockwood, S. F. Mol. Cell. Biochem. 2006, 283, 23-30. (c) Gross, 
G. J.; Lockwood, S. F. Life Sci. 2004, 75, 215-224. (d) Gross, G. J.; Lockwood, S. F. Mol. Cell. 
Biochem. 2005, 272, 221-227. 
15 Ryu, S. K.; King, T. J.; Fujioka, K.; Pattison, J.; Pashkow, F. J.; Tsimikas, S. Atherosclerosis 
2012, 222, 99-105. 
16 (a) Burton, G. W.; Ingold, K. U. Science 1984, 224, 569-573. (b) Krinsky, N. I. Pure and Appl. 
Chem. 1979, 51, 649-660. (c) Liebler, D. C. Ann. N. Y. Acad. Sci. 1993, 691, 20-31. (d) Burton, 
G. W. J. Nutr. 1989, 119, 109-111. 
17 Rengel, D.; Díes-Navajas, A.; Serna-Rico, P.; Veiga, P.; Muga, A.; Milicua, J. C. G. Biochim. 
Biophys. Acta. 2000, 1463, 179-187.  
18 Liebler, D. C. Ann. N Y Acad. Sci. 1993, 691, 20-31. 
19 El-Agamey, A.; Lowe, G. M.; McGarvey, D. J.; Mortensen, A.; Phillip, D. M.; Truscott, T. 
G.; Young, A. J. Arch. Biochem. Biophys. 2004, 430, 37-48. 
20 Hirayama, O.; Nakamura, K.; Hayama, S.; Kobayashi, Y. Lipids 1994, 29, 149-150.   
21 (a) Schafer, F.; Wang, H. P.; Kelley, E. E.; Cueno, K. L.; Martin, S. M.; Buettner, G. R. Biol. 
Chem. 2002, 383, 671-681. (b) Wisniewska, A.; Subczynski, W. K.; Biochim. Biophys. Acta. 
1998, 1368, 235-246. 
22 Brocks, J. J.; Schaeffer, P. Geochimica et Cosmochimica Acta 2008, 72, 1396-1414.   
23 Martin, H-D.; Kock, S.; Scherrers, R.; Lutter, K.; Wagener, T.; Hundsdörfer, C.; Frixel, S.; 
Schaper, K.; Ernst, H.; Schrader, W.; Görner, H.; Stahl, E. Angew. Chem. Int. Ed. 2008, 47, 1-5. 
24 Wagener, S.; Völker, T.; De Spirt, S.; Ernst, H.; Stahl, W. Free Radical Biol. Med. 2012, 53, 
457-463. 
25 (a) Bachilo, S. M.; Spangler, C. W.; Gilbro, T. Chem. Phys. Lett. 1998, 283, 235-242. (b) 
Drenth, W.; Wiebenga, E. H. Acta Cryst. 1955, 8, 755. 
26 Gabrielska, J.; Gruszecki, W. I. Biochim. Biophys. Acta. 1996, 1285, 167-174. 
27 (a) Mohamed, H. E.; van de Meene, A. M. L.; Roberson, R. W.; Vermaas, W. F. J. J. 
Bacteriol. 2005, 187, 6883-6892. (b) Anwar, M.; Khan, T. H.; Prebble, J.; Zagalsky, P. F. Nature 
 60 
                                                                                                                                             
1977, 270, 538-540. (c) Rohmer, M.; Bouvier, P.; Ourisson, G. Proc. Natl. Acad. Sci. USA 1979, 
76, 847-851. 
28 Graham, J. E.; Lecomte, J. T.; Bryant, D. A. J. Nat. Prod. 2008, 71, 1647-1650. 
29 Nomura, C. T.; Sakamoto, T.; Bryant, D. A. Arch. Microbiol. 2006, 185, 471-479. 
30 Swern, D. J. Am. Chem. Soc. 1947, 69, 1692-1698. 
31 Xhu, Y.; Graham, J. E.; Ludwig, M.; Xiong, W.; Alvey, R. M.; Shen, G.; Bryant, D. A. Arch. 
Biochem. Biophys. 2010, 504, 86-99. 
32 Graham, J. E.; Bryant, D. A. J. Bacteriol. 2008, 190, 7966-7974. 
33 Ernst, H. Pure. Appl. Chem. 2002, 74, 2213-2226. 
34 (a) McMurry, J. E.; Fleming, M. P. J. Am. Chem. Soc. 1974, 96, 4708-4709. (b) Ishida, A.; 
Mukaiyama, T. Chem. Lett. 1976, 1127-1130. 
35 (a) Fontán, N.; Domínguez, M.; Alvarez, R.; de Lera, A. R. Eur. J. Org. Chem. 2011, 33, 
6704-6712. (b) Kajikawa, T.; Iguchi, N.; Katsumura, S. Org. Biomol. Chem. 2009, 7, 4586-4589. 
(c) Fontán, N.; Alvarez, R.; de Lera, A. R. J. Nat. Prod. 2012, 75, 975-979. 
36 Álvarez, R.; Vaz, B.; Gronemeyer, H.; de Lera, Á. R. Chem. Rev. 2014, 114, 1-125. 
37 Negishi, E.; Alimardanov, A.; Xu, C. Org. Lett. 2000, 2, 65-67. 
38 Vaz, B.; Alvarez, R.; de Lera, A. R. J. Org. Chem. 2002, 67, 5040-5043. 
39 Fontán, N.; Vaz, B.; Álvarez, R.; de Lera, Á. R. Chem. Commun. 2013, 49, 2694-2696. 
40 Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2007, 129, 6716-6717.  
41 For recent reviews on iterative cross-coupling, see: (a) Wang, C.; Glorius, F. Angew. Chem. 
Int. Ed. 2009, 48, 5240-5244. (b) Tobisu, M.; Chatani, N. Angew. Chem. Int. Ed. 2009, 48, 
3565-3568. (c) E. P. Gillis, M. D. Burke, Aldrichimica Acta 2009, 42, 17-27. 
42 Lee, S. J.; Gray, K. C.; Peak, J. S.; Burke, M. D. J. Am. Chem. Soc. 2008, 130, 466-468. 
43 Lee, S. J.; Anderson, T. M.; Burke, M. D. Angew. Chem. Int. Ed. 2010, 49, 1-6. 
44 Woerly, E. M.; Cherney, A. H.; Davis, E. K.; Burke, M. D. J. Am. Chem. Soc. 2010, 132, 
6941-6943. 
45 Polyenylboronic acids are notoriously unstable: (a) Roush, W. R.; Brown, B. B. J. Am. Chem. 
Soc. 1993, 115, 2268-2278. (b) Torrado, A.; Iglesias, B.; L!pez, S.; de Lera, A. R. Tetrahedron 
1995, 51, 2435-2454. 
46 Kaiser, F.; Schwink, L.; Velder, J.; Schmalz, H-G. Tetrahedron 2003, 59, 3201-3217. 
 61 
                                                                                                                                             
47 For an example of polarity reversal leading to improved yields in silicon-based cross-coupling, 
see: (a) Denmark, S. E.; Liu, J. H-C.; Muhuhi, J. M. J. Am. Chem. Soc. 2009, 131, 14188-14189. 
(b) Denmark, S. E.; Liu, J. H-C.; Muhuhi, J. M. J. Org. Chem. 2011, 76, 201-215. 
48 Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483. 
49 Zim, D.; Nobre, S. M.; Monteiro, A. L. J. Mol. Catal. A: Chem. 2008, 287, 16-23. 
50 (a) Kinzel, T; Zhang, Y.; Buchwald, S. L. J. Am. Chem. Soc. 2010, 132, 14073-14075. (b) 
Barder, T. E.; Walker, S. D.; Martinelli, J. R.; Buchwald, S. L. J. Am. Chem. Soc. 2005, 127, 
4685-4696.  
51 (a) Kuivila, H. G.; Reuwer, J. F.; Mangravite, J. A. Can. J. Chem. 1963, 41, 3081-3090. (b) 
Kuivila, H. G.; Reuwer, J. F.; Mangravite, J. A. J. Am. Chem. Soc. 1964, 86, 2666-2670. 
52 Wong, M. S.; Zhang, X. L. Tetrahedron Lett. 2001, 42, 4087-4089 
53 (a) Zim, D.; Monteiro, A. L.; Dupont, J. Tetrahedron Lett. 2000, 41, 8199-8202. (b) LeBlond, 
C. R.; Andrews, A. T.; Sun, Y.; Sowa, Jr. J. R. Org. Lett. 2001, 3, 1555-1557. 
54 Spiesecke, H.; Schneider, W. G. J. Chem. Phys. 1961, 35, 731-738. 
55 Moore, J. S.; Weinstein, E. J.; Wu, Z. Teterahedron Lett. 1991, 32, 2465-2466. 
56 Zhang, J.; Moore, J. S.; Xu, Z.; Aguirre, R. A. J. Am. Chem. Soc. 1992, 114, 2273-2274. 
57 (a) Brown, H. C.; Hamaoka, T.; Ravindran, N. J. Am. Chem. Soc. 1973, 95, 5786-5788. (b) 
Brown, H. C.; Hamaoka, T.; Ravindran, N. J. Am. Chem. Soc. 1973, 95, 6456-6457. 
58 Gray, K. C. Semisynthesis of Amphotericin B and Its Derivatives via Iterative 
Cross-Coupling. PhD. Dissertation, University of Illinois at Urbana-Champaign, 2011.  
59 Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2008, 130, 14084-14085.  
60 Struble, J. R.; Lee, S. J.; Burke, M. D. Tetrahedron 2010, 66, 4710-4718. 
61 Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-6963. 
62 Thompson, A. L. S.; Kabalka, G. W.; Akula, M. R.; Huffman, J. W. Synthesis 2005, 4, 
547-550. 
63 Negishi, E.; Alimardanov, A.; Xu, C. Org. Lett. 2000, 2, 65-67.  
64 For other examples of selective functionalization of bisborylated building blocks, see: (a) 
Desurmont, G.; Klein, R.; Uhlenbrock, S.; Laloë, E.; Deloux, L.; Giolando, D. M.; Kim, Y. W.; 
Pereira, S.; Srebnik, M. Organometallics 1996, 15, 3323-3328. (b) Ishiyama, T.; Miyaura, N. J. 
 62 
                                                                                                                                             
Organomet. Chem. 2000, 611, 392-402. (c) Ref. 42 (d) Noguchi, H.; Shioda, T.; Chou, C-M.; 
Suginome, M. Org. Lett. 2008, 10, 377-380. 
65 (a) Zeng, F.; Negishi, E. Org. Lett. 2001, 5, 719-722. (b) Ghasemi, H.; Antunes, L. M.; Organ, 
M. G. Org. Lett. 2004, 17, 2913-2916. 
66 Laganis, E. D.; Chenard, B. L. Tetrahedron Lett. 1984, 25, 5831-5834. 
67 Stavber, S.; Kralj, P.; Zupan, M. Synlett 2002, 4, 598 - 600. 
68 Limited characterization data has been reported for renierapurpurin: (a) Yamaguchi, M. Bull. 
Chem. Soc. Jpn. 1960, 33, 1560-1562. (b) Cooper, R D. G.; Davis, J. B.; Weedon, B. C. L. J. 
Chem. Soc. 1963, 5720-5723. 
69 Rengel, D.; Diez-Navajas, A.; Serna- Rico, A.; Veiga, P.; Muga, A.; Milicua, J. C. Biochem. 
Biophys. Acta 2000, 1463, 179-187. 
70 (a) Jones, C. M.; Burkitt, M. J. J. Am. Chem. Soc. 2003, 125, 6946-6954. (b) Pinchuk, I.; 
Schnitzer, E.; Lichtenberg, D. Biochim. Biophys. Acta 1998, 1389, 155-172. (c) Patel, R. P.; 
Svistunenko, D.; Wilson, M. T.; Darley-Usmar, V. M. Biochem. J. 1997, 322, 425-433. 
71 Tang, L.; Zhang, Y.; Qian, Z.; Shen, X. Biochem. J. 2000, 352, 27-36. 
72 Janero, D. R. Free Radical Biol. Med. 1998, 9, 515-540.  
73 (a) Esterbauer, H.; Cheeseman, K. H. Methods Enzym. 1990, 186, 407-421. (b) Yu, L. W.; 
Latriano, L.; Duncan, S.; Hartwick, R. A.; Witz, G. Anal. Biochem. 1986, 156, 326-333. 
74 Woerly, E. W. Total Synthesis and Study of the Antilipoperoxidant Peridinin, Synthesis of 
Versatile MIDA Boronate Building Blocks, and a General Strategy for the Synthesis of Polyenes. 
PhD. Dissertation, University of Illinois at Urbana-Champaign, 2013. 
75 See Experimental Section Figure 2-8. 
76 See Experimental Section Figure 2-7. 
 63 
CHAPTER 2 
EXPERIMENTAL SECTION 
 
Materials. Commercial reagents were purchased from Sigma-Aldrich, TCI America, Alfa Aesar, 
Strem Chemicals Inc. or Fisher Scientific and used without further purification unless otherwise 
noted. Solvents were purified via passage through packed columns as described by Pangborn and 
coworkers1 (THF, Et2O, CH3CN, CH2Cl2: dry neutral alumina; hexane, benzene, and toluene: dry 
neutral alumina and Q5 reactant; DMSO, DMF: activated molecular sieves). All water was 
deionized prior to use. The following compounds were prepared by their literature methods: 
2.202, 2.103, and 2.424. The following compounds were prepared as previously described: 1-
triethylgermanium-2-tributyltin ethylene 2.275, MIDA boronate 2.366, and vinyl stannane 2.25.7   
 
General Experimental Procedures. All reactions were performed in flame- or oven (125 °C)-
dried glassware equipped with a stir bar under an atmosphere of dry argon unless otherwise 
stated. Organic solutions were concentrated via rotary evaporation under reduced pressure with a 
bath temperature of 30-40 °C. Reactions were monitored by analytical thin layer chromatography 
(TLC) on Merck silica gel 60 F254 plates (0.25 mm) using the indicated solvent system. 
Compounds were visualized by exposure to UV light (254 nm) or potassium permanganate 
(KMnO4) followed by brief heating with a Varitemp heat gun. MIDA boronates are compatible 
with standard silica gel chromatography, including standard loading techniques. Column 
chromatography was performed using standard methods8 or on a Teledyne- Isco CombiFlash Rf 
purification system using Merck silica gel grade 9385 60Å (230-400 mesh). For loading, 
compounds were adsorbed onto non acid-washed Celite in vacuo from an acetone solution. 
Specifically, for a 1 g mixture of crude material the sample is dissolved in reagent grade acetone 
(25 to 50 mL) and to the flask is added Celite 545 Filter Aid (5 to 15 g). The mixture is then 
concentrated in vacuo to afford a powder, which is then loaded on top of a silica gel column. 
Flash column chromatography was performed as described by Still and coworkers1 using Merck 
silica gel 60 (230-400 mesh). RP-HPLC purification was performed on Agilent 1100 series 
HPLC system equipped with a SunfireTM C18 5 micron 10 x 250 mm column (Waters Corp. 
Milford, MA) with indicated eluent, flow rate, and wavelength. 
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Structural Analysis. 1H NMR spectra were recorded at 23 °C using one of the following 
instruments: Varian Unity Inova 500 (500 MHz), Varian VXR 500 (500 MHz), and Varian Unity 
Inova 500NB (500 MHz). Chemical shifts are reported in parts per million (ppm) downfield 
from tetramethylsilane and referenced to residual protium in the NMR solvent (CDCl3, ! = 7.26; 
acetone-d6, ! = 2.04; CD2Cl2, ! = 5.32, center line). When solvent mixtures were used, spectra 
were referenced to an internal standard of tetramethylsilane (! = 0.00). Spectral data are 
presented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
quint = quintet, sext = sextet, m = multiplet, b = broad), coupling constant (J), and integration. 
13C NMR spectra were recorded at 23 °C using one of the following instruments: Varian Unity 
Inova 500 (500 MHz), Varian VXR 500 (500 MHz), or Varian Unity Inova 600 (600 MHz).  
Chemical shifts are reported in parts per million (ppm) downfield from tetramethylsilane and 
referenced to carbon resonances in the NMR solvent (CDCl3, ! = 77.0; acetone-d6, ! = 29.8; 
CD2Cl2, ! = 53.8; DMSO-d6, ! = 49.0; CD3CN, ! = 118.2, center line) or to added 
tetramethylsilane (! = 0.00). Many of the carbon bearing boron substituents were not observed 
(quadrupole relaxation). 11B NMR were recorded at 23 °C on a Varian Unity Inova 400 
instrument and referenced to an external standard of BF3•Et2O. High-resolution mass spectra 
(HRMS) were performed by Furong Sun, Elizabeth Eves, and Dr. Haijun Yao at the University 
of Illinois School of Chemical Sciences Mass Spectrometry Laboratory. Data are reported in the 
form of m/z. Infrared spectra were collected from a thin film on NaCl plates on a Mattson 
Galaxy Series FT-IR 5000 spectrometer. Absorption maxima (#max) are reported in wavenumbers 
(cm-1). X-ray crystallographic analysis was carried out by Dr. Danielle Gray at the University of 
Illinois George L. Clark X-Ray facility. 
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I. TOTAL SYNTHESIS OF SYNECHOXANTHIN 
 
Synthesis of Building Block 2.17 
 
 
Aryl bromide 2.21. A 500 mL round bottom flask was charged with NaH (60 wt% in mineral oil, 
2.911 g, 72.8 mmol, 1.22 equiv.) and THF (200 mL, 0.24 M) and the reaction mixture was 
cooled to 0 oC for 30 min. A 100 mL pear-shaped flask was charged with 2.20 (12 g, 59.7 mmol, 
1.0 equiv.) and THF (50 mL x 2) to afford a clear, pale yellow solution. The solution containing 
2.20 was transferred dropwise via cannula into the reaction flask over 20 min at 0 oC while 
vigorous H2 evolution was observed. The reaction mixture was warmed to 23 oC over 30 min. 
The reaction mixture was cooled again to 0 oC and MOMCl (6.0 mL, 79.4 mmol, 1.33 equiv.) 
was added dropwise to the reaction mixture over 10 min. The reaction mixture was warmed to 23 
oC with stirring over 2 h under positive Ar pressure. After 2 h, saturated aqueous NH4Cl (500 
mL) was added to the reaction mixture. The resulting biphasic mixture was transferred to a 2-L 
separatory funnel, rinsing with diethyl ether (500 mL) for quantitative transfer. The layers were 
separated and the aqueous layer was extracted with diethyl ether (500 mL). The combined 
organic layers were washed with 1M aqueous NaOH (2 x 200 mL), H2O (200 mL), and brine 
(200 mL), dried over MgSO4, filtered through a plug of Celite and silica gel, and concentrated in 
vacuo to afford 2.21 as a clear yellow oil (12.37 g, 85%). 
 
TLC (hexanes:EtOAc 3:1) 
Rf = 0.64, stained by KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
! 7.32 (d, J = 9.0 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 5.16 (s, 2H), 3.47 (s, 3H), 2.37 (s, 
3H), 2.24 (s, 3H). 
 
 
OH
Br
Me
Me NaH, THF; O
Br
Me
Me OMe
MOMCl
2.20 2.21
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13C-NMR (125 MHz, CDCl3) 
! 154.3, 137.2, 129.8, 128.0, 117.7, 113.3, 94.8, 56.0, 20.0, 13.1 
 
HRMS (EI+) 
 Calculated for C10H13O2Br: 244.00989 
 Found:    244.00851 
 
IR (thin film, cm-1) 
2992, 2927, 2854, 2825, 2073, 1641, 1573, 1461, 1403, 1382, 1307, 1253, 1205, 1157.08, 
1099, 1066, 1002, 923, 892, 802. 
 
 
Benzoic acid 2.22. A 100 mL round bottom flask was charged with 2.21 (4.27 g, 17.4 mmol, 1.0 
equiv). THF (58 mL, 0.3M) was added to afford a clear, pale yellow solution and the reaction 
mixture was cooled to -78 oC over 10 min. n-BuLi (2.5M, 7.45 mL, 18.63 mmol) was added 
dropwise to the reaction mixture, which was stirred for 10 min at -78 oC. CO2 (g) was bubbled 
through the reaction mixture at -78 oC for 10 min while the reaction mixture turned from pale 
yellow to bright red, then back to pale yellow over 10 min. The reaction mixture was warmed to 
23 oC over 30 min. The crude mixture was quenched by the addition of 1M HCl (50 mL) and 
transferred to a separatory funnel, diluting with EtOAc (50 mL). The layers were separated and 
the aqueous layer was extracted with EtOAc (50 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude solid was washed with hexanes, 
filtered, and concentrated in vacuo to afford 2.22 as a pale pink solid (2.37 g, 65%). 
 
TLC (hexanes:EtOAc 3:1) 
Rf = 0.19, stained by KMnO4 
 
 
 
O
Br
Me
Me OMe n-BuLi, THF; O
Me
Me
O
HO
OMe
CO2 (g)
2.21 2.22
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1H-NMR (500 MHz, CDCl3) 
! 7.87 (d, J = 9.0 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 5.26 (s, 2H), 3.49 (s, 3H), 2.58 (s, 
3H), 2.23 (s, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 173.4, 158.4, 141.4, 130.5, 127.0, 122.5, 110.5, 94.2, 56.2, 17.2, 12.0 
 
HRMS (ESI+) 
Calculated for C11H14O4Na:  233.0790 
Found:    233.0793 
 
IR (thin film, cm-1) 
3438, 3330, 3060, 2962, 2923, 2865, 2854, 2362, 1681, 1579, 1479, 1432, 1384, 1257.36, 
1189, 1174, 1151, 1097, 1066, 1027, 914. 
 
 
Methyl Benzoate 2.23. A 100 mL round bottom flask was charged with benzoic acid 2.22 (2.49 
g, 11.86 mmol, 1.0 equiv.), H2SO4 (1.0 mL, 1.0 equiv.) and MeOH (40 mL, 0.3 M). The flask 
was fitted with a reflux condenser and a gas inlet needle and flushed with N2. The reaction 
mixture was refluxed in an oil bath for 13 h. The reaction mixture turned clear brown. After 13 h, 
the reaction mixture was cooled to 23 oC and concentrated in vacuo. The crude mixture was 
dissolved in diethyl ether (50 mL) and neutralized with K2CO3, dried over MgSO4, filtered 
through a plug of silica gel, and concentrated in vacuo to afford 2.23 as an off-white solid (1.91g, 
89%). 
 
TLC (hexanes:EtOAc 5:1) 
Rf = 0.23, stained by KMnO4 
 
 
OH
Me
Me
O
MeO
2.23
H2SO4
MeOH
O
Me
Me
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1H-NMR (500 MHz, CDCl3) 
! 7.64 (d, J = 8.5 Hz, 1H), 6.64 (d, J = 8.5 Hz, 1H), 5.02 (s, 1H), 3.85 (s, 3H), 2.52 (s, 
3H), 2.20 (s, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 168.6, 156.4, 140.9, 129.4, 123.7, 123.2, 112, 51.7, 17.1, 11.7 
 
HRMS (ESI+) 
Calculated for C10H13O3:  180.0865 
Found:    180.0872 
 
IR (thin film, cm-1) 
3467, 3419, 3037, 2996, 2948, 2117, 1650, 1581, 1490, 1446, 1432, 1373, 1340, 1278, 
1191, 1174, 1147, 1072. 
 
 
Triflate 2.24. A 50 mL round bottom flask was charged with NaH (60 wt% in mineral oil, 231 
mg, 5.78 mmol, 1.0 equiv.) and DMF (7.0 mL) and cooled to 0 oC. A 50-mL pear flask was 
charged with 2.23 (1.042 g, 5.78 mmol, 1.0 equiv) and DMF (12 mL) to afford a clear yellow 
solution. The solution containing 2.23 was added dropwise to the reaction flask at 0 oC. The 
reaction mixture turned greenish grey. The reaction mixture was warmed to 23 oC and stirred for 
30 min. After 30 min, the reaction flask was once again cooled to 0 oC and NPhTf2 (2.065 g, 5.78 
mmol, 1.0 equiv.) was added in small portions. The reaction mixture was slowly warmed to 23 
oC overnight with stirring. After 12 h, the yellow/brown reaction mixture was diluted with 
saturated aqueous NH4Cl (60 mL) while stirring. The mixture was transferred to a separatory 
funnel, rinsing with diethyl ether (60 mL). The aqueous layer was extracted with ether (60 mL x 
2). The combined organic layers were washed with water to remove residual DMF. The organic 
layer was dried over MgSO4, filtered, and concentrated in vacuo to afford a yellow oil. The crude 
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material was adsorbed onto Celite from an acetone solution and purified by MPLC (Hexanes ! 
Hexanes: EtOAc 4:1) to afford 2.24 as a clear, yellow oil (1.65 g, 89% yield). 
 
TLC (hexanes:EtOAc 5:1) 
Rf = 0.56, stained by KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
! 7.69 (d, J =8.5 Hz, 1H), 7.16 (d, J = 8.5 Hz, 1H), 3.91 (s, 3H), 2.52 (s, 3H), 2.33 (s, 
3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 167.7, 150.0, 141.3, 131.1, 131.0, 128.9, 119.8, 118.4, 52.3, 17.3, 13.4 
 
HRMS (ESI+) 
Calculated for C11H12O5SF3:  313.0358 
Found:    313.0361 
 
IR (thin film, cm-1) 
3033, 3014, 2956, 2881, 2352, 2090, 1725, 1643, 1585, 1477, 1425, 1297, 1253, 1224.58, 
1160, 1141, 1060, 1031, 931. 
 
 
Building block 2.17. In a glovebox, to a 20 mL vial charged with triflate 2.24 (252 mg, 0.81 
mmol, 1.0 equiv.) was added bispinacolatodiboron (307 mg, 1.21 mmol. 1.5 equiv.), 
PdCl2dppf•CH2Cl2 (33 mg, 0.041 mmol, 5 mol%), and KOAc (238.5 mg, 2.43 mmol, 3.0 equiv.) 
were added followed by dioxane (4 mL, 0.2 M). The vial was sealed with a PTFE-lined cap 
under Ar, removed from the glovebox, placed in an 80 oC aluminum heat block and maintained 
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at that that temperature with stirring for 18 h. After 18 h, the reaction mixture was cooled to 23 
oC and diluted with EtOAc and filtered through a plug of silica gel and concentrated in vacuo. 
The crude mixture was adsorbed onto Celite from an acetone solution and purified via normal 
phase MPLC (Hexanes ! 1:4 EtOAc:Hexanes) and the collected fractions were concentrated in 
vacuo to afford pinacol boronic ester 2.17 as a white solid (200.5 mg, 90% yield). 
 
TLC (hexanes:EtOAc 1:1) 
 Rf = 0.84, stained by KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
" 7.59 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 3.88 (s, 3H), 2.51 (s, 3H), 2.42 (s, 
3H), 1.36 (s, 12H). 
 
13C-NMR (125 MHz, CDCl3) 
" 169.4, 144.1, 136.7, 133.2, 132.4, 125.9, 83.8, 51.9, 24.8, 19.0, 16.8 
 
11B-NMR (128 MHz, acetone-d6) 
" 31.4 
 
HRMS (ESI+) 
 Calculated for C16H24BO4: 291.1768 
 Found:    291.1768 
  
IR (thin film, cm-1) 
2992, 2979, 2956, 2103, 1724, 1641, 1483, 1438, 1375, 1353, 1282, 1247, 1145, 1056, 
1027, 964, 898, 856, 782, 732 
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Synthesis of Building Block 2.18 
 
 
Vinyl iodide 2.26. A 100 mL round bottom flask was charged with stannane 2.25 (1.5 g, 3.0 
mmol, 1 equiv.) and topped with a septum and a gas inlet needle. Dichloromethane (6 mL) was 
added to afford a pale yellow solution, and the flask was cooled to 0 oC. A 50 mL pear-shaped 
flask was charged with I2 (822 mg, 3.24 mmol, 1.05 equiv.) and dichloromethane (29 mL). The 
I2 solution was added dropwise to the reaction flask over the course of 1 h and stirred at 0 oC for 
an additional 15 min. The reaction mixture was quenched by the addition of saturated Na2S2O3 
solution (20 mL) and stirred at 10 oC until the reaction mixture became clear. The mixture was 
transferred to a separatory funnel, rinsing with EtOAc (70 mL) and brine (30 mL). The aqueous 
layer was extracted with EtOAc (3 x 50 mL) and the combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo to afford a white solid. The crude material was 
adsorbed onto Celite from an acetone solution and purified by SiO2 chromatography (Et2O ! 
Et2O:MeCN 10:1 !  7:1 ! 5:1) to yield 2.26 as a white solid (725 mg, 75%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.4, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 6.22 (s, 1H), 4.25 (d, J = 17.0 Hz, 2H), 4.11 (d, J = 17.0 Hz, 2H), 3.12 (s, 3H), 2.61 (s, 
3H). 
 
13C-NMR (125 MHz, acetone-d6) 
" 168.6, 110.9, 62.5, 47.2, 33.2 
 
11B-NMR (128 MHz, acetone-d6) 
" 9.58 
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HRMS (EI+) 
Calculated for C8H11BINO4:  321.98625 
Found:               321.98653 
 
IR (thin film, cm-1) 
 3008, 2972, 2951, 2916, 1757, 1620, 1466, 1450, 1429, 1340, 1290, 1124, 1090, 1066, 
1001, 964, 887 
 
X-ray quality crystals were grown by layering pentane on top of a solution of 2.26 in acetone.  
 
 
 
Dieneyl germane 2.28. In a glovebox, to a 7 mL vial charged with 1-triethylgermanium-2-
tributyltin ethylene 2.27 (443 mg, 0.93 mmol, 1.5 equiv.) and vinyl iodide 2.26 (200 mg, 0.62 
mmol, 1.0 equiv.) was added Pd2dba3 (14 mg, 0.016 mmol, 2.5 mol%), Ph3As (9.5 mg, 0.03 
mmol, 9.5 mol%), DMF (9.3 mL, 0.05M) and THF (3 mL). The vial was sealed with a PTFE-
lined cap, removed from the glove box, and placed in a 60 oC aluminum heat block and 
maintained at that temperature with stirring for 15 h. The reaction was cooled to 23 oC and 
transferred to a separatory funnel. EtOAc (20 mL) and brine (20 mL) were added, and the layers 
were separated. The aqueous phase was extracted with EtOAc (3 x 20 mL), dried over MgSO4, 
filtered, and concentrated in vacuo. The resulting brown oil was adsorbed onto Celite from an 
acetone solution and purified by silica gel chromatography (1:1 petroleum ether:EtOAc ! 
EtOAc ! 9:1 EtOAc:MeCN) to afford dienyl germane 2.28 as a white solid (204.5 mg, 86%). 
2.26
Pd2dba3, Ph3As
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TLC (EtOAc) 
 Rf = 0.38, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
! 6.61 (d, J = 18.5 Hz, 1H), 6.04 (d, J = 19.0 Hz, 1H), 5.42 (s, 1H), 4.21 (d, J = 17.0 Hz, 
2H), 4.05 (d, J = 17.0 Hz, 2H), 3.03 (s, 3H), 1.92 (s, 3H), 1.03 (t, 9H), 0.88 (q, 6H). 
 
13C-NMR (125 MHz, acetone-d6) 
! 169.1, 152.0, 149.5, 126.5, 62.6, 47.2, 15.1, 9.36, 5.06 
 
11B-NMR (128 MHz, acetone-d6) 
! 10.9 
 
HRMS (ESI+) 
 Calculated for C16H29BNO4Ge: 384.1401 
 Found:     384.1404 
  
IR (thin film, cm-1) 
2954, 2871, 2088, 1741, 1648, 1456, 1338, 1292, 1128, 1022, 985, 885, 848, 819. 
 
 
Building Block 2.18. A 250 mL round bottom flask was charged with dienyl germane 2.28 (1.41 
g, 3.7 mmol, 1.0 equiv.) and topped with a septum and gas inlet needle. MeCN (70 mL) was 
added to afford a clear solution and the flask was cooled to 0 oC in an ice bath. A 100 mL pear-
shaped flask was charged with N-iodo succinimide (NIS) (2.49 g, 11.1 mmol, 3.0 equiv.) 
followed by MeCN (60 mL). The NIS solution was added dropwise to the reaction mixture at 0 
oC over 30 min. The resulting reaction mixture was stirred at 0 oC for 2 h. The reaction mixture 
was quenched with saturated Na2S2O3 solution (100 mL) and the mixture was transferred to a 
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separatory funnel and diluted with EtOAc (100 mL). The layers were separated and the aqueous 
phase was extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The resulting yellow solid was adsorbed onto Celite 
from an acetone solution and purified by silica gel chromatography (1:1 petroleum ether:EtOAc 
! EtOAc) to afford dienyl iodide 2.18 as a white solid (1.07 g, 83%). 
 
TLC (EtOAc) 
 Rf = 0.38, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 7.16 (d, J = 14.5 Hz, 1H), 6.56 (d, J = 15.0 Hz, 1H), 5.42 (s, 1H), 4.24 (d, J = 17.0 Hz, 
2H), 4.05 (d, J = 17.0 Hz, 2H), 3.04 (s, 3H), 1.92 (s, 3H). 
 
13C-NMR (125 MHz, acetone-d6) 
" 168.7, 152.8, 148.3, 77.6, 62.2, 46.9, 14.8 
 
11B-NMR (128 MHz, acetone-d6) 
" 10.5 
 
HRMS (ESI+) 
 Calculated for C10H14BNO4I:  350.0061 
 Found:                350.0066 
  
IR (thin film, cm-1) 
3066, 3007, 2956, 2923, 2360, 1770, 1711, 1606, 1452, 1338, 1294, 1184, 1128, 1026, 
991. 
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Synthesis of MIDA boronate 2.31 via Original ICC Pathway 
 
 
MIDA boronate 2.29. In a glovebox, to a 20 mL vial charged with 2.17 (205.9 mg, 0.75 mmol, 
1.3 equiv.) and 2.18 (200.2 mg, 0.57 mmol, 1.0 equiv.) was added PdCl2dppf•CH2Cl2 (23 mg, 
0.03 mmol, 5 mol%), finely ground anhydrous K3PO4 (731 mg, 3.4 mmol, 6.0 equiv.), and 
DMSO (9 mL). The vial was sealed with a PTFE-lined cap and removed from the glove box. The 
vial was placed in a 45 oC aluminum heat block and maintained at that temperature with stirring 
for 24 h. The reaction was cooled to 23 oC and transferred to a separatory funnel, diluting with 
EtOAc (20 mL). The organic layer was washed with brine:H2O (1:1, 2 x 40 mL) to remove 
DMSO, dried over MgSO4, filtered, and concentrated in vacuo to afford a yellow solid. The 
crude material was adsorbed onto Celite from an acetone solution and purified by SiO2 
chromatography (hexanes:EtOAc 1:1 ! EtOAc) to afford 2.29 as a pale yellow solid (140 mg, 
60%). 
 
TLC (EtOAc) 
Rf = 0.39, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 7.55 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 16.0 Hz, 1H), 6.82 (d, J 
= 15.5 Hz, 1H), 5.62, (s, 1H), 4.24 (d, J = 17.0 Hz, 2H), 4.07 (d, J = 17.0 Hz, 2H), 3.83 
(s, 3H), 3.01 (s, 3H), 2.45 (s, 3H), 2.33 (s, 3H), 2.10 (s, 3H). 
 
13C-NMR (125 MHz, acetone-d6) 
" 169.3, 169.0, 148.5, 141.0, 140.4, 138.3, 136.4, 128.0, 126.6, 123.8, 117.5, 62.4,  
52.1, 47.1, 17.2, 15.8, 15.6 
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11B-NMR (128 MHz, acetone-d6) 
! 10.9 
 
HRMS (ESI+) 
Calculated for C20H25BNO6: 386.1775   
Found:       386.1779 
 
IR (thin film, cm-1) 
3220, 3178, 3139, 3006, 2964, 2927, 2127, 1760, 1710, 1637, 1600, 1448, 1286, 1245, 
1151, 983, 889. 
 
 
Pinacol boronic ester 2.30. A 20 mL vial was charged with MIDA boronate 2.29 (145 mg, 
0.376 mmol, 1.0 equiv.), pinacol (88.9 mg, 0.752 mmol, 2.0 equiv.), and solid NaHCO3 (158 mg, 
1.88 mmol, 5.0 equiv.). The vial was flushed with N2 and MeOH (1.9 mL) was added. The 
reaction mixture was placed in a 45 oC aluminum heat block and stirred at that temperature for 3 
h. The reaction mixture was cooled to 23 oC and filtered through a pad of Celite, rinsing with 
Et2O. The collected solution was concentrated in vacuo and the resulting residue was azeotroped 
with toluene to afford a yellow oil. To remove residual pinacol, finely ground CaCl2 (584 mg, 
5.26 mmol, 14.0 equiv.), solid NaHCO3 (158 mg, 0.75 mmol, 5.0 equiv), and toluene (12.5 mL, 
0.03M) were added to the crude material. The resulting suspension was stirred at 23 oC for 1 h 
and filtered through a pad of Celite, rinsing with Et2O. The collected solution was concentrated 
in vacuo to afford 2.30 as a yellow solid (124 mg, 92%). 
 
TLC (EtOAc) 
 Rf = 0.88, stained by KMnO4 
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1H-NMR (500 MHz, acetone-d6) 
! 7.63 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 16 Hz, 1H), 6.83 (d, J = 
15.5 Hz, 1H), 5.49 (s, 1H), 3.84 (s, 3H), 2.44 (s, 3H), 2.33 (s, 3H), 2.24 (s, 3H), 1.27 (s, 
12H). 
 
13C-NMR (125 MHz, acetone-d6) 
! 169.1, 155.8, 140.3, 138.8, 138.2, 136.6, 131.3, 129.4, 127.9, 123.9, 83.5, 52.0, 25.0,  
17.1, 16.6, 15.7 
 
11B-NMR (128 MHz, acetone-d6) 
! 30.1 
 
HRMS (ESI+) 
 Calculated for C21H29BO4Na:  379.2057 
 Found:                379.2055 
  
IR (thin film, cm-1) 
2974, 2931, 2852, 2360, 2330, 1722, 1599, 1437, 1363, 1437, 1363, 1286, 1242, 1144, 
968. 
 
 
Tetraenyl MIDA boronate 2.31. In a glovebox, to a 7 mL vial charged with 2.30 (123.7 mg, 
0.35 mmol, 1.3 equiv.) and 2.18 (93.2 mg, 0.27 mmol, 1.0 equiv.) was added PdCl2dppf•CH2Cl2 
(10.9 mg, 0.014 mmol, 5 mol%), finely ground anhydrous K3PO4 (340 mg, 1.60 mmol, 6.0 
equiv.), and DMSO (3.8 mL). The vial was sealed with a PTFE-lined cap and removed from the 
glove box. The vial was placed in a 45 oC aluminum heat block and maintained at that 
temperature with stirring for 24 h. The reaction was cooled to 23 oC and transferred to a 
separatory funnel, diluting with EtOAc (20 mL). The organic layer was washed with brine:H2O 
(1:1, 2 x 40 mL) to remove DMSO, dried over MgSO4, filtered, and concentrated in vacuo to 
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afford a yellow-orange solid. The crude material was adsorbed onto Celite from an acetone 
solution and purified by SiO2 chromatography (hexanes:EtOAc 1:1 ! EtOAc) to afford 2.31 as a 
yellow solid (60.2 mg, 50%). 
 
TLC (EtOAc) 
Rf = 0.39, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 7.56 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 6.96 (d, J = 15.5 Hz, 1H), 6.90 (d, J 
= 16.0 Hz, 1H), 6.75, (dd, J = 15.0 Hz, 11.0 Hz, 1H), 6.46 (d, J = 14.5 Hz, 1H), 6.40 (d, 
J = 12.0 Hz, 1H), 5.49 (s, 1H), 4.22 (d, J = 17.0 Hz, 2H), 4.05 (d, J = 17.0 Hz, 2H), 3.83 
(s, 3H), 3.04 (s, 3H) 2.45 (s, 3H), 2.34 (s, 3H), 2.08 (s, 3H), 2.03 (s, 3H). 
 
13C-NMR (125 MHz, acetone-d6) 
" 168.7, 168.3, 148.4, 141.6, 140.4, 137.8, 137.2, 136.2, 135.5, 133.8, 130.2, 127.4,  
125.5, 125.0, 122.9, 61.8, 51.4, 46.5, 16.7, 15.2, 15.0, 12.3 
 
11B-NMR (128 MHz, acetone-d6) 
" 11.1 
 
HRMS (ESI+) 
Calculated for C25H31BNO6: 452.2244   
Found:       452.2263 
    
IR (thin film, cm-1) 
3012, 2962, 2595, 2098, 1760, 1710, 1643, 1450, 1340, 1288, 1243, 1189, 1151, 1093, 
1066, 1024, 985, 964, 889. 
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Synthesis of Building Block 2.32 
 
 
Neopentyl glycol boronic ester 2.38. In a glove box, to a 40 mL vial charged with 2.24 (949 mg, 
3.04 mmol, 1.0 equiv.) was added neopentylglycolatodiboron (1.03 g, 4.56 mmol. 1.5 equiv.), 
PdCl2dppf•CH2Cl2 (124 mg, 0.15 mmol, 5 mol%), and KOAc (895 mg, 9.11 mmol, 3.0 equiv.), 
followed by dioxane (15 mL, 0.2 M). The vial was sealed with a PTFE-lined cap under Ar and 
removed from the glovebox. The vial was placed in an 80 oC aluminum heat block and 
maintained at that temperature with stirring for 18 h. After 18 h, the reaction mixture was cooled 
to 23 oC and diluted with EtOAc and filtered through a plug of silica gel. The crude mixture was 
adsorbed onto Celite from an acetone solution and purified by MPLC (Hexanes! 1:4 
EtOAc:Hexanes) and the collected fractions were concentrated in vacuo to afford neopentyl 
glycol boronic ester 2.38 as a white solid (555 mg, 66% yield). 
 
TLC (hexanes:EtOAc 4:1) 
 Rf = 0.68, stained by KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
" 7.52 (s, 2H), 3.88 (s, 3H), 3.79 (s, 4H), 2.47 (s, 3H), 2.43 (s, 3H), 1.05 (s, 6H).   
 
13C-NMR (125 MHz, CDCl3) 
" 169.6, 142.9, 136.7, 132.4, 131.3, 126.0, 72.4, 51.9, 31.6, 21.9, 19.1, 16.8 
 
11B-NMR (128 MHz, acetone-d6) 
" 27.8 
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HRMS (EI+) 
 Calculated for C15H21O4B: 276.15330 
 Found:    276.15268 
  
IR (thin film, cm-1) 
 3531, 3419, 2956, 2893, 1724, 1556, 1479, 1419, 1377, 1317, 1284, 1155, 1078, 1074. 
 
 
Building block 2.32. A 20 mL vial was charged with neopentylglycol boronic ester 2.38 (555 
mg, 2.01 mmol, 1.0 equiv.) and THF:H2O (1:1, 0.8 mL, 2.5 M) to afford a pale yellow solution 
and the vial was cooled to 0 oC. A solution of NaI (1.63 g, 2.51 mmol, 1.25 equiv.) in H2O (2.5 
mL) was added dropwise to the reaction vial followed by chloroamine-T (915 mg, 4.02 mmol, 
2.0 equiv.) in THF:H2O (1:1, 8.04 mL, 0.5 M). The reaction mixture was stirred under N2 at 0 oC 
and warmed to 23 oC over 13 h. The reaction mixture turned from dark purple to orange over the 
course of the reaction. The mixture was quenched with saturated Na2S2O3 solution (5 mL) and 
transferred to a separatory funnel, rinsing with diethyl ether (40 mL) and H2O (40 mL). The 
layers were separated and the aqueous layer was extracted with diethyl ether (2 x 40 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
resulting solid was adsorbed onto Celite from an acetone solution and purified by SiO2 
chromatography (100:1 petroleum ether:EtOAc) to afford 2.32 as a pale yellow solid (445 mg, 
76%). 
 
TLC (hexanes:EtOAc 4:1) 
 Rf = 0.63, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
! 7.75 (d, J = 8.5 Hz, 1H), 7.23 (d, J = 8.5 Hz, 1H), 3.84 (s, 3H), 2.47 (s, 3H), 2.45 (s, 
3H).  
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13C-NMR (125 MHz, acetone-d6) 
! 168.7, 141.4, 138.7, 137.3, 132.5, 129.2, 106.9, 52.3, 26.0, 18.6 
 
HRMS (EI+) 
 Calculated for C10H11O2I: 289.98041 
 Found:    289.98135    
  
IR (thin film, cm-1) 
 3347, 3261, 2926, 2357, 2341, 1722, 1567, 1527, 1433, 1398, 1230, 1248, 1159, 1097,  
            1051, 903, 816, 766, 669. 
 
Synthesis of Building Block 2.33 
 
 
Pinacol boronic ester 2.37. A 500 mL round bottom flask was charged with MIDA boronate 
2.36 (17.2 g, 36.4 mmol, 1.0 equiv.), pinacol (8.61 g, 72.9 mmol, 2,0 equiv), solid NaHCO3 
(15.3 g, 182.2 mmol, 5.0 equiv), and MeOH (180 mL). The reaction flask was topped with a 
septum and a gas inlet needle and flushed with N2. The reaction mixture was placed in a 45 oC 
oil bath and maintained at that temperature with stirring for 3 h. The reaction mixture was cooled 
to 23 oC and filtered through a pad of Celite, rinsing with Et2O. The collected solution was 
concentrated in vacuo in a 500 mL round bottom flask. The resulting residue was azeotroped 
with toluene to afford a clear oil. To remove residual pinacol, finely ground CaCl2 (40.0 g, 364.4 
mmol, 10 equiv.), solid NaHCO3 (15.3 g, 182.2 mmol, 5.0 equiv), and toluene (200 mL) were 
added to the flask containing the crude material. The resulting suspension was stirred at 23 oC for 
1 h and filtered through a pad of silica gel, rinsing with Et2O. The collected solution was 
concentrated in vacuo to afford 2.37 as a clear oil (15.8 g, 98%). 
 
TLC (hexanes) 
Rf = 0.38, stained by KMnO4 
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NaHCO3, CaCl2,
    toluene
BO
O
MeMe
Me
Me
SnBu3
2.36 2.37
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1H-NMR (500 MHz, acetone-d6) 
! 7.52 (d, J = 22.0 Hz, 1H), 6.28 (d, J = 22.0 Hz, 1H), 1.54 (quint, J = 7.5 Hz, 6H), 1.33 
(sext, J = 7.5 Hz, 6H), 1.23 (s, 12 H), 0.95 (t, J = 7.5 Hz, 6H), 0.89 (t, J = 7.5 Hz, 9 H). 
 
13C-NMR (125 MHz, acetone-d6) 
! 159.1, 83.7, 27.9, 25.2, 13.9, 11.9, 9.9 
 
11B-NMR (128 MHz, acetone-d6) 
! 28.0 
 
HRMS (ESI+) 
Calculated for C20H41BO2SnNa: 467.2119    
Found:                       467.2108 
 
IR (thin film, cm-1) 
3205, 2977, 2958, 2927, 2871, 2854, 2362, 2341, 2100, 1641, 1573, 1369, 1328, 1265, 
1145, 1018, 970, 848. 
 
 
Building block 2.33.  In a glovebox, to a 20 mL vial charged with stannane 2.37 (280.5 mg, 0.63 
mmol, 1.3 equiv.) and iodide 2.26 (157 mg, 0.49 mmol, 1.0 equiv) was added trans-
bis(acetonitrile)palladium dichloride (6.3 mg, 0.024 mmol, 5 mol%), DMF (7 mL) and THF (2.4 
mL). The vial was sealed with a PTFE-lined cap and removed from the glovebox. The vial was 
placed in a 45 oC aluminum heat block and maintained at that temperature with stirring for 15 h. 
The reaction mixture was transferred into a separatory funnel containing brine (50 mL), rinsing 
with EtOAc (20 mL), and the layers were separated. The aqueous layer was extracted with 
EtOAc (2 x 30 mL). The combined organic layers were washed with brine:H2O (1:1, 50 mL), 
DMF:THF (3:1)
PdCl2(MeCN)2
BO
O
MeMe
Me
Me
SnBu3
2.37
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O
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dried over MgSO4, filtered, and concentrated in vacuo to afford an off-white solid. The crude 
material was adsorbed onto Celite from an acetone solution and purified by SiO2 
chromatography (hexanes:EtOAc 1:1 ! EtOAc) to afford 2.33 as a white solid (135 mg, 80%). 
 
TLC (EtOAc) 
Rf = 0.33, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 7.06 (d, J = 18.5 Hz, 1H), 5.64 (s, 1H), 5.54 (d, J = 18.0 Hz, 1H), 4.26 (d, J = 16.5 Hz, 
2H), 4.09 (d, J = 17.0 Hz, 2H), 3.08 (s, 3H), 1.97 (s, 3H), 1.27 (s, 12H). 
 
13C-NMR (125 MHz, acetone-d6) 
" 168.9, 157.3, 149.1, 83.7, 62.4, 47.1, 25.1, 14.8 
 
11B-NMR (128 MHz, acetone-d6) 
" 30.3, 10.7 
 
HRMS (ESI+) 
Calculated for C16H25 B2NO6Na: 372.1766    
Found:                       372.1777     
 
IR (thin film, cm-1) 
2977, 2929, 2871, 2732, 2142.54, 1754, 1710, 1596, 1454, 1336, 1186, 1143, 995, 890, 
850, 728, 651. 
 
X-ray quality crystals were grown by layering ether on top of a solution of 2.33 in MeCN.  
  
2.33
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Synthesis of MIDA boronate 2.31 via RP-ICC 
 
 
Dienyl MIDA boronate 2.29. In a glovebox, to a 20 mL vial charged with 2.32 (240 mg, 0.83 
mmol, 1.3 equiv.) and 2.33 (222.3 mg, 0.637 mmol, 1.0 equiv.) was added PdCl2dppf•CH2Cl2 
(26 mg, 0.032 mmol, 5 mol%), finely ground anhydrous K3PO4 (811 mg, 3.8 mmol, 6.0 equiv.), 
and DMSO (9 mL). The vial was sealed with a PTFE-lined cap and removed from the glove box. 
The vial was placed in a 45 oC aluminum heat block and maintained at that temperature with 
stirring for 24 h. The reaction was cooled to 23 oC and transferred to a separatory funnel, diluting 
with EtOAc (20 mL). The organic layer was washed with brine:H2O (1:1, 2 x 40 mL) to remove 
DMSO, dried over MgSO4, filtered, and concentrated in vacuo to afford a yellow solid. The 
crude material was adsorbed onto Celite from an acetone solution and purified by SiO2 
chromatography (hexanes:EtOAc 1:1 ! EtOAc) to afford 2.29 as a  pale yellow solid (171 mg, 
70%). 
 
For characterization data, see section: Synthesis of MIDA boronate 2.31 via Original ICC 
Pathway. 
 
 
Dienyl iodide 2.39. In a glovebox, a 7 mL vial was charged with NaOMe (67.9 mg, 1.26 mmol, 
5.0 equiv.). The vial was sealed with a PTFE-lined septum cap and removed from the glove box, 
and MeOH (2.0 mL) and THF (1.0 mL) were added to afford a clear solution. A separate 7 mL 
vial was charged with I2 (192 mg, 0.756 mmol, 3.0 equiv) and THF (3.8 mL, 0.2M with respect 
to I2). A 20 mL vial was charged with 2.29 (96.9 mg, 0.252 mmol, 1.0 equiv.) and THF (2.0 mL). 
The NaOMe solution was added dropwise to the reaction vial over 5 min. The reaction mixture 
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+
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was vigorously stirred at 23 oC. TLC analysis indicated complete deprotection of the MIDA 
boronate to the boronic acid in 10 min. The I2 solution was dropwise added to the vigorous 
stirring mixture and the resulting dark purple mixture was stirred at 23 oC for 20 min. The 
reaction mixture was quenched with pH7 phosphate buffer (20 mL) and transferred to a 
separatory funnel, rinsing with EtOAc (20 mL) and the layers were separated. The organic layer 
was washed with saturated Na2S2O3 (2 x 20 mL) and the aqueous layer was back-extracted with 
EtOAc (10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo to afford 2.39 as a yellow solid (89 mg, 99%). 
 
TLC (EtOAc) 
Rf = 0.90, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
! 7.55 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 16.0 Hz, 1H), 6.94 (d, J 
= 15.5 Hz, 1H), 6.77, (s, 1H), 3.83 (s, 3H), 2.44 (s, 3H), 2.32 (s, 3H), 2.13 (s, 3H). 
 
13C-NMR (125 MHz, acetone-d6) 
! 169.2, 146.3, 140.3, 138.4, 136.5, 133.6, 131.3, 128.0, 127.9, 123.7, 86.2, 52.1, 20.2, 
17.2, 15.9  
 
HRMS (ESI+) 
Calculated for C15H18O2I: 357.0352   
Found:       357.0345 
 
IR (thin film, cm-1) 
3216, 3116, 2950, 2360, 2341, 1718, 1643, 1592, 1432, 1407, 1380, 1282, 1243, 1207, 
1187, 1147, 1066, 1037, 960. 
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MIDA boronate 2.31. In a glovebox, to a 7 mL vial charged with 2.39 (125.4 mg, 0.35 mmol, 
1.3 equiv.) and 2.33 (94.5 mg, 0.27 mmol, 1.0 equiv.) was added PdCl2dppf•CH2Cl2 (11.1 mg, 
0.014 mmol, 5 mol%), finely ground anhydrous K3PO4 (345 mg, 1.62 mmol, 6.0 equiv.), and 
DMSO (3.9 mL). The vial was sealed with a PTFE-lined cap and removed from the glove box. 
The vial was placed in a 45 oC aluminum heat block and maintained at that temperature with 
stirring for 24 h. The reaction was cooled to 23 oC and transferred to a separatory funnel, diluting 
with EtOAc (20 mL). The organic layer was washed with brine:H2O (1:1, 2 x 40 mL) to remove 
DMSO, dried over MgSO4, filtered, and concentrated in vacuo to afford a yellow-orange solid. 
The crude material was adsorbed onto Celite from an acetone solution and purified by SiO2 
chromatography (hexanes:EtOAc 1:1 ! EtOAc) to afford 2.31 as a yellow solid (78.9 mg, 65%). 
 
For characterization data, see section: Synthesis of MIDA boronate 2.31 via Original ICC 
Pathway. 
 
Total Synthesis of Synechoxanthin 2.6 
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Synechoxanthin dimethyl ester 2.16. 
Preparation of stock solutions. In a glovebox, a 7 mL vial was added XPhos and THF (8.6 
mg/mL) to afford a clear solution. To another 7 mL vial was added Pd(OAc)2 and THF (2.2 
mg/mL) to afford a pale yellow-orange solution. To a separate 7 mL vial was added 2.104 and 
THF (21.1 mg/mL). 
 
The freshly prepared stock solutions were used in the following reaction: 
In a glovebox, to a 7 mL vial charged with MIDA boronate 2.31 (100 mg, 0.22 mmol, 2.2 equiv.) 
was added solid NaOH (56 mg, 1.4 mmol, 14.0 equiv.) and THF (0.56 mL). The stock solution 
of 2.10 in THF (1.11 mL) was added to the reaction vial followed by the XPhos stock solution 
(0.56 mL, which contains 4.7 mg, 0.01 mmol, 10 mol%) and the Pd(OAc)2  stock solution (0.56 
mL, which contains 1.2 mg, 0.005 mmol, 5 mol%). The vial was sealed with a PTFE-lined 
septum cap, removed from the glovebox, and stirred at 23 °C for 5 min. Degassed DI H2O (0.66 
mL, 0.15 M) was added dropwise. The solution was stirred in a subdued light environment at 
23 °C for 1 h. The reaction mixture was quenched with pH 7 phosphate buffer (10 mL) and 
transferred to a separatory funnel, rinsing with Et2O (10 mL). The layers were separated and the 
aqueous layer was extracted with Et2O (2 x 10 mL), dried over MgSO4, filtered, and 
concentrated in vacuo to afford a bright orange-red solid. The resulting residue was adsorbed 
onto Celite from an acetone solution and purified by SiO2 chromatography (hexanes:EtOAc 20:1 
! 10:1) to afford a mixture of synechoxanthin dimethyl ester 2.16 as a red solid (32.6 mg, 53%) 
and byproduct 2.40 (13.1 mg, 21%). Due to difficulty in separating 2.40 from 2.16, the semi-
purified mixture was carried forward to the deprotection step. 
 
 
 
TLC (hexanes:EtOAc 4:1) 
 Rf = 0.57, visualized by visible light (orange) 
 
Me Me
Me Me
Me
Me
Me
Me
OMe
MeO
O
O synechoxanthin methylester 2.16
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1H-NMR (500 MHz, CD2Cl2) 
 ! 7.57 (d, J = 8.5 Hz, 2H), 7.40 (d, J =8.5 Hz, 2H), 6.89 (d, J = 16.0 Hz, 2H), 6.83 (d, J 
= 16.0 Hz, 2H), 6.73-6.69 (m, 4H), 6.47 (d, J =15.0 Hz, 2H), 6.39 (d, J =11.5 Hz, 2H), 
6.33 (d, J =10.0 Hz, 2H), 3.86 (s, 6H) 2.47 (s, 6H), 2.34 (s, 6H), 2.09 (s, 6H), 2.01 (s, 
6H). 
 
13C-NMR (125 MHz, CD2Cl2) 
169.3, 140.5, 139.0, 138.2, 137.2, 137.2, 136.2, 135.8, 134.3, 133.6, 130.8, 130.1, 127.6,  
125.7, 125.4, 122.9, 52.2, 17.4, 15.9, 13.1, 12.9 
 
HRMS (ESI+) 
 Calculated for C42H49O4:  617.3631 
 Found:    617.3625 
 
IR (thin film, cm-1) 
3280, 3174, 3066, 2960, 2237, 1643 (broad), 1413 
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13C NMR data for synechoxanthin dimethyl ester !C/ppm 
Natural synechoxanthin 
dimethyl ester 2.16 (literature 
reference, 600 MHz, CD2Cl2)9 
Synthetic synechoxanthin 
dimethyl ester 2.16 
(500 MHz, CD2Cl2) 
169.3 169.3 
140.7 140.5 
139.2 139.0 
138.2 138.2 
137.2 137.2 
137.2 137.2 
136.4 136.2 
135.7 135.8 
134.3 134.3 
133.7 133.6 
130.9 130.8 
130.1 130.1 
127.6 127.6 
125.7 125.7 
125.4 125.4 
123.0 122.9 
52.2 52.2 
17.5 17.4 
16.0 15.9 
13.2 13.1 
13.1 12.9 
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1H NMR data for synechoxanthin dimethyl ester !H/ppm 
Natural synechoxanthin dimethyl 
ester 2.16 (literature reference,9  
600 MHz, CD2Cl2) 
Synthetic synechoxanthin 
dimethylester 2.16 
(500 MHz, CD2Cl2) 
7.57 7.57 
7.40 7.40 
6.89 6.89 
6.83 6.83 
6.73 6.73-6.69 
6.69 6.73-6.69 
6.47 6.47 
6.39 6.39 
6.33 6.33 
3.86 3.86 
2.47 2.47 
2.33 2.34 
2.08 2.09 
2.01 2.01 
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Synechoxanthin (2.6). In a glovebox, to a 20 mL vial charged with a mixture of synechoxanthin 
dimethyl ester 2.16 and octaene 2.40 (45.7 mg, 0.073 mmol, 1.0 equiv.) was added KOSiMe3 (43 
mg, 1.46 mmol, 20 equiv.) and THF (7.3 mL, 0.01 M). The vial was sealed with a PTFE-lined 
cap and removed from the glove box. The vial was placed in a 65 oC aluminum heat block and 
maintained at that temperature with stirring for 1 h. The reaction mixture was cooled to 23 oC 
and concentrated in vacuo to afford a bright red solid. The crude material was filtered through a 
small pad of celite with MeOH and DMSO and purified by preparatory HPLC (70% MeOH in 25 
mM NH4OAc buffer ! 95% MeOH in 25 mM NH4OAc buffer) to afford 2.41 as a bright red 
solid (7.6 mg, 14% over 2 steps) and synechoxanthin (2.6) as a bright red solid (16.6 mg, 53%, 
28% over steps). 
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TLC (hexanes:EtOAc:AcOH 4:1:0.5) 
 Rf = 0.43, visualized by visible light (orange) 
 
HPLC 
 tR = 10.2 min; flow rate = 25 mL/min, gradient of 70% ! 95% MeOH in 25 mM  
NH4OAc buffer over 10 min followed by 95% MeOH in 25 mM NH4OAc buffer over 10 
min. Detect at  "= 478 nm. 
 
1H-NMR (500 MHz, CD3OD:DMSO-d6, 1:1) 
 # 7.37 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 7.5 Hz, 2H), 6.91 (d, J = 16.0 Hz, 2H), 6.84 (d, J 
= 16.0 Hz, 2H), 6.78-6.73 (m, 4H), 6.49 (d, J = 15.0 Hz, 2H), 6.49 (d, J = 11.5 Hz, 2H), 
6.39 (d, J = 8.0 Hz, 2H), 2.37 (s, 6H), 2.30 (s, 6H), 2.07 (s, 6H), 2.00 (s, 6H). The proton 
signal for the carboxylic acid (2H) was not observed. 
 
13C-NMR (150 MHz, DMSO-d6) 
 # 16.9, 15.3, 12.7, 12.5 (partial assignment due to low solubility of 1 in DMSO) 
 
HRMS (ESI+) 
 Calculated for C40H44O4Na:  611.3137 
 Found:    611.3130 
 
IR (thin film, cm-1) 
3461, 3419, 3365, 3234, 3089, 2919, 2360, 2132, 1751, 1644, 1047, 1025, 991. 
 
 
 
TLC (hexanes:EtOAc:AcOH 4:1:0.5) 
 Rf = 0.43, visualized by visible light (orange) 
Me Me
Me Me
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HPLC 
 tR = 9.4 min; flow rate = 25 mL/min, gradient of 70% ! 95% MeOH in 25 mM  
NH4OAc buffer over 10 min followed by 95% MeOH in 25 mM NH4OAc buffer over 10 
min. Detect at  "= 478 nm. 
 
1H-NMR (500 MHz, CD3OD: DMSO-d6, 1:1) 
 # 7.37 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 6.91 (d, J = 15.5 Hz, 2H), 6.85 (d, J 
= 15.5 Hz, 2H), 6.79-6.74 (m, 2H), 6.60 (s, 2H), 6.57 (d, J = 15.0 Hz, 2H), 6.43 (d, J = 
11.0 Hz, 2H), 2.38 (s, 6H), 2.29 (s, 6H), 2.07 (s, 6H), 2.01 (s, 6H). The proton signal for 
the carboxylic acid (2H) was not observed. 
 
HRMS (ESI+) 
 Calculated for C38H42O4Na:  585.2981 
 Found:    585.2979 
 
 
In order to verify the structure of byproduct SI-9, SI-10 was subjected to methylation: 
 
 
 
Octaene 2.40. A 1.5-mL vial was charged with 2.41 (3 mg, 0.005 mmol, 1.0 equiv.) and flushed 
with N2. MeOH:DCM (1:1. 0.5 mL) was added and the reaction vial was cooled to 0 oC. TMS-
diazomethane (2.0 M in ether, 0.2 mL) was added dropwise and stirred at 0 oC for 30 min. The 
reaction was warmed to 23 oC for 1 h. The reaction was quenched by the addition of a few drops 
of acetic acid and the mixture was concentrated in vacuo to afford a bright red solid. The crude 
material was dissolved in dichloromethane and filtered through a plug of Celite and silica gel and 
concentrated in vacuo to afford 2.40 as a bright red solid (2 mg, 64%). 
TMS-CH2N2
MeOH:DCM
Me Me
Me Me
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Me
Me
Me
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O
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TLC (hexanes:EtOAc 4:1) 
 Rf = 0.57, visualized by visible light (orange) 
 
1H-NMR (500 MHz, CD2Cl2) 
 ! 7.57 (d, J = 8.5 Hz, 2H), 7.40 (d, J =8.0 Hz, 2H), 6.89 (d, J = 16.0 Hz, 2H), 6.84 (d, J 
= 15.5 Hz, 2H), 6.74 (dd, J = 15.0 Hz, J = 11.5 Hz, 2H), 6.55 (s, 2H), 6.53 (d, J =15.0 
Hz, 2H), 6.40 (d, J =11.5 Hz, 2H), 3.86 (s, 6H) 2.47 (s, 6H), 2.33 (s, 6H), 2.09 (s, 6H), 
2.03 (s, 6H). 
 
13C-NMR (125 MHz, CD2Cl2) 
169.3, 140.6, 139.5, 138.3, 137.5, 137.2, 136.2, 135.8, 134.3, 130.1, 129.4,  
127.6, 125.7, 125.3, 122.9, 52.1, 17.4, 15.9, 13.1, 12.9 
 
HRMS (ESI+) 
 Calculated for C40H46O4Na:  613.3294 
 Found:    613.3291 
 
IR (thin film, cm-1) 
2920, 2848, 2364, 2341, 1714, 1589, 1554, 1431, 1236, 1146, 957. 
 
II. TOTAL SYNTHESIS OF RENIERAPURPURIN 
 
 
MIDA boronate 2.43. In a glovebox, to a flame-dried 20 mL vial charged with aryl iodide 2.42 
(150 mg, 0.610 mmol, 1.2 equiv.) and bisborylated diene 2.33 (177 mg, 0.508 mmol, 1.0 equiv.) 
was added PdCl2(dppf)!DCM (20.7 mg, 0.0254 mmol, 5 mol%), finely ground anhydrous K3PO4 
(647 mg, 3.05 mmol, 6.0 equiv.) and DMSO (4 mL). The vial was sealed with a PTFE-lined cap 
and removed from the glove box. The vial was stirred at 45 °C in an aluminum heat block for 24 
+
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h and was then cooled to 23 °C. The reaction was transferred to a separatory funnel, diluting with 
10 mL EtOAc. The organic layer was washed with brine:H2O (1:1, 2 x 20 mL) to remove DMSO, 
dried over MgSO4, filtered, and concentrated in vacuo to afford an orange oil. The crude material 
was adsorbed onto Celite from an acetone solution and purified by SiO2 flash chromatography 
(petroleum hexanes:EtOAc 1:1 ! EtOAc) to afford MIDA boronate 2.43 as a light orange solid 
(121 mg, 70%). 
 
TLC (EtOAc)  
 Rf = 0.57, visualized by UV and stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6)  
" 7.23 (d, J = 7.9Hz, 1H), 6.95 (d, J = 8.1, 1H), 6.90 (d, J = 15.9, 1H), 6.69 (d, J  = 15.9, 
1H), 5.51 (s, 1H), 4.22 (d,  J = 17.0, 2H), 4.06 (d, J = 16.9, 2H), 3.06 (s, 3H), 2.27 (s, 3H), 
2.24 (s, 3H), 2.17 (s, 3H), 2.07 (s, 3H). 
 
HRMS (ES+)  
 Calculated for C19H25BNO4:    342.1877 
 Found:       342.1878 
 
 
Pinacol boronic ester 2.44. To a 7 mL vial equipped with a stirbar was added MIDA boronate 
2.43 (59.6 mg, 0.175 mmol, 1.0 equiv.), pinacol (41.3 mg, 0.349 mmol, 2.0 equiv.), and solid 
NaHCO3 (73.4 mg, 0.874 mmol, 5.0 equiv.). The vial was sealed with a PTFE- lined cap, flushed 
with nitrogen, and MeOH (0.9 mL) was added via syringe to afford a cloudy light orange 
solution. The vial was stirred at 45 °C in an aluminum heat block for 3 h and was then cooled to 
23 °C. The reaction mixture was filtered through a pad of Celite, rinsing with Et2O, and the 
solution concentrated in vacuo in a 50 mL round bottom flask. To remove residual pinacol, 
finely ground CaCl2 (271 mg, 2.45 mmol, 14 equiv.), solid NaHCO3 (73.4 mg, 0.874 mmol, 5.0 
equiv.), and toluene (5.8 mL) were added to the flask containing the crude material. The 
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resulting cloudy suspension was stirred at 23 °C for 1 h and filtered through a pad of Celite, 
rinsing with Et2O, and concentrated in vacuo to afford an orange oil. The crude material was 
adsorbed onto Celite from an acetone solution and purified by SiO2 flash chromatography 
(hexanes:EtOAc 9:1) to afford aryl pinacol boronic ester 2.44 as a light orange solid (46.4 mg, 
85%). 
 
TLC (hexanes:EtOAc 9:1)  
 Rf = 0.25, visualized by UV and stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6)  
! 7.26 (d, J = 8.0Hz, 1H), 7.05 (d, J = 15.9, 1H), 6.97 (d, J = 7.8, 1H), 6.71 (d, J = 15.8,  
1H), 5.40 (s, 1H), 2.28 (s, 3H), 2.25 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 1.26 (s, 12H). 
 
 
Tetraenyl MIDA boronate 2.45. In a glovebox, to a flame-dried 20 mL vial equipped with a 
stirbar and charged with pinacol boronic ester 2.44 (322 mg, 1.03 mmol, 1.2 equiv.) and dienyl 
iodide 2.18 (300 mg, 0.860 mmol, 1.0 equiv.) was added PdCl2(dppf)!DCM (35.1 mg, 0.0430 
mmol, 5 mol%), finely ground anhydrous K3PO4 (1.10 g, 5.16 mmol, 6.0 equiv.) and DMSO (5.8 
mL). The vial was sealed with a PTFE- lined cap and removed from the glove box. The vial was 
stirred at 45 °C in an aluminum heat block for 24 h and was then cooled to 23 °C. The reaction 
was transferred to a separatory funnel, diluting with 15 mL EtOAc. The organic layer was 
washed with brine:H2O (1:1, 2 x 30 mL) to remove DMSO. The aqueous phase was extracted 
with EtOAc (1 x 15 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo to afford an orange oil. The crude material was adsorbed onto Celite from 
an acetone solution and purified by SiO2 flash chromatography (hexanes:EtOAc 1:1 " EtOAc) 
to afford tetraenyl MIDA boronate 2.45 as an orange solid (137 mg, 39%). 
 
TLC (EtOAc)  
 Rf = 0.26, visualized by UV (# = 365 nm) 
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1H-NMR (500 MHz, acetone- d6)  
! 7.27(d, J = 8.0Hz, 1H), 6.96 (d, J = 7.9Hz, 1H), 6.93 (d, J = 15.7Hz, 1H), 6.75 (d, J =  
16.1 Hz, 1H), 6.42 (d, J = 15.3 Hz, 1H), 6.32 (d, J = 11.3 Hz, 1H), 5.46 (s, 1H), 4.21 (d, J  
= 16.9 Hz, 2H), 4.04 (d, J =17.0 Hz, 2H), 3.03 (s, 3H), 2.28 (s, 3H), 2.24 (s, 3H), 2.17 (s,  
3H), 2.06 (s, 3H), 2.02 (s, 3H). 
 
HRMS (ES+) 
 Calculated for C24H31BNO4:     408.2346 
 Found:                                       408.2352 
 
 
 
Renierapurpurin (2.5). 
Preparation of stock solutions. In a glovebox, to a 7 mL vial was added XPhos and THF (4.3 
mg/mL) to afford a clear solution. To a second 7 mL vial was added Pd(OAc)2 and THF (1.1 
mg/mL) to afford a pale yellow-orange solution. To a separate 7 mL vial was added 2.10 and 
THF (21.0 mg/mL). 
 
The freshly prepared stock solutions were used in the following reaction: In a glovebox, to a 7 
mL vial equipped with stirbar and charged with tetraenyl MIDA boronate 2.45 (19.7 mg, 0.0484 
mmol, 2.2 equiv.) was added finely ground solid NaOH (12 mg, 0.307 mmol, 14.0 equiv.). The 
stock solution of 2.10 in THF (0.244 mL, containing 5.12 mg, 0.0220 mmol, 1.0 equiv.) was 
added to the reaction vial followed by the XPhos stock solution (0.244 mL, containing 1.05 mg, 
0.00220 mmol, 10 mol%) and the Pd(OAc)2 stock solution (0.244 mL, containing 0.268 mg, 
0.00110 mmol, 5 mol%). The vial was sealed with a PTFE-lined septum cap, removed from the 
glovebox, and stirred at 23 °C for 5 min. Degassed DI H2O (0.147 mL, 0.15 M) was added 
dropwise. The solution was stirred in a subdued light environment at 23 °C for 1 h. The reaction 
mixture was quenched with pH 7 phosphate buffer (10 mL) and transferred to a separatory 
Me Me
Me MeMe
Me
Me
Me
Me
Me
Pd(OAc)2
Xphos
NaOH
THF:H2O
BrI
2.10
2.45 +
renierapurpurin 2.5
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funnel with Et2O (10 mL). The layers were separated and the aqueous layer was extracted with 
Et2O (2 x 10 mL), dried over MgSO4, filtered, and concentrated in vacuo to afford a dark red 
solid. The resulting residue was adsorbed onto Celite from an acetone solution and purified by 
SiO2 chromatography (hexanes) to afford 2.5 (isolated yield not yet obtained, semi-purified yield 
containing homocoupled byproduct is ~20% in this unoptimized condition). 
 
TLC (hexanes:EtOAc 10:1)  
 Rf = 0.89, visualized by visible light (orange) 
 
1H-NMR (500 MHz, CD2Cl2) 
 ! 7.25(d, J = 8.0Hz, 1H), 6.97 (d, J = 8.5Hz, 1H), 6.89 (d, J = 15.5, 1H), 2.30 (s, 3H),  
 2.28 (s, 3H), 2.21 (s, 3H), 2.07 (s, 3H). All peaks not assigned. 
 
HRMS (ES+)  
Calculated for C40H48:      528.3756  
Found:                              528.3763 
 
III. LIPOPEROXIDATION ASSAY 
 
Materials. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:1 PC, POPC) was 
obtained as a 25 mg/mL solution in CHCl3 from Avanti Polar Lipids (catalog number 850457C), 
and 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4 PC, PUFA) was obtained 
as a 10 mg/mL solution in CHCl3 from Avanti Polar Lipids (catalog number 850469C) and were 
stored at -20 oC under an atmosphere of dry nitrogen and used within 1.5 months. Prior to 
preparing the lipid film, the solution was warmed to ambient temperature to prevent 
condensation from contaminating the solution. Astaxanthin was a generous donation from BASF. 
Synechoxanthin was synthesized as above and was HPLC purified to >95% prior to use. "-
carotene was purchased from Sigma Aldrich. 
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General Liposome Preparation 
 
Preparation of lipid films: To separate 12 x 75 mm test tubes was added 150 µL POPC solution 
and 125 µL PUFA solution via Hamilton syringe. The solvent was removed under a gentle 
stream of nitrogen and the resulting lipid film was stored under high vacuum for a minimum of 
12 h prior to use to remove any residual solvent. 
 
Preparation of LUVs: The lipid film was hydrated with 300 µL 150 mM KCl/0.5 mM HEPES 
pH 7.4 aqueous buffer (K buffer) and vortexed vigorously for 1 minute (until the film no longer 
coated the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs). The 
resulting lipid suspension was transferred into a Hamilton 1 mL gastight syringe and the syringe 
was placed in an Avanti Polar Lipids Mini-Extruder with a second collection syringe on the 
opposite side. The lipid solution was then passed through a 0.20 µm Whatman polycarbonate 
filter (supported on both sides by a 10 mm Whatman drain disk) 21 times. The resulting large 
unilamellar vesicle (LUV) suspension was collected in the syringe that did not contain the 
original suspension of MLVs to prevent the carryover of MLVs into the LUV solution. All LUV 
suspensions were added to separate clean 12 x 75 mm test tubes. 
 
Preparation of blank sample: Blank liposome samples were directly purified following extrusion. 
The LUVs were purified by gel exclusion chromatography with a Sephadex G50-150 column (1 
cm column, 1.0 g unswelled resin, resin swelled with K buffer, eluted with K buffer). The 
purified LUVs were collected in 13 x 100 mm test tubes for phosphorous analysis and dilution. 
 
Preparation of carotenoid-containing samples: Carotenoid solutions were prepared. Astaxanthin 
and !-carotene stock solutions were prepared in uninhibited THF, and stock solutions for octaene 
2.41 and synechoxanthin 2.6 were prepared in DMSO + 5% Et3N : THF solvent mixture. To a 
vortexing suspension of LUVs under a stream of dry nitrogen was dropwise added appropriate 
µL of the carotenoid stock solution.  
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Sample concentrations used are as follows: 
- Astaxanthin in THF (8.3 mM) prepared, 60 µL addition led to 8.3% incorporation.  
- !-carotene in THF (25 mM) prepared, 50 µL addition led to 6.4% incorporation.  
- Octaene 2.41 in DMSO + 5% Et3N : THF (1:1) (10 mM) prepared, 60 µL addition led to 3.2% 
incorporation.  
- Synechoxanthin 2.6 [0.783 mg dissolved in DMSO + 5% Et3N (100 uL) + THF (50 uL) + Et3N 
(3 uL)], 60 µL addition led to 3.9% incorporation.  
- Blank: 50 µL of DMSO + 5% Et3N : THF (1:1) was added as an additional control. 
 
All carotenoid-impregnated LUVs were purified by gel exclusion chromatography with a 
Sephadex G50-150 column (1 cm column, 1.0 g unswelled resin, resin swelled with K buffer, 
eluted with K buffer). Separate columns were used for astaxanthin, !-carotene, octaene, and 
synechoxanthin containing liposomes. The purified carotenoid containing LUVs were collected 
in 13 x 100 mm test tubes for phosphorous analysis and dilution. 
 
Determination of phosphorus content and liposome dilution  
 
The total phosphorous content for each liposome suspension was determined to allow dilution to 
1 mM phosphorous. Determination of total phosphorus was adapted from the report of Chen and 
coworkers.10 
 
Preparation of a standard curve: To 7 mL vials in triplicate were added the following amount of 
phosphorus standard solution (0.65 mM phosphorus as KH2PO4, Sigma Aldrich, catalog number 
P3869): 20 µL, 40 µL, 60 µL, 80 µL, 100 µL, and 120 µL. To these vials and to 3 separate vials 
containing no phosphorus to be used as blanks, was added 450 µL of 8.9 M aqueous H2SO4. The 
samples were incubated open to ambient atmosphere in a 225 °C aluminum heating block for 25 
min and then removed to 23 °C for 5 min. To each sample was added 150 µL of 30% w/v 
aqueous hydrogen peroxide and the vials were returned to the 225 °C heating block for 30 min 
after which the samples were removed to 23 °C for 5 min. To each sample was added 4.0 mL DI 
H2O. To each vial was then added 500 µL of 2.5% w/v ammonium molybdate tetrahydrate. The 
vials were capped and the resulting mixtures were vortexed briefly and vigorously. Subsequently, 
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500 µL of 10% w/v L-(+)-ascorbic acid was added to each vial. The vials were capped and the 
resulting mixtures were vortexed briefly and vigorously. The capped vials were then placed in a 
100 °C aluminum heating block for 7 min. The samples were removed to 23 °C and cooled for 
approximately 20 minutes to 23 °C prior to analysis by UV/Vis spectroscopy. Total phosphorus 
was determined by observing the absorbance at 820 nm. A standard curve was prepared by 
plotting µmol of phosphorus vs the absorbance at 820 nm. 
 
Analysis of phosphorous content in liposomes: To 7 mL vials in triplicate was added 10 µL of the 
purified LUV suspensions. Three separate vials containing no LUVs to be used as blanks were 
prepared. Total phosphorous content in each LUV suspension was analyzed as described above. 
Total phosphorus was determined by observing the absorbance at 820 nm and comparing these 
values to the standard curve. The liposome suspensions were each diluted to a phosphorous 
concentration of 1 mM. 
 
Determination of carotenoid content 
 
To HPLC vials were added 100 µL of the 1 mM liposome suspension and 200 µL of 4:1:1 
acetone : MeOH : 0.2 M BHT in EtOH. The mixtures were shaken to give clear solutions. The 
samples were analyzed by analytical HPLC (Agilent Technologies, 1200 Series) and the 
carotenoid content was determined by comparing the peak area to standard curves prepared from 
carotenoid solutions of known concentrations.  
 
HPLC method: Agilent Zorbax Eclipse XDB-C18 column, 75 µL sample injection, flow 2 
mL/min. 
 
Astaxanthin: 90 : 10, MeOH : H2O; detect at 478 nm  
!-carotene: 25 : 40 : 35, THF : MeCN : MeOH; detect at 464 nm 
Octaene 2.41: 70 : 30, MeOH : 25 mM NH4OAc: detect at 478 nm 
Synechoxanthin 2.6: 70 : 30, MeOH : 25 mM NH4OAc: detect at 478 nm 
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Copper-based lipid peroxidation assay (TBARS) 
 
To 7 mL vials in triplicate was added 2 mL of the 1 mM liposome suspensions. To each sample 
was added 20 µL of 11 mM CuCl2 in DI H2O. The vials were capped and incubated in a 37 °C 
aluminum heating block. At 1.5 h intervals (including an initial time point directly following 
CuCl2  addition), the vials were inverted to mix the suspensions and aliquots were removed from 
each sample and analyzed for TBARS. At each timepoint, a 100 µL aliquot was removed from 
each liposome assay sample to a 1.5 mL HPLC vial containing 500 µL of TBA solution (0.4% 
w/v thiobarbituric acid in 0.1 M NaOAc, pH 3.5). The vials were capped and incubated in a 
100 °C aluminum heating block for 15 min. The samples were removed to 23 °C and cooled for 
approximately 10 min to 23 °C prior to analysis by HPLC.  
 
HPLC method: Agilent Zorbax Eclipse XDB-C18 column, inject 75 µL sample, flow 2 mL/min. 
TBA/MDA adduct: 72 : 17 : 11, 50 mM KH2PO4 : MeOH : MeCN; detect at 535 nm. 
 
 
 
Figure 2-7. TBA-MDA adduct formation over time was evaluated with octaene 2.41, !-carotene and 
astaxanthin-incorporated liposomes. Each sample was run in triplicate (plotted as average ±1 standard 
deviation). Peak area of 400 " 6 x 10-3 mM TBA-MDA adduct. DMSO + 5% Et3N control had no effect 
compared to the blank liposome. 
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Control experiments 
 
Following the standard protocols for copper-based lipid peroxidation assay, formation of MDA-
TBA adduct was measured over time while incubated at 100 °C (Figure 2-8A). Following the 
standard liposome preparation and carotenoid incorporation, changes in percent incorporation of 
astaxanthin was monitored after subsequent size-exclusion columns (Figure 2-8B). In addition, 
changes in percent incorporation of the carotenoid content was assessed at two different 
temperatures, 37 oC (incubation temperature) and 3 oC (fridge temperature) over the course of 65 
h following the general carotenoid content determination protocol (Figure 2-8C).   
 
 
Figure 2-8. Control experiments for TBARS assay. A. Longer heating times increase production of MDA. 
B. The change in percent incorporation of astaxanthin in liposomes is not affected by the number of times 
the liposome is passed through a size exclusion column. C. Changes in percent incorporation of 
astaxanthin were measured at two different temperatures (37 oC and 3 oC) over the course of 3 days. 
Error bars = ±1 standard deviation, runs in duplicate. 
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CHAPTER 3 
SYNTHESIS OF SMALL MOLECULES VIA  
A COMMON AND AUTOMATED ICC PLATFORM 
 
ABSTRACT 
More than a century of advances have enabled the laboratory synthesis of many small 
molecules. However, because the strategies and reactions employed are usually customized to 
each target or class of targets, the synthesis process has remained a complex and time-intensive 
process practiced exclusively by specialists. As a collective result, synthesis is still the slow step 
in efforts to access the extraordinary functional potential that these compounds possess. Building 
on the work described in Chapter 2, this chapter describes a major step toward generalizing and 
automating the iterative cross-coupling (ICC) strategy to access a range of different small 
molecules. Specifically, this chapter describes the collaborative effort to develop a small 
molecule synthesizer. The key to establishing this automated platform for small molecule 
synthesis was the discovery that N-methyliminodiacetic acid (MIDA) boronates have general 
binary elution properties on silica gel, which permits any intermediate that contains this 
functional group motif to be automatically purified via a novel type of catch-and-release 
chromatography. This small molecule synthesizer employed cross-coupling reactions to 
iteratively assemble a variety of MIDA boronate building blocks into many different types of 
small molecules including materials, pharmaceuticals, complex natural products, and their 
derivatives. In concert with the development of the synthesizer, the ICC platform was expanded 
to include C-N and Csp3-Csp2 bond formations, dramatically increasing the chemical space of 
the small molecule targets that can be accessed using this synthesis strategy.  
Dr. Steven G. Ballmer contributed to the construction and implementation of the current 
small molecule synthesizer and conducted the majority of the automated syntheses in 
collaboration with Gregory F. Morehouse and Michael J. Schmidt. For small molecule targets 
listed in Figures 3-8 and 3-11, Dr. Steven G. Ballmer (oligothiophene 3.9, BTP2 3.78), Junqi Li 
(oligophenylene 3.14, crocacin C 3.22), and Gregory F. Morehouse (!-parinaric acid 3.26) 
contributed to the synthesis of non-commercial building blocks and performed manual 
experiments used to determine and optimize reaction conditions used for automation. Gram-scale 
synthesis of building block 3.27 was accomplished in collaboration with Matthew J. Clark. 
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Manual optimization of ratanhine library synthesis was conducted in collaboration with Junqi Li. 
Junqi Li executed the post-automation manual deprotections for the ratanhine library. Manual 
experiments for cyclic target 3.83 were performed in collaboration with Andrea M. E. Palazzolo, 
and synthesis of building block 3.101 was performed in collaboration with Jonathan W. 
Lehmann. Manual experiments for citreofuran 3.79 and indene core 3.81 were conducted by 
Junqi Li. Dr. Eric P. Gillis contributed to the design and construction of the initial synthesizer 
and early configurations of the software.  
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3-1 AUTOMATING ITERATIVE CROSS-COUPLING TOWARD A GENERAL PLATFORM 
FOR SMALL MOLECULE SYNTHESIS 
As described in Chapter 1, peptides, oligonucleotides, and oligosaccharides can now be 
synthesized using automated synthesis platforms.1 These advances have increased the efficiency 
with which these compounds can be prepared and even extended this access to non-specialists. 
Developing a similarly generalized and automated platform capable of accessing many different 
types of small molecules is challenging because of the high level of structural diversity that this 
class of compounds represents. However, these and many others small molecules are inherently 
modular and many of them can be viewed as a collection of building blocks linked by C-C or C-
heteroatom bonds. In fact, many materials, pharmaceuticals, and biological probes represent 
oligomers of aryl or heteroaryl fragments. Many natural products are inherently modular because 
they are biosynthesized via iterative assembly of common building blocks. Even many 
topologically complex macrocyclic and polycyclic natural products are biosynthetically derived 
from relatively simple and modular linear precursors that are then cyclized into the final 
framework.2 
To harness this modularity, ICC strategy was developed by Dr. Eric Gillis in 2007 to 
enable the precise iterative assembly of haloboronic acid building blocks employing N-
methyliminodiacetic acid (MIDA) as a protecting group that can reversibly attenuate the 
reactivity of a boronic acid, similar to the way a fluorenylmethoxycarbonyl (Fmoc) group 
protects an amine.3 This permits recursive C–C bond formation between a free boronic acid and 
the halide terminus of a MIDA protected haloboronic acid building block using the Suzuki-
Miyaura cross-coupling,4 an increasingly general reaction for making certain types of C–C bonds. 
Since its initial report, this ICC strategy has been applied to the manual synthesis of many 
different types of small molecules including natural products,5 natural product derivatives,6 and 
pharmaceuticals. 7  More than 160 MIDA boronate building blocks are now commercially 
available from Sigma Aldrich, extending the use of this method to a wider range of scientists.  
Even with a general strategy and commercially available building blocks in hand, the 
process of making small molecules still requires considerable amount of person time. This 
provides very little time for the researcher to explore other aspects of the small molecule 
discovery process while the synthesis is in progress. We recognized that if we wanted to 
accelerate the understanding of small molecule function, the synthesis process needed to be 
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simple and ideally, automated. Importantly, it was crucial to have a general platform capable of 
accessing a wide range of small molecules instead of a customized platform specific for each 
target. Inspired by the way peptides, oligonucleotides, and oligosaccharides can now be made in 
a fully automated fashion, we questioned whether automating the ICC strategy would provide a 
starting point to achieving a similarly general and automated platform for small molecule 
synthesis.  
 
3-2 CHALLENGES FOR AUTOMATION 
Transforming the ICC platform into a fully automated process foremost required the 
development of a general strategy for purifying synthetic intermediates. Peptides, 
oligonucleotides and oligosaccharides, all contain common functional group handles for 
attachment to a solid support (Figure 3-1A). This enables automated purification by solid-phase 
synthesis, in which excess reagents and byproducts are removed via simple filtration (Figure 3-
1B).1 In contrast, small molecules do not contain such a universal functional group handle, thus 
cannot be generally purified using solid-phase purification (Figure 3-2A).8 We noted, however, 
that all of the intermediate coupling products in an ICC-based synthesis contain a MIDA 
boronate motif (Figure 3-2B). 
 
 
Figure 3-1. A. Peptides, oligonucleotides, and oligosaccharides all contain common functional group 
handles for attachment to a solid support. B. Schematic of an automated solid-phase purification. 
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Figure 3-2. A. Small molecules do not contain a common functional group handle that is required for 
generalized purification via solid-phase synthesis. B. MIDA boronate serves as a common functional 
group handle in an ICC-based synthesis. [D] = deprotection, [C] = cross-coupling, [P] = purification. 
 
This prompted us to develop a general strategy for purifying compounds that contain this 
functional group. In this vein, we had observed ad hoc that certain MIDA boronates demonstrate 
binary elution properties on silica gel with specific pairs of eluents. We thus questioned whether 
we could identify a single pair of eluents in which all MIDA boronates would demonstrate such 
behaviour and thereby enable generalized purification via a novel type of catch-and-release 
chromatography.  
Silica gel chromatography is a standard method for purifying small molecules, but 
variable affinities of different compounds for this stationary phase typically necessitate 
optimization of a customized eluent for each purification. In stark contrast, after surveying many 
solvent combinations, we discovered that MIDA boronates of different sizes, polarities, and 
functional group content, 3.1a-3.1t, all show zero mobility on a thin layer chromatography 
(TLC) plate eluted with a mixture of 1.5% MeOH in Et2O, a polar eluent that causes rapid 
elution of most other compounds and reagents (Figure 3-3, left). In contrast, all of the same 
MIDA boronates are rapidly eluted with tetrahydrofuran (THF) (Figure 3-3, right).  
 
materials pharmaceuticals natural products
no common functional group handle
S
S
S
Me
S
Me
O
H
MeO
OH
Me
O
Me
O
O
OH
N
O
N
MeO
N
A.
B.
B(OH)2D C
crude
P
purified
PCD
X
small
molecule
MeN
O
OB
O
O
MeN
O
OB
O
O
MeN
O
OB
O
O
MeN
O
OB
O
O
X
MeN
O
OB
O
O
MeN
O
OB
O
O
 110 
 
Figure 3-3. Universal binary elution of MIDA boronates on silica gel is illustrated in a photograph of TLC 
plates spotted with a wide range of commercially available MIDA boronates, eluted with 1.5% (v/v) MeOH 
in Et2O or THF and stained with KMnO4. 
 
This universal binary elution profile enabled the development of a general and readily 
automatable catch-and-release purification system (Figure 3-4). In this approach, the MIDA 
boronate is temporarily caught on a plug of silica gel while excess reagents and byproducts are 
removed via washing with a copious volume of 1.5% (v/v) MeOH in Et2O. Thereafter, the 
MIDA boronate is cleanly and rapidly released by switching the eluent to THF. This purification 
strategy has the added advantage of permitting all of the deprotection and coupling reactions to 
be executed in solution phase, thus avoiding the substantial challenges associated with running 
heterogeneous reactions in the solid phase format.  
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Figure 3-4. The binary elution profile of MIDA boronates on silica gel enabled the development of an 
automated catch-and-release purification strategy for MIDA boronates.  
 
Further facilitating the automation of ICC, we found additional features of MIDA 
boronates that collectively enable general conditions for the deprotection and cross-coupling 
steps. In contrast to other boronic acid derivatives,9 the rates of hydrolysis of MIDA boronates 
are exceptionally similar.10 MIDA deprotections are also generally free of side reactions, and the 
water-soluble ligand can be easily separated from the resulting boronic acid. For the cross-
coupling reactions, some generality was achieved using PdXPhos as catalyst,11 anhydrous K3PO4 
as base, and THF as solvent, but these conditions still failed to provide good yields in some cases. 
We identified boronic acid decomposition, both before and during the cross-coupling reaction, as 
a major cause.10 Overcoming this limitation, we found that clean hydrolysis of bench-stable 
MIDA boronates immediately prior to a cross-coupling ensures that every reaction starts with a 
pure boronic acid. Moreover, slow addition of such freshly prepared boronic acids into reactions 
minimizes the in situ decomposition caused by heat, base, and/or catalyst in the reaction mixture. 
 
3-3 DEVELOPMENT OF A SMALL MOLECULE SYNTHESIZER  
Based on all these enabling features of MIDA boronates, a small molecule synthesizer 
was designed and constructed by Dr. Eric Gillis and Dr. Steven Ballmer (Figure 3-5).8 The 
execution of each automated synthesis simply requires the placement of pre-loaded cartridges 
onto the synthesizer and pressing “Start”. Thus, the person time required to execute the 
synthesizer is minimal.  
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Figure 3-5. A photograph of the small molecule synthesizer, which is comprised of three modules that 
promote the deprotection, cross-coupling, and purification steps required for each ICC cycle. Each 
module is a computer-controlled liquid-handling system that uses syringe pumps to transfer substrates 
through a series of reagent-containing disposable cartridges. 
 
A schematic representation of one automated ICC cycle is described in Figure 3-6. 
Specifically, the deprotection module (Figure 3-6, top) adds THF and water to a cartridge 
containing the starting MIDA boronate and solid NaOH. This system is agitated using pulses of 
argon gas at room temperature for 20 minutes. This is followed by a reaction quench with pH 6 
potassium phosphate buffer and diethyl ether and the resulting ethereal solution of the freshly 
prepared boronic acid is separated from the water-soluble MIDA ligand. The organic layer is 
dried over anhydrous MgSO4 and molecular sieves mixed with Celite. The organic solution is 
then concentrated and deoxygenated with argon sparging to remove diethyl ether and afford a 
dry, deoxygenated THF solution of freshly prepared boronic acid. 
The cross-coupling module then heats and stirs a reaction cartridge containing a coupling 
partner, PdXPhos, K3PO4, THF, and a magnetic stir bar (Figure 3-6, middle). The solution of 
boronic acid in THF is then slowly added to the cross-coupling reaction. Finally, the purification 
module (Figure 3-6, bottom) executes catch-and-release chromatography on the crude reaction 
mixture using a series of eluents (4:1 hexanes:THF ! 1.5% (v/v) MeOH in diethyl ether ! 
diethyl ether ! THF). The first three series of eluents remove non-MIDA boronate containing 
impurities including unreacted boronic acid, decomposition byproducts associated with 
protodeborylation, and catalyst components. THF is conveniently used to release the purified 
MIDA boronate, enabling transfer of the resulting concentrated solution of the purified MIDA 
boronate product directly into the deprotection module to start the next ICC cycle. 
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Figure 3-6. Schematic representations of fully automated modules for the deprotection [D], cross-
coupling [C], and purification [P] steps of ICC. 
 
Having constructed the modules for deprotection, cross-coupling, and purification, Dr. 
Steven Ballmer in collaboration with Gregory Morehouse first tested this platform to 
automatically execute one cycle of ICC with a series of commercially available aryl (3.2a-c), 
heteroaryl (3.2d-f), and vinyl MIDA boronates (3.2g-i) using the same conditions for each 
module to construct C-C bonds (Figure 3-7). The conversion at each step was quantified as well 
as yield and purity of the final MIDA boronate products. Without any modifications of any of the 
general conditions, excellent conversions of all MIDA boronates 3.2 to the corresponding 
boronic acids 3.3, and excellent conversions of bifunctional building block 3.4 to provide good 
isolated yields of the desired cross-coupling products 3.5 were observed (Figure 3-7). Most 
importantly, all of the final MIDA boronate products 3.5a-i were isolated in excellent purity as 
analyzed by 1H NMR. 
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Figure 3-7. A range of structurally diverse MIDA boronate building blocks were subjected to one fully 
automated cycle of deprotection [D], cross-coupling [C], and purification [P] using the same set of general 
conditions in each module. General condition for deprotection: MIDA boronate 3.2 (1 mmol, 3 equiv.) 
NaOH (9 equiv.), THF (0.1 M), 23 oC, 20 min. General condition for cross-coupling: MIDA boronate 3.4 (1 
equiv.), PdXPhos (5 mol%, XPhos = 2-dicyclohexylphosphino-2!,4!,6!-triisopropylbiphenyl), K3PO4 (9 
equiv.), THF (0.028 M), 55 oC, 16 h. General condition for catch-and-release purification: SiO2, 
MeOH:Et2O (1.5:98.5, 36 mL), Et2O (36 mL), THF (12 mL). % Conversions and % purity were determined 
via 1H NMR. 
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3-4 TOTAL SYNTHESIS OF A RANGE OF DIFFERENT SMALL MOLECULES VIA 
AUTOMATED ICC 
We next tested whether the synthesizer could prepare a wide range of structurally and 
functionally diverse small molecules that are composed mainly of C-C bonds in their backbones. 
We targeted milligram quantities of these small molecules, sufficient for discovery assays. Since 
small molecules are not as large as macromolecules, it was expected that most small molecules 
could be synthesized from three or four building blocks. The results summarized in Figure 3-8 
demonstrate that a single automated run of two or three ICC cycles successfully delivered each 
of the targeted compounds in milligram quantities, fulfilling the requirements of most functional 
discovery assays. The percent yields reported represent the yield of the final step starting from 1 
equiv. of the capping building block. Importantly, while at least 4 days of full time commitment 
is required to manually synthesize each of these targets from the same building blocks, loading 
the reaction cartridges and starting the synthesizer takes only 1 hour of person time. This 
difference represents 4 days that could be committed to many other aspects of the small molecule 
discovery process. 
Specifically, we first targeted a pair of materials components that are comprised of 
repeating heteroaryl or phenylene units, important structures found in solar cells and light-
emitting diodes, respectively.12 Using the same set of previously described general conditions for 
the deprotection, cross-coupling, and purification, building blocks 3.6-3.8 were readily 
assembled to generate quaterthiophene 3.9 (Figure 3-8, entry 1). In a similar fashion, building 
blocks 3.10 – 3.12 were assembled to synthesize oligophenylene 3.14 (Figure 3-8, entry 2). We 
next questioned whether the synthesizer could also prepare important pharmaceutical compounds. 
Encouragingly, phosphodiesterase inhibitor 3.18,13 a small molecule for treating asthma, was 
readily prepared from building blocks 3.15 – 3.17 under the same exact conditions used to make 
the two materials targets (Figure 3-8, entry 3).  
 116 
 
Figure 3-8. Automated synthesis of materials, pharmaceuticals, and natural products. Similar to 
automated peptide, oligonucleotide and oligosaccharide syntheses, all of the synthesizer-generated 
products were readily purified using standard chromatographic techniques, and any protecting groups (Et 
= ethyl) other than MIDA were easily removed in a separate step. Yield reflects the quantity of each small 
molecule target that was generated with a single run on the synthesizer. All % yields are based on one 
equivalent of the final halide building block.  
 
Natural products represent the most structurally complex and diverse class of small 
molecules and are thus the most challenging targets for a general and automated synthesis 
platform. Similar to the changes in reaction conditions often employed for automated synthesis 
of more complex peptides, minor modifications to the phosphine ligand, base, and/or reaction 
temperature in some cases enabled us to successfully expand the scope to include natural product 
targets representing common small molecule biosynthetic pathways (Figure 3-8, entries 4-6).  
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Hybrid polyketide/peptide crocacin C (3.22), 14  an antifungal natural product with 
potential to inhibit the mitochondrial cytochrome bc1 segment of complex III in the respiratory 
transport chain,15 was readily assembled from stereochemically complex building blocks 3.19-
3.21 (Figure 3-8, entry 4). We then synthesized fatty acid !-parinaric acid (3.26)16, a widely used 
fluorescent probe for structural and functional studies of lipid bilayer membranes.17 Assembly of 
alkenyl building blocks 3.23-3.25 afforded 3.26 with complete retention of olefin 
stereochemistry (Figure 3-8, entry 6).16  
Polyterpene all-trans-retinal (3.31) has the ability to transduce solar energy into 
mechanical energy and is a critical functional component of the light-driven proton pump found 
in bacteria and the photoreception machinery utilized by most animals.18 A modular and flexible 
automated synthesis toward this natural product will enable systematic structure-function studies 
of this natural product. Synthesis of 3.31 required manual optimization and development before 
an automated synthesis can be achieved due to the inaccessibility of building block 3.27, the 
instability of the polyenyl boronic acid intermediates, and the potential for isomerization before 
or after cross-coupling.  
First, synthesis of building block 3.27 was investigated using known reaction conditions 
starting from commercially available !-ionone to afford boronic acid 3.32 in four steps19 
followed by complexation with MIDA anhydride20 to afford the target building block (Scheme 3-
1). Through this route, 3.27 was synthesized in only 16% overall yield over 5 steps via handling 
of unstable intermediates that could not be isolated. In particular, boronic acid 3.32 is an unstable 
boronic acid and decomposes upon concentration and isolation.19 We therefore sought an 
alternate method to synthesize this building block that involved stable intermediates and fewer 
steps. Since all-trans retinal structurally represents half of !-carotene, we questioned whether 
building block 3.27 could be constructed in the same manner carotenoid intermediates were 
constructed (see Chapter 2 for details). This involved coupling sterically hindered and 
unactivated vinyl iodide 3.3321 and 3.1r, a key bisborylated building block used in the synthesis 
of synechoxanthin5b and renierapurpurin that is now commercially-available (Scheme 3-1). 
Encouragingly, this approach afforded building block 3.27 in 70% yield on gram-scale. This 
synthetic route further highlighted the potential utility of building block 3.1r as a general 
building block for polyene synthesis. Unlike boronic acid 3.32, the corresponding MIDA 
boronate 3.27 was stable to isolation and silica gel chromatography. 
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Scheme 3-1. Synthesis of building block 3.27. 
 
 
 
Scheme 3-2. Manual synthesis of all-trans retinal 3.31. 
 
With the key building block in hand, synthetic route toward 3.31 was first investigated 
manually. Conditions from the literature were translated to the first deprotection and coupling 
steps to afford tetraenyl MIDA boronate 3.34 (Scheme 3-2).16 However, the second coupling 
proved problematic under similar conditions. We discovered that unprotected version of 
aldehyde building block 3.29 was prone to isomerization and gave at best 50% yield of the target. 
This prompted us to protect this capping building block as an acetal. Cross-coupling boronic acid 
3.35 with acetal 3.29 encouragingly provided protected all-trans retinal 3.30 in 74% yield with 
>95% trans stereochemistry.22 
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3-5 AUTOMATED LIBRARY SYNTHESIS OF NATURAL PRODUCT DERIVATIVES 
The development of new medicines, biological probes, and materials with optimized 
functional properties often requires access to many structural derivatives of a specific small 
molecule. In medicinal chemistry, natural products are rich sources for identification of a drug 
lead. However, as described in Chapter 2, isolation of small molecules from natural sources is 
difficult, thus biological studies are sometimes conducted with a mixture of natural product 
isolates which makes the specific source of the activity, such as in herbal drugs, challenging to 
probe. In order to facilitate understanding and optimization of the active compounds and/or their 
modes of action, a systematic understanding of structure-activity relationships is required for 
each member of the natural product family as well as their derivatives.  
This is especially true for polyphenolpropanoid natural products23 of the medicinal plant 
Ratanhiae radix, an anti-inflammatory herb, some of which have shown promise to contribute to 
the biological activity of this plant.24 For this reason, we targeted an automated synthesis of 
natural products previously isolated from this medicinal plant with the larger goal of creating a 
library of natural product derivatives to drive understanding of their functions. Specifically, 
ratanhiaphenol III (3.36) has shown promising activity in the inhibition of protein tyrosine 
phosphate 1B (PTP1B) that is considered to be effective for combating insulin resistance and 
type II diabetes,25 and ratanhine (3.37) 26 represents the largest and most complex natural product 
isolated from this medicinal plant and intriguingly, its biological activity has not yet been tested 
(Figure 3-9). 
To accomplish this goal, we set out to realize a 20-membered library of natural product 
derivatives and questioned whether the small molecule synthesizer could execute this experiment 
without ad-hoc optimizing the deprotection, cross-coupling, and purification steps for each 
library member. Given the modularity of small molecules, we retrosynthesized natural product 
ratanhiaphenol III (3.36) and family member ratanhine (3.37) into three and four building blocks 
respectively (Figure 3-9). Guided by this retrosynthesis, we incorporated four sets of building 
blocks representing common sub-structural elements found throughout the neolignan family of 
medicinal natural products and other pharmaceutically relevant motifs to create a diverse set of 
building blocks (Figure 3-9). These building blocks include variations in oxidation states, 
methylation patterns, fluorine content, aromatic ring identity, and size. We planned to mix and 
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match these building blocks in all possible combinations for both the trimer (2 x 2 x 3 = 12 
members) and tetramer (2 x 2 x 1 x 2 = 8 members) libraries. 
 
 
Figure 3-9. Strategy for a 20-membered natural product library synthesis.  
 
Two main challenges had to be solved for this library synthesis to be efficient and 
practical. First, identification of orthogonal protecting groups were important for compatibility 
with cross-coupling and deprotection reactions in addition to achieving general conditions for a 
global deprotection. Second, a general set of cross-coupling conditions to couple a variety of 
different coupling partners was necessary to avoid ad hoc optimizations for each library target. 
Moreover, ratanhine (3.37) is a challenging target for cross-coupling due to its acid-sensitive 
functionality and relatively unstable boronic acid intermediates.3a To solve the initial challenge, 
various protecting groups were first explored in a manual fashion in collaboration with Junqi Li, 
including MOM and SEM, but these protecting groups were difficult to remove. After 
optimization, we discovered that silyl protecting groups (TIPS, TMSE, TBDPSE) were 
appropriate protecting groups that have the capacity to survive cross-coupling conditions as well 
as be readily deprotected under milder conditions.  
To solve the second challenge, we started by manually optimizing the Suzuki-Miyaura 
cross-coupling conditions for the most challenging target of the trimer library 3.48 (Scheme 3-3). 
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After optimization, employing SPhos as the ligand and K2CO3 as the base, building blocks 3.39 
and 3.41 were coupled under otherwise standard cross-coupling conditions used in Figure 3-2, 
affording MIDA boronate 3.49 in 81% yield. Deprotection of MIDA boronate 3.49 to its 
corresponding boronic acid and slow addition of this intermediate to the second cross-coupling 
reaction with capping halide 3.42 afforded the protected library member 3.50 in 89% yield. After 
some investigation, TBAF in DMPU and DMSO was identified as a potentially general 
deprotection condition for silyl protecting groups. This condition was employed by Junqi Li to 
deprotect both TIPS and TBDPSE protecting groups in one pot to afford the fully-deprotected 
trimer library member 3.48 (Scheme 3-3). 
 
 
Scheme 3-3. Cross-coupling and deprotection conditions for trimer library members. 
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3.51 was first investigated manually in the laboratory (Scheme 3-4). Encouragingly, the same 
exact reaction conditions employed to make 3.50 translated well to the synthesis of MIDA 
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compared to 3 equiv) were necessary to complete full hydrolysis of MIDA boronate 3.52. For the 
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higher catalyst loading (10 mol% vs. originally 5 mol%) and longer reaction time (24 h vs. 
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intermediate was identified as the major byproduct in this reaction. Finally, a two-step 
deprotection sequence was developed by Junqi Li to remove all three silyl protecting groups. 
With TBDPSE as the protecting group for capping building block 3.47, there was a ~1:4 ratio of 
benzoate-cleaved byproduct to 3.51. To optimize this reaction even further, we switched this 
protecting group to TMSE, which cleanly afford the fully-deprotected tetramer library member 
3.51 without formation of any benzoate-cleaved byproduct (Scheme 3-4). Moreover, it was later 
discovered that the conversion of triply protected derivative such as 3.53m can be deprotected 
using just CsF in DMSO in a one-step procedure. 
 
 
 
Scheme 3-4. Cross-coupling and deprotection conditions for tetramer library members. 
 
With general cross-coupling conditions in hand, we turned towards translating these 
conditions on the synthesizer to prepare the 20-membered library without ad hoc optimizations 
of conditions. We reasoned that both the general deprotection and purification conditions (Figure 
3-7) could be applied for this library synthesis. Encouragingly, the manual conditions translated 
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complex target ratanhine (3.37) was readily prepared via fully automated ICC of building blocks 
3.38, 3.40, 3.45, and 3.47 (Figure 3-10).  
 
 
 
Figure 3-10. Automated synthesis of a 20-membered natural product library. A. General scheme of 
the automated ICC sequence, highlighting the general cross-coupling conditions for each step. B. All 20 
targeted library members were successfully synthesized in a fully automated fashion using the same 
series of deprotection, cross-coupling, and purification conditions for each step. Unless otherwise noted, 
the quantity of material indicated below each product represents the yield from a single run on the 
synthesizer. All percent yields are based on one equivalent of the final halide building block. All protecting 
groups other than MIDA (TIPS (triisopropylsilyl), TBDPSE = tert-butylpdiphenylsilylethyl, TMSE = 
trimethylsilylethyl, or Bz (benzoyl)) were successfully removed in a separate manual step.  
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this four-component matrix of building blocks (Figure 3-10). It is worth mentioning that in 
addition to 3.36 and 3.37, library member 3.55 (CAS # 143001-80-3) is a known isolate from 
both roots of Krameria grayi and Krameria interior, a genus of plants used medicinally to fight 
eye infections and body weakness.27 If preformed independently in a manual fashion, these 20 
syntheses would have required about three months of full time commitment. In contrast, 
initiating all of the corresponding automated assembly of 3-4 building blocks required a total of 
only 20 hours of person time. 
 
3-6 EXPANDING ICC TO INCLUDE FORMATION OF CARBON-HETEROATOM BONDS 
Up to this point, all of our small molecule targets were made by using the Suzuki-
Miyaura cross-coupling reaction to form Csp2-Csp2 bonds. This reaction alone has allowed 
access to functionally and structurally diverse small molecules. However, we questioned whether 
we could expand this strategy to access chemical space that has not yet been accessed to date 
using ICC, especially in the context of this automated platform. In this vein, not all small 
molecules can be assembled via only C-C bond-formations; in fact, many pharmaceuticals 
contain C-N bonds in their backbones.28 Because many C-heteroatom bonds can also be formed 
using cross-coupling,7a we envisioned employing the same modular ICC platform to incorporate 
not only different building blocks, but also different types of bond formations. We further 
recognized that, as long as the intermediate contains a MIDA boronate in the ICC sequence, the 
same automated catch-and-release purification would be effective. Combined with the 
compatibility of MIDA boronates with many different types of reactions,14 this opened the 
possibility of expanding the coupling chemistry to access a wider range of different linkages 
including C-N bonds.  
In this vein, we targeted the automated synthesis of two pharmaceutical compounds with 
C-N linkages in their backbones. For the synthesis of anticancer B-Raf kinase inhibitor 3.74,29 
the first step involved a Buchwald-Hartwig cross coupling between pyrimidine 3.71 and 
isoquinoline 3.72. Remarkably, the same general conditions employed for the previously 
described materials and pharmaceutical targets (Figure 3-8) enabled efficient C-N bond 
formation between these building blocks. In the second step, Suzuki-Miyaura cross-coupling of 
an intermediate boronic acid with capping building block 3.73 completed the sequence to yield 
3.74 (Figure 3-11, entry 1).  
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As a second example, we questioned whether BTP 2 (3.78), an inhibitor of Ca influx in 
T-cells,30 can be prepared on this synthesizer simply by inputting different building blocks under 
appropriate reaction conditions. Synthesis of this pharmaceutical involved an amide bond 
formation and a C-N bond formation. Supporting our hypothesis, amide bond formation between 
carboxylic acid 3.75 and amine 3.76 was successful using DCC. In the second step, we took 
advantage of the fact that boronic acids are versatile functional groups that can undergo useful 
transformations other than Suzuki-Miyaura cross-coupling, such as Chan-Lam couplings31. The 
intermediate MIDA boronate formed from union of building blocks 3.75 and 3.76 was thus 
deprotected to its corresponding boronic acid under general deprotection conditions and reacted 
with heterocycle 3.77 to afford target 3.78 (Figure 3-11, entry 2). 
 
 
 
Figure 3-11. Automated synthesis of pharmaceuticals via C-N and C-C bond formations. Similar to 
automated peptide, oligonucleotide and oligosaccharide syntheses, all of the synthesizer-generated 
products were readily purified using standard chromatographic techniques. Yield reflects the quantity of 
each small molecule target that was generated with a single run on the synthesizer. All % yields are 
based on one equivalent of the final building block. Entry 1 conditions: see Figure 3-8. Entry 2 conditions: 
1st [C] = N,N’-dicyclohexylcarbodiimide (DCC), THF, RT, 4 h. 2nd [C] = pyridine, Cu(OAc)2, molecular 
sieves, THF, RT, 48 h. [D] and [P] unchanged from general conditions. 
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3-7 EXPANDING ICC TO ACCESS CYCLIC SMALL MOLECULES 
As a final test for this synthesis platform, we are currently pursuing whether the same 
automated iterative assembly of building blocks could enable access to complex macrocyclic and 
polycyclic natural products and natural product-like skeletons (Figure 3-12). At first glance, 
these targets may appear beyond reach with this approach. However, we were encouraged by the 
recognition that Nature makes many such small molecules via a common strategy in which a 
linear precursor is first prepared via an iterative building block assembly followed by 
cyclization(s) that ultimately yield the complex cyclic architecture found in the corresponding 
natural product (Scheme 3-5A).2  
 
 
Figure 3-12. Selected structures of cyclic natural products and natural product-like skeletons. 
 
For example, natural product citreofuran (3.79) can be retrosynthesized to linear 
precursor 3.85, which, in the forward direction can undergo a macrocyclization to afford the 
cyclic small molecule.32 We also recognized that both the steroid lanosterol (3.86)33 and the 
highly complex daphniphyllum alkaloid (3.88)34 could be prepared from similar linear precursors 
(3.87 and 3.89) derived from terpene-like building blocks (Scheme 3-5B). These linear 
precursors can then be retrosynthesized into building blocks that can be mapped back to the 
target molecules highlighting the fact that even in these complex cases, small molecules are 
inherently modular in their constitution.  
Furthermore, in total synthesis efforts, the time and labor-intensive requirements of linear 
precursor syntheses often represent the slow step in completion of the target molecule. 
Addressing this unmet challenge by developing a general strategy to access these motifs in a 
method that has potential for rapid derivatization can have great impact. The time relieved from 
making linear precursors can now be shifted towards designing different linear precursors, 
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developing better methods to cyclize these linear precursors, and/or understanding the functions 
of these cyclic natural products.  
 
 
Scheme 3-5. A. Retrosynthesis of cyclic small molecules to linear precursors. In the forward direction, 
linear precursors can be cyclized to form cyclic targets. B. Biosynthesis-inspired retrosynthesis of cyclic 
natural products to their corresponding linear precursors. 
 
Topologically complex small molecules are derived from linear precursors that contain 
an increased amount of saturation and flexibility capable of cyclization (Scheme 3-5B). Thus, in 
order to access these natural product frameworks through this automated synthesis platform, two 
main challenges had to be addressed: 1) synthesis of building blocks that contain increased 
abundance of saturated Csp3 carbon atoms pre-installed and 2) development of efficient methods 
to cross-couple Csp3 carbons. ICC can now be routinely used to synthesize targets with Csp2-
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or Csp3-Csp3 variants for Suzuki-Miyaura cross-coupling and it is currently an area of intense 
interest in the synthetic community.  
 To explore this potential on the synthesizer, we sought to prepare complex cyclic small 
molecules through automated assembly of corresponding MIDA boronate building blocks via 
formation of Csp3-Csp2 bonds to synthesize biosynthesis-inspired linear precursors (Figure 3-13). 
After automated preparation of linear precursors, we planned to execute manual application of 
state-of-the-art chemical methods to promote the desired stereoselective macrocyclizations or 
polycyclizations (Figure 3-13).   
 
 
Figure 3-13. Outline of the synthetic plan toward automated synthesis of linear precursors for five cyclic 
small molecules. 
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3-8 BUILDING BLOCK SYNTHESIS AND MANUAL INVESTIGATIONS OF Csp3-Csp2 
CROSS-COUPLING CONDITIONS 
Synthesis of most building blocks that contain increased number of Csp3 carbons were 
readily accessed in a few steps from commercial or known starting materials. For example, 
bifunctional building block 3.98 was synthesized in four steps starting from known homoallylic 
alcohol 3.106 (Scheme 3-6). After conversion of alcohol 3.106 to iodide 3.107,35 this unactivated 
iodide was subjected to Miyaura borylation with bispinacolatodiboron to afford pinacol boronic 
ester 3.108.36 Transesterification of 3.108 yielded the corresponding MIDA boronate 3.109,5a 
followed by iododesilyation of the dimethyl(phenyl)silyl group with hexafluoroisopropanol 
(HFIP)37 as the solvent completed the synthesis of bifunctional building block 3.98 (Scheme 3-6). 
 
 
 
Scheme 3-6. Synthesis of bifunctional building block 3.98. 
 
Several larger building blocks that also contain increased saturation such as 3.101 and 
3.103 were synthesized by joining two fragments together using Negishi cross-coupling. 
Specifically, synthesis of capping building block 3.101 for the alkaloid target was accomplished 
in seven linear steps from known phosphonoacetate 3.11138 and aldehyde 3.11039 (Scheme 3-7). 
Horner-Wadsworth-Emmons reaction of the two starting materials afforded !,"-unsaturated 
methyl ester 3.112, and this ester was reduced to alcohol 3.113 using DIBAL-H. Alcohol 3.113 
was protected as a benzoate to afford 3.70, and the TBS group was cleanly deprotected to afford 
3.114 in high yields. Next, the homoallylic alcohol was converted to the corresponding bromide 
3.115. Zn metal insertion to the C-Br bond afforded the Negishi reagent in situ, which then 
enabled a bromide-selective Csp3-Csp2 Negishi cross-coupling with vinyl bromide 3.11640 to 
afford building block 3.101 in 70% yield (Scheme 3-7). 
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Scheme 3-7. Synthesis of vinyl bromide building block 3.101. 
 
With these building blocks in hand, our focus shifted toward assembling these building 
blocks. We recognized that all of the targets shown in Figure 3-12 require at least one Csp3-
Csp2(vinyl) cross-coupling of a primary alkyl boronic acid to a vinyl halide, which is a 
challenging bond formation due to increased propensity for an alkyl boronic acid to undergo side 
reactions such as !-hydride elimination compared to its Csp2 counterparts. In addition, there are 
only a limited number of reports on Suzuki-Miyaura cross-coupling of alkyl boron reagents with 
vinyl halides compared to aryl halides in the literature.41 In constrast, Negishi cross-coupling 
with alkyl zinc reagents and vinyl halides are well precedented.42 We thus sought to investigate 
both of these cross-coupling reactions manually to decide which reaction would be most 
applicable to the current synthesizer. 
First, Suzuki-Miyaura cross-coupling between boronic acid 3.119 derived form MIDA 
boronate 3.118 and bifunctional building block 3.98 was investigated (Scheme 3-8). Silver (I) 
oxide has been shown to be effective in promoting Suzuki-Miyaura cross-coupling with primary 
alkyl boronic acids and activated boronic esters.43 Building on this precedent, several Pd sources 
and phosphine ligands were investigated in combination with Ag2O or Ag2O/K2CO3. However, 
these conditions, in addition to conditions employing other bases, showed no successful cross-
coupling, either resulting in no conversion or consumption of the starting materials toward 
MeO2C
Me
P
O
OCH2CF3
OCH2CF3
Me
CO2Me
OTBS
Me
OTBS
OH
Ph Cl
O
Me
OTBS
OBz
Me
OH
OBz
Me
Br
OBz
Br
CO2EtBr
O OTBS
Me
ZnBr
OBz
KHMDS, 18-crown-6
DMF
 -78 oC, 1 h
86%
DIBAL-H, THF
-45 oC to -15 oC
 4 h, 83%3.110
3.111
3.112 3.113
DMAP, Et3N
0 oC, 30 min
90% 3.70 3.114 3.115
HCl, EtOH
0 oC, 30 min
97%
PPh3, CBr4
MeCN
0 oC to RT, 3 h
95%
Br
Me
OBz
CO2Et
3.101
+
Zn dust, I2
DMF
80 oC, 8 h
PdCl2(PPh3)2
THF:DMF
45 oC, 6 h
70%3.116
 131 
unproductive side reactions (Scheme 3-8, entries 1-4). As a model system, commercially 
available octyl boronic acid was subjected to cross-coupling with 3.98. Product formation was 
observed employing the conditions described for entries 4-6 (Scheme 3-8), as analyzed by 1H 
NMR and high-resolution mass spectrometry. Additional control experiments showed that 
boronic acid 3.119 smoothly coupled to 4-bromoacetophenone affording the desired product 
under conditions shown for entries 5-7 (Scheme 3-8). However, switching from the aryl halide to 
the vinyl halide 3.98 resulted in >5 different MIDA boronates, product formation being minor 
(Scheme 3-8). To further understand the reactivity landscape for this reaction, we also explored a 
general cross-coupling condition for vinyl halides44 (Scheme 3-8, entry 8). However, in this 
condition, boronic acid 3.119 was recovered while vinyl halide 3.98 was fully consumed to form 
undesired byproducts. These results indicated that further development of optimal conditions are 
needed to efficiently couple these two unactivated substrates under conditions that are 
compatible with the MIDA boronate and amenable to automation.  
 
 
Scheme 3-8. Suzuki-Miyaura cross-coupling of alkyl boronic acid 3.119 to vinyl iodide 3.98. 
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complicated by the necessity to quench the excess 3.97 and other byproducts. Alternatively 
starting from 5-iodo-2-methyl-2-pentene, an alkyl halide with a lower bond dissociation energy, 
was briefly explored, but a simpler activation method showed greater promise. Specifically, Zn 
insertion into the C-Br bond of 5-bromo-2-methyl-2-pentene using Zn dust and I2 in DMF45 
formed alkyl zinc bromide 3.97 in situ, which was reacted with 3.98 (Scheme 3-9 bottom). With 
this approach, the intermediate MIDA boronate was successfully synthesized in 70% yield. The 
key to transferring this method onto the synthesizer required optimization of the solvent 
composition. With >5% DMF in THF as the reaction solvent, a biphasic mixture was observed in 
the purification module, thus disabling the catch-and-release purification to operate efficiently. 
However, with increasing the concentration of the alkyl zinc bromide to 2.5 M and decreasing 
the overall amount of DMF in the reaction to <5%, the intermediate was successfully purified 
using a simple aqueous work up and the general catch-and-release purification module.  
 
 
Scheme 3-9. Negishi cross-coupling of alkyl zinc bromide 3.97 to vinyl iodide 3.98. 
 
With the first step of the cross-coupling conditions established, manual optimization of 
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MIDA boronate 3.120 to boronic acid 3.121 and coupling 3.121 to aryl bromide 3.99 employing 
Pd[P(o-tol)3]2, an air-stable and commercially available catalyst, and a base combination of 
Ag2O/K2CO346 afforded linear precursor 3.100 in 60% yield (Scheme 3-10). The ortho-methyl 
groups of Pd[P(o-tol)3]2 are proposed to block the open coordination site of Pd, thus minimizing 
the unproductive !-hydride elimination pathway.47  This condition also afforded the Csp3-
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Employing only Ag2O as the base at higher concentration (0.3 M) resulted in less than 50% 
conversion to product. In the final cyclization step, a catalyst-controlled enantioselective cation-! 
cyclization of linear precursor 3.100 was promoted by the 1:1 complex of o,o’-dichloro-BINOL 
and SbCl5 to afford the tricyclic steroid-like skeleton 3.83 using conditions reported in the 
literature.48 
 
 
Scheme 3-10. Manual Csp3-Csp2 Suzuki-Miyaura cross-coupling of boronic acid 3.121 to aryl bromide 
3.99 affords linear precursor 3.100, which can be cyclized to form steroid-like tricyclic core 3.83. 
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the rest of the parameters constant, but all of these conditions showed no improvements on the 
ratios of product to side products. The use of K2CO3 alone led to decomposition of the starting 
materials and the use of Ag2O alone led to incomplete conversion with the presence of side 
products. The use of CsF showed complete decomposition of both starting materials, and the use 
of other bases (KF and K3PO4) resulted in no conversion of 3.101. Future work in this area 
involves exploring different Pd(0) and Pd(II) sources with P(t-Bu)2Me. 
 
 
 
Scheme 3-11. Prelimiary study on the manual Csp3-Csp2 Suzuki-Miyaura cross-coupling of boronic acid 
3.121 to vinyl bromide 3.101. 
 
After identification of a cross-coupling condition that can be translated to the synthesizer 
for automation, the following sequence could be applied for the cyclization of this linear 
precursor to its corresponding alkaloid target. Following two reductions and an oxidation to 
afford 3.124, a Heathcock-like biosynthesis-inspired cascade of intramolecular ammonium 
condensation, trans-annular Diels-Alder, and Prins-type cyclizations are expected to afford 
alkaloid core 3.82 (Scheme 3-12).50 
 
 
 
Scheme 3-12. Manual cyclization plan from linear precursor 3.102 to alkaloid core 3.82. 
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3-9 SEMI-AUTOMATED SYNTHESIS OF CYCLIC SMALL MOLECULES 
We very recently achieved the semi-automated synthesis of a natural product and several 
natural-product cores on the synthesizer applying the cross-coupling conditions mentioned above. 
Specifically, in an automated fashion, the complex macrocyclic natural product citreofuran 3.79 
was prepared by my colleagues Junqi Li and Dr. Steve Ballmer by the iterative assembly of 
building blocks 3.90-3.92 via fully automated cross-coupling of challenging Csp3 and 2-furanyl 
halide boronic acid intermediates to generate linear precursor 3.85 (Scheme 3-13). A subsequent 
substrate-controlled diasteroselective macrocyclization and benzyl ether deprotections provided 
rapid access to citreofuran as a single stereoisomer.32 Importantly, the required stereochemical 
information for this synthesis is pre-encoded in the chiral nonracemic MIDA boronate building 
block 3.90.  
 
 
 
Scheme 3-13. Semi-automated synthesis of citreofuran natural product (3.79). 
 
In a similar fashion, linear precursor 3.96 of an indene natural product derivative was 
readily prepared by Dr. Steve Ballmer in collaboration with Michael Schmidt via fully automated 
stereospecific assembly of stereo-defined building blocks 3.93-3.95 using the manually 
optimized conditions developed by Junqi Li (Scheme 3-14). Catalyst-controlled intramolecular 
Diels-Alder reaction is expected to generate the targeted tricycle in a highly stereoselective 
fashion.51 
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Scheme 3-14. Semi-automated synthesis of indene core 3.81. 
 
In a similar fashion, translating the manual experimental results, linear precursor 3.100 
was prepared via fully automated stereospecific assembly of building blocks 3.97 and 3.98 via 
Negishi cross-coupling under the conditions described in Scheme 3-10 (Scheme 3-15). In the 
second step, building block 3.99 was successfully coupled to the boronic acid derived form 
MIDA boronate 3.120 to afford 3.100 (Scheme 3-15). Polycyclization of this linear precursor is 
expected to generate the targeted tricycle in a highly stereoselective fashion.49 
 
 
 
Scheme 3-15. Semi-automated synthesis of polyterpene core 3.83. 
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3-10 SUMMARY AND CONCLUSIONS 
With the ultimate goal of accelerating the functional discoveries of small molecules, a 
small molecule synthesizer has been developed. This synthesizer is capable of making a wide 
range of small molecules: materials, pharmaceuticals, natural products, and natural product 
derivatives via fully-automated iterative assembly of MIDA boronate building blocks. In concert 
with automation of ICC, we have expanded this platform to include C-N and Csp3-Csp2 bond 
formations, thus increasing the scope and flexibility of this building block approach. Moreover, 
this platform can provide simple, rapid, and flexible access to even topologically complex cyclic 
small molecule targets by automated synthesis of their respective linear precursors. All of these 
small molecules can be prepared in the manner of 1 h of person time regardless of the number of 
building blocks required, significantly decreasing the overall time commitment of a researcher 
by several days. In the future, with thousands of potentially applicable building blocks already 
commercially available, we envision that a wide range of small molecules can be delivered on-
demand to all scientists through this automated platform, thus leading to the advancement and 
acceleration of the small molecule discovery process.  
However, we recognize that this is only the starting point. Increases in the scope of this 
automated platform and access to a larger chemical space will continue to be driven by rapidly 
expanding new methods for making and cross-coupling suitable building blocks. Specifically, 
efficient and general methods to make new types of heterocycles will contribute to adding a new 
collection of reoccurring structures in materials, pharmaceuticals, as well as natural products. In 
addition, further advances in developing efficient and general methods to couple heteroatoms to 
form C-O and C-S bonds, in addition to C-N bonds, will substantially expand the chemical space 
this platform can access. As described in Chapter 2, MIDA boronates represent protecting groups 
for not only boronic acids, but also halides. In addition, since boronic acids are versatile 
functional groups, they can be oxidized to their corresponding phenols in one-step. Therefore, 
this platform shows promise to incorporate coupling reactions with functional groups other than 
boronic acids, as long as all the intermediates contain a MIDA boronate. Lastly, the development 
of increasingly general conditions to couple Csp3-hybridized atoms will be crucial in accessing 
flexible, cyclic, and topologically complex small molecules. Harnessing these advances in 
concert with further improvements in the speed and generality of this synthesizer will ultimately 
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broaden the access of small molecules to non-specialists and accelerate the discovery of small 
molecule function. 
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CHAPTER 3 
EXPERIMENTAL SECTION 
 
Materials. Commercial reagents were purchased from Sigma-Aldrich, EMD Millipore, Fisher 
Scientific, Alfa Aesar, Frontier Scientific, Oakwood Products, or Strem and were used without 
further purification unless otherwise noted. Most of the building blocks used in these studies are 
available from Sigma-Aldrich® [3.1a (697311), 3.1b (700231), 3.1c (721573), 3.1d (710032), 
3.1e (MIDA071), 3.1f (698229), 3.1g (697494), 3.1h (698164), 3.1i (698016), 3.1j (698148), 
3.1k (704547), 3.1l (MIDA032), 3.1m (736600), 3.1n (748714), 3.1o (723711), 3.1p (738514), 
3.1q (699861), 3.1r (MIDA020), 3.1s (MIDA076), 3.1t (704873), 3.2a (730335), 3.2b (699853), 
3.2c (699160), 3.2d (708828), 3.2e (701017), 3.2f (733539), 3.2g (710024), 3.2h (703710), 3.2i 
(707252), 3.4 (698083), 3.6 (MIDA080), 3.7 (701092), 3.10 (MIDA083), 3.11 (MIDA084), 3.12 
(363774), 3.15 (723711), 3.16 (MIDA081), 3.17 (C70223), 3.72 (MIDA085), 3.19 (698032), 
3.23 (MIDA034), 3.28 (MIDA013), 3.38 (701831), 3.40 (MIDA014), 3.45 (MIDA017), 3.39 
(MIDA039), 3.41 (MIDA015), 3.76, 3.77, 3.75, 3.93 (699292)], Frontier Scientific, Inc. [3.8 
(B1644), 3.73 (B10713), 3.43 (B1851)], or Aurora Fine Chemicals LLC [3.71 (A00.242.706)]. 
 
General Experimental Procedures. Unless otherwise noted, manual building block syntheses 
were carried out in oven- or flame-dried glassware under a dry inert atmosphere. Unless 
otherwise noted: Celite™ refers to Celite™ 545 filter aid (not acid washed); Darco® refers to 
activated carbon, Darco® G-60, -100 mesh, powder; and K3PO4 and K2CO3 were both anhydrous 
and were freshly and finely ground in a 120 °C mortar and pestle. XPhos 2nd generation 
palladacycle refers to chloro(2-dicyclohexylphosphino-2!,4!,6!-triisopropyl-1,1!-biphenyl)[2-(2!-
amino-1,1!-biphenyl)]palladium(II) (741825, Sigma-Aldrich) (21). Solvents were purified via 
passage through packed columns as described by Pangborn and coworkers1 (THF, Et2O, CH3CN, 
CH2Cl2: dry neutral alumina; hexanes, benzene, toluene: dry neutral alumina and Q5 reactant; 
DMSO, DMF: activated molecular sieves. Water was deionized. Thin layer chromatography 
(TLC) was performed using the indicated eluent on E. Merck silica gel 60 F254 plates (0.25 mm). 
Compounds were visualized by exposure to a UV lamp (" = 254 and/or 366 nm) and/or a basic 
solution of KMnO4 followed by brief heating with a Varitemp® heat gun. Flash chromatography 
was performed as described by Still and coworkers2 using EM Merck silica gel 60 (230-400 
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mesh). RP-HPLC purification was performed on Agilent 1100 series HPLC system equipped 
with an Agilent Prep-C18, 10 !m, 30 x 150 mm (product number: 413910-302) column or 
Sunfire Prep-C18, 5 !m, 30 x 150 mm (product number: 186002797) with indicated eluent, flow 
rate, and wavelength.  
 
Structural Analysis. 1H NMR spectra were recorded at room temperature on one of the 
following instruments: Varian Unity 500, Varian VXR 500, or Varian Unity Inova 500NB. 
Chemical shifts (") are reported in parts per million (ppm) downfield from tetramethylsilane and 
referenced to residual protium in the NMR solvent (CDCl3, " = 7.26; (CD3)2CO, " = 2.05, center 
line; CD2Cl2, " = 5.32, center line; (CD3)2SO, " = 2.50, center line). Data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, m = 
multiplet, br = broad, app = apparent, dd = doublet of doublets, dt = doublet of triplets, dq = 
doublet of quartets), coupling constant (J) in Hertz (Hz), and integration. 13C NMR spectra were 
recorded at room temperature on one of the following instruments: Varian Unity 500 or Varian 
VXR 500. Chemical shifts (") are reported in ppm downfield from tetramethylsilane and 
referenced to carbon resonances in the NMR solvent (CDCl3, " = 77.16, center line; (CD3)2CO, " 
= 29.84, center line; CD2Cl2, " = 53.84; (CD3)2SO, " = 39.52, center line). Carbons bearing 
boron substituents were not observed due to quadrupolar relaxation. High-resolution mass 
spectra (HRMS) were performed by Furong Sun and Elizabeth Eves at the University of Illinois 
School of Chemical Sciences Mass Spectrometry Laboratory. 
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EXPERIMENTAL PROCEDURES 
 
I. DESIGN OF THE SMALL MOLECULE SYNTHESIZER3 
 
 
 
Design of the Deprotection Module  
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The deprotection module consists of two J-KEM® Scientific V6 programmable syringe pumps 
(part # SYR-1400PC). Both are fitted with a 10-mL glass/PTFE syringe (part # SPGS-10000) 
and an 8-port distribution valve (part # SPDV-8). One pump (the Primary Pump) is utilized as 
the organic liquid handling pump and the other (the Wet Pump) is used exclusively as the 
aqueous liquid handling pump. The module utilizes an additional five 8-port distribution valves 
(part # SPDV-CS8) housed in four separate quad stack KEM select distribution modules (part # 
SYR-CS4) for liquid handling. A source of dry nitrogen and dry argon are used for liquid 
handling and deoxygenation/concentration processes. Connections between valves are made with 
FEP tubing (1/16’’ OD, 0.030’’ ID).  
 
To the Deprotection Cartridge, the Primary Pump adds THF and the Wet Pump adds water. The 
reaction is then agitated with pulses of argon gas. The Wet Pump then adds aqueous potassium 
phosphate buffer (pH = 6) and the Primary Pump adds Et2O. The resulting biphasic system is 
agitated with pulses of nitrogen gas and the aqueous layer is drawn off and disposed of by the 
Wet Pump. The Wet Pump adds 50% saturated aqueous NaCl. The resulting biphasic system is 
agitated with pulses of nitrogen and the aqueous layer is drawn off and disposed of by the Wet 
Pump. The Primary Pump transfers the wet organic solution to a Predrying, and subsequently 
Drying Cartridge, containing drying agents and agitates the mixture by repeatedly 
withdrawing/injecting the solution. The Primary Pump transfers the dried organic solution to a 
Concentration/Deoxygenation Cartridge and concentrates/deoxygenates the solution with pulses 
of argon gas.   
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Design of the Cross-Coupling Module 
 
 
 
The cross-coupling module consists of one J-KEM® Scientific V6 programmable syringe pump 
(part # SYR-1400PC), the Primary Pump described above. The module utilizes one additional 8-
port distribution valve (part # SPDV-CS8) housed in one separate quad stack KEM select 
distribution module (part # SYR-CS4) for liquid handling (shared with the deprotection module). 
A source of dry nitrogen and dry argon are used for liquid handling and deoxygenation processes 
(shared with the deprotection module). Two IKA® RET control visc IKAMAG® safety control 
heating stir plates (part # 3364001) and one IKA® RCT basic IKAMAG® safety control heating 
stir plate (part # 3810001) are used for reaction stirring and temperature control. Connections 
between valves are made with FEP tubing (1/16’’ OD, 0.030’’ ID).  
 
The Reaction Cartridge, agitated with a magnetic stir bar, is deoxygenated with pulses of argon 
gas. The Primary Pump adds THF to the reaction cartridge and then slowly adds the 
dried/deoxygenated THF solution of boronic acid. After the addition, the reaction is allowed to 
agitate.  
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Design of the Purification Module 
 
 
 
The purification module consists of two J-KEM® Scientific V6 programmable syringe pumps 
(part # SYR-1400PC). One is the Primary Pump described above. The other pump (the Auxillary 
Pump) is used exclusively as the column eluent and waste handling pump. The module utilizes 
an additional six 8-port distribution valves (part # SPDV-CS8) housed in three separate quad 
stack KEM select distribution modules (part # SYR-CS4) for liquid handling. Five of these 
distribution valves are shared with the deprotection and cross-coupling modules. Two IKA® RET 
control visc IKAMAG® safety control heating stir plates (part # 3364001), shared with the cross-
coupling module, and one IKA® RCT basic IKAMAG® safety control heating stir plate (part # 
3810001) are used. Connections between valves are made with FEP tubing (1/16’’ OD, 0.030’’ 
ID).  
 
The Auxillary Pump adds hexanes to the Precipitation Cartridge, agitated with a magnetic stir 
bar. The Primary Pump adds portions of the crude reaction solution to the Precipitation Cartridge. 
The Auxillary Pump then withdraws the solvent through the Silica Gel Plug. This process is 
repeated until the Reaction Cartridge is empty. The Primary Pump then adds 1.5% MeOH in 
Et2O to the Precipitation Cartridge and then the Auxillary Pump withdraws the solvent through 
the Silica Gel Plug. The Primary Pump then adds Et2O to the Precipitation Cartridge and then the 
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Auxillary Pump withdraws the solvent through the Silica Gel Plug. The Auxillary Pump then 
adds THF to the Precipitation Cartridge and the Primary Pump removes the resulting solution 
and transfers it to the next Deprotection Cartridge.   
 
Description of the Software 
The synthesizer is controlled remotely on a Windows-based computer by a custom software 
program written in VB.NET (based on code written for the J-KEM® Scientific V6 programmable 
syringe pumps). The software program is designed to interpret instructions to the synthesizer 
written in simple custom scripting language. Pre-set series of instructions enable all of the steps 
required for a synthesis to be executed in a fully automated fashion after the operator simply 
presses “Start.”  
 
 
II. GENERAL METHOD FOR ONE AUTOMATED ICC CYCLE 
 
The following cartridges (unless otherwise noted, cartridge refers to a 12-g Luknova column 
capped with a 12-g Luknova column screw cap) were prepared: 
First Deprotection Cartridges contain solid NaOH and the starting MIDA boronate. 
Second and Third Deprotection Cartridges contain solid NaOH. 
Predrying Cartridges contain Celite™ (800 mg) and anhydrous MgSO4 (2.1 g). These solids 
are mixed thoroughly and a plastic 5-mL syringe plunger is placed on top of the mixed solids. 
This is topped with an aluminum foil cover. 
Drying Cartridges contain Celite™ (300 mg) with 4 Å molecular sieves (activated, powder, -
325 mesh) (3.6 g) layered on top. A plastic 5-mL syringe plunger is placed on top of the layered 
solids.  
Concentration/Deoxygenation Cartridges are empty.  
First Reaction Cartridges contain a PTFE-coated magnetic stir bar, coupling partner, catalyst 
and ligand, and base. For this cartridge, the factory-supplied fiber frit has been removed and a 
medium porosity glass frit installed. The cap is pierced with a 1.5-inch 18 G needle and topped 
with an empty 4-g Luknova column (capped with a 4-g Luknova column screw cap). This cap is 
tethered to another cap PTFE tubing (1/16-inch I.D., 1/8-inch O.D.). This additional cap, pierced 
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with a 1.5-inch 18 G needle, is attached to the Reaction Filtration Cartridge. The PTFE tubing is 
adjusted to place the end of the tubing approximately 5 mm above the frit of the First Reaction 
Cartridge and approximately 20 mm below the screw cap of the Reaction Filtration Cartridge. 
The luer ports of both screw caps are packed with a small ball of rolled Kimberly-Clark® 
Kimwipes™. 
Reaction Filtration Cartridges contain a PTFE-coated magnetic stir bar and a mixture of 
Celite™ (2.5 g) and Florisil® (1.25 g). This is tethered to the First Reaction Cartridge as 
described above. 
Second and Third Reaction Cartridges contain a PTFE-coated magnetic stir bar, coupling 
partner, catalyst and ligand, and base. 
Precipitation Cartridges contain a PTFE-coated magnetic stir bar, Celite™ (150 mg), and 3-
aminopropyl functionalized silica gel (250 mg). Hexanes (10 mL) is added and the cartridge is 
swirled vigorously to suspend and homogenize the mixture of solids. The stir bar and solids are 
allowed to settle over 30 seconds and the supernatant hexanes is pushed out of the cartridge with 
an overhead pressure of air. The stir bar is now embedded in the mixture of solids wet with 
hexanes. 
Silcia Gel Plugs contain silica gel, tightly packed, topped with a 4-g Luknova column frit. This 
is capped with a 4-g Luknova column screw cap, using four layers of PTFE tape on the sealing 
insert to ensure a leak-free seal. 
 
General Automated Procedure for One ICC Cycle  
 
 
 
The following set of cartridges [Predrying, Drying, Concentration/Deoxygenation, Reaction 
Filtration, Precipitation, Silica Gel Plug] were prepared. In addition, the Deprotection Cartridge 
was charged with the starting MIDA boronate 3.2 (1.0 mmol) and NaOH (3.0 mmol), and the 
NaOH
THF:H2O
23 °C, 20 min
3.2 3.3
3.4
SiO2
Et2O:MeOH;
THF
PdXPhos
K3PO4, THF
55 °C, 16 h
3.5
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D C PB(OH)2
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O
OB
O
O
MeN
O
OB
O
O
MeN
O
OB
O
O
 
 
 150 
Reaction Cartridge was equipped with a magnetic stir bar, coupling partner (0.33 mmol), XPhos 
2nd generation palladacycle (0.017 mmol), and K3PO4 (3.0 mmol). The cap was pierced with a 
1.5-inch 18 G needle and topped with an empty 4-g Luknova column with a screw cap. All 
cartridges were placed on the synthesizer and the reaction was initiated by pressing “Start” on a 
computer. The reaction was stirred at 55 °C for a total of 16 h. No human intervention was 
required throughout the completion of the synthesis and purification of the targeted product.  
 
Detailed Automated Procedure for One ICC Cycle  
 
The small molecule synthesizer executes the following steps once the operator presses “Start”. 
In the deprotection module, to a Deprotection Cartridge containing a starting MIDA boronate 3.2 
(1.0 mmol) and NaOH (3.0 mmol, 120 mg) is added 12 mL THF followed by 3 mL water. After 
20 minutes agitation at 23 °C, 3 mL aqueous potassium phosphate buffer (pH = 6) and 5 mL 
Et2O are added and the layers are separated. Then 3 mL 50% saturated aqueous NaCl are added 
and the layers are separated. The THF/Et2O solution of boronic acid is dried using a Predrying 
and Drying Cartridge. The resulting dry THF/Et2O solution is transferred to a 
Concentration/Deoxygenation Cartridge. The drying agents are washed with 6 mL THF, which is 
added to the Concentration/Deoxygenation Cartridge. The organic solution is concentrated to 10 
mL (evaporating most of the Et2O) and the drying agents are washed with an additional 6 mL 
THF, which is added to the Concentration/Deoxygenation Cartridge. The organic solution (now 
only THF) is concentrated to 9 mL.  
 
In the cross-coupling module, to a deoxygenated First Reaction Cartridge agitated and heated at 
55 °C and containing bifunctional MIDA boronate 3.4 (0.33 mmol, 104 mg), XPhos 2nd 
generation palladacycle (0.017 mmol, 13.1 mg, 5 mol%), and K3PO4 (3.0 mmol, 637 mg), is 
added 3 mL THF. The THF solution of boronic acid is added over 4 h (0.0375 mL/min). At the 
end of the addition the reaction is stirred for an additional 12 h.   
 
In the purification module, to a Reaction Filtration Cartridge is added the crude cross-coupling 
solution and to a Precipitation Cartridge/Silica Gel Plug is added 12 mL hexanes. Then 3 mL of 
the crude cross-coupling solution (filtered through the Reaction Filtration Cartridge) is added and 
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the solvent is removed. This process is performed ten times, using 3 mL THF to wash the 
Reaction Cartridge and Reaction Filtration Cartridge for each cycle. Then 12 mL 1.5% MeOH in 
Et2O are added and the solvent is removed a total of three times (36 mL total). Then 12 mL Et2O 
are added and the solvent is removed a total of three times (36 mL total). Finally, 12 mL THF are 
added and the resulting purified solution of 3.5 is added to the Second Deprotection Cartridge. In 
the event, all cartridges are connected to the synthesizer and the synthesis is initiated by pressing 
“Start”. From this point forward, no human intervention is required throughout the completion of 
the synthesis and purification of targeted product 3.5.  
 
Analysis of Conversion and Yield (Figure 3-7) 
 
In order to characterize the progress of the automated reaction sequences, the following analysis 
was performed. At the end of the deprotection quench, a 500-!L aliquot of the organic layer is 
removed manually from the First Deprotection Cartridge. The sample is concentrated, a 1H NMR 
sample is prepared and a spectrum is acquired immediately. The percent conversion for the 
deprotection step is determined via integration of the resonances corresponding to the boronic 
acid product and any remaining MIDA boronate starting material. At the end of the synthesis, the 
final THF solution of purified 3.5 is concentrated and a 1H NMR spectrum is acquired. The 
percent conversion for the cross-coupling is determined via integration of the resonances 
corresponding to the cross-coupling product 3.5 and any remaining MIDA boronate starting 
material 3.4. The purity of cross-coupling product 3.5 is determined via integration of the 
resonances corresponding to 3.5 and any impurities observed in the spectrum. 
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Representative 1H NMR analysis: 
 
 
 
 
(3'-methyl-[1,1'-biphenyl]-4-yl)boronic acid MIDA ester (3.5a). The general procedure was 
followed using 251.7 mg (1.02 mmol) aryl MIDA boronate 3.2a and 104.0 mg (0.333 mmol) 
bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 99% and the 
conversion for the cross-coupling step was 98%. The desired aryl MIDA boronate 3.5a was 
obtained as a colorless solid of >95% purity (65.3 mg, 0.202 mmol, 61% yield).  
 
TLC (20% MeCN in Et2O) 
Rf = 0.37, visualized by UV and KMnO4 stain 
 
 
3.5a
Me MeN
O
OB
O
O
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1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
! 7.64 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.48 (s, 1H), 7.45 (dd, J = 7.5, 0.5 Hz, 
1H), 7.34 (t, J = 7.5 Hz, 1H), 7.17 (dd, J = 7.5, 0.5 Hz, 1H), 4.34 (d, J = 17.5 Hz, 2H), 
4.13 (d, J = 17 Hz, 2H), 2.54 (s, 3H), 2.37 (s, 3H). 
 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
 ! 169.1, 140.7, 140.1, 138.0, 132.9, 128.7, 128.0, 127.2, 125.9, 123.7, 61.8, 47.6, 21.0. 
 
HRMS (EI+)  
Calculated for C18H18BNO4:   323.13289 
Found:     323.13253 
 
 
(4-(naphthalen-2-yl)phenyl)boronic acid MIDA ester (3.5b). The general procedure was 
followed using 284.5 mg (1.00 mmol) aryl MIDA boronate 3.2b and 104.3 mg (0.334 mmol) 
bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 99% and the 
conversion for the cross-coupling step was 99%. The desired aryl MIDA boronate 3.5b was 
obtained as an off-white solid of >90% purity (77.7 mg, 0.216 mmol, 65% yield). 
 
TLC (20% MeCN in Et2O) 
Rf = 0.28, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
! 8.23 (d, J = 1 Hz, 1H), 7.99 (d, J = 8 Hz, 2H), 7.92 (dd, J = 7.5, 1.5 Hz, 1H), 7.85 (dd, J 
= 9.0, 2 Hz, 1H), 7.82 (d, J = 8 Hz, 2H), 7.59 (d, J = 8 Hz, 2H), 7.56-7.49 (m, 2H), 4.38 
(d, J = 17 Hz, 2H), 4.16 (d, J = 17 Hz, 2H), 2.57 (s, 3H). 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
! 169.6, 140.5, 137.6, 133.5, 133.3, 132.4, 128.7, 128.4, 127.6, 126.6, 126.4, 126.3, 125.3, 
125.2, 62.0, 47.8. 
 
3.5b
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HRMS (EI+) 
Calculated for C21H18BNO4:   359.13289 
Found:      359.13333 
 
 
(3'-methoxy-[1,1'-biphenyl]-4-yl)boronic acid MIDA ester (3.5c). The general procedure was 
followed using 263.5 mg (1.00 mmol) aryl MIDA boronate 3.2c and 104.4 mg (0.335 mmol) 
bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 97% and the 
conversion for the cross-coupling step was 86%. The desired aryl MIDA boronate 3.5c was 
obtained as a colorless solid of >80% purity (69.2 mg, 0.204 mmol, 61% yield).  
 
TLC (20% MeCN in Et2O) 
Rf = 0.31, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
! 7.66 (d, J = 8 Hz, 2H), 7.52 (d, J = 7.5 Hz, 2H), 7.37 (t, J = 7.5 Hz, 1H), 7.23 (d, J =  
7.5 Hz, 1H), 7.18 (s, 1H), 6.93 (dd, J = 8, 2.5 Hz, 1H), 4.35 (d, J = 17.5 Hz, 2H), 4.13 (d,  
J = 17 Hz, 2H), 3.80 (s, 3H), 2.54 (s, 3H). 
 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
! 169.7, 160.0, 141.8, 140.7, 133.3, 130.3, 126.3, 119.2, 113.3, 112.3, 62.0, 55.3, 47.8. 
 
HRMS (EI+)  
Calculated for C18H18BNO5:   339.12780 
Found:      339.12732 
 
 
 
3.5c
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(4-(thiophen-2-yl)phenyl)boronic acid MIDA ester (3.5d). The general procedure was 
followed using 242.1 mg (1.01 mmol) aryl MIDA boronate 3.2d and 104.1 mg (0.3334 mmol) 
bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 98% and the 
conversion for the cross-coupling step was 98%. The desired aryl MIDA boronate 3.5d was 
obtained as an off-white solid of >95% purity (78.7 mg, 0.250 mmol, 75% yield).  
 
TLC (20% MeCN in Et2O) 
Rf = 0.38, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
! 7.64 (d, J = 8.5 Hz, 2H), 7.52 (m, 2H), 7.47 (d, J = 8 Hz, 2H), 7.13 (dd, J = 4.5, 4 Hz,  
1H), 4.34 (d, J = 17 Hz, 2H), 4.12 (d, J = 17 Hz, 2H), 2.53 (s, 3H). 
 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
 ! 169.7, 143.6, 134.4, 133.4, 128.8, 125.9, 124.9, 124.0, 62.0, 47.8. 
 
HRMS (EI+)  
Calculated for C15H14BNO4S:  315.07366 
Found:      315.07412 
 
 
(4-(furan-2-yl)phenyl)boronic acid MIDA ester (3.5e). The general procedure was followed 
using 225.5 mg (1.01 mmol) aryl MIDA boronate 3.5e and 104.4 mg (0.335 mmol) bifunctional 
MIDA boronate 3.4. The conversion for the deprotection step was 97% and the conversion for 
the cross-coupling step was 93%. The desired aryl MIDA boronate 3.5e was obtained as an off-
white solid of >90% purity (72.4 mg, 0.242 mmol, 72% yield).  
S
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TLC (20% MeCN in Et2O): 
Rf = 0.33, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
 ! 7.73 (d, J = 2 Hz, 1H), 7.68 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8 Hz, 2H), 6.95 (d, J = 3  
Hz, 1H), 6.58 (dd, J = 3.5, 2 Hz, 1H), 4.34 (d, J = 17 Hz, 2H), 4.12 (d, J = 17.5 Hz, 2H),  
2.51 (s, 3H). 
 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
! 169.7, 153.3, 143.2, 133.2, 131.0, 123.0, 112.4, 106.3, 62.0, 47.8. 
 
HRMS (EI+)  
Calculated for C15H14BNO5:   299.09650 
Found:      299.09715 
 
 
(4-(1-(tert-butoxycarbonyl)-1H-pyrrol-2-yl)phenyl)boronic acid MIDA ester (3.5f). The 
general procedure was followed using 325.4 mg (1.01 mmol) aryl MIDA boronate 3.2f and 104.4 
mg (0.335 mmol) bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 
99% and the conversion for the cross-coupling step was 99%. The desired aryl MIDA boronate 
3.5f was obtained as an off-white solid of >95% purity (110.9 mg, 0.278 mmol, 83% yield).  
 
TLC (20% MeCN in Et2O) 
Rf = 0.46, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5)  
! 7.43 (d, J = 8 Hz, 2H), 7.33 (dd, J = 3, 1.5 Hz, 1H), 7.30 (d, J = 8.5 Hz, 2H), 6.26 (t, J  
= 3.5 Hz, 1H), 6.23 (dd, J = 3, 1.5 Hz, 1H), 4.34 (d, J = 17 Hz, 2H), 4.13 (d, J = 17 Hz,  
2H), 2.54 (s, 3H), 1.28 (s, 9H). 
3.5f
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13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
! 169.7, 149.1, 134.7, 134.4, 132.0, 128.2, 123.0, 114.7, 111.2, 83.9, 62.1, 47.9, 27.3. 
 
HRMS (ESI+)  
Calculated for C20H24BN2O6:  399.1727 
Found:     399.1723 
 
 
(4-(1-phenylvinyl)phenyl)boronic acid MIDA ester (3.5g). The general procedure was 
followed using 261.1 mg (1.01 mmol) aryl MIDA boronate 3.2g and 105.1 mg (0.337 mmol) 
bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 98% and the 
conversion for the cross-coupling step was 95%. The desired aryl MIDA boronate 3.5g was 
obtained as a colorless solid of >90% purity (75.7 mg, 0.226 mmol, 67% yield). 
 
TLC (20% MeCN in Et2O) 
Rf = 0.36, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
! 7.44 (d, J = 8.5 Hz, 2H), 7.38-7.32 (m, 3H), 7.28 (app dd, J = 8 Hz, 4H), 5.50 (s, 1H),  
5.47 (s, 1H), 4.34 (d, J = 17 Hz, 2H), 4.12 (d, J = 17 Hz, 2H), 2.54 (s, 3H). 
 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
! 169.7, 149.4, 141.4, 140.9, 132.7, 128.6, 128.2, 128.1, 127.4, 115.0, 62.0, 47.8. 
 
HRMS (EI+)  
Calculated for C19H18BNO4:   335.13289 
Found:      335.13356 
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(E)-(4-(2-cyclohexylvinyl)phenyl)boronic acid MIDA ester (3.5h). The general procedure was 
followed using 265.9 mg (1.00 mmol) aryl MIDA boronate 3.2h and 105.6 mg (0.339 mmol) 
bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 98% and the 
conversion for the cross-coupling step was 99%. The desired aryl MIDA boronate 3.5h was 
obtained as an off-white solid of >95% purity (77.7 mg, 0.228 mmol, 67% yield).  
 
TLC (20% MeCN in Et2O) 
 Rf = 0.44, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
 ! 7.35 (s, 4H), 6.34 (d, J = 16.5 Hz, 1H), 6.25 (dd, J = 16.5, 7 Hz, 1H), 4.31 (d, J = 17  
Hz, 2H), 4.08 (d, J = 17 Hz, 2H), 2.47 (s, 3H), 2.13-2.06 (m, 1H), 1.74-1.68 (m, 4H),  
1.63-1.60 (m, 1H), 1.31-1.23 (m, 2H), 1.18-1.11 (m, 3H). 
 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
 ! 169.6, 138.1, 136.8, 132.7, 127.3, 125.4, 61.9, 47.7, 40.6, 32.6, 25.8, 25.6. 
 
HRMS (EI+)  
Calculated for C19H24BNO4:   341.17984 
Found:      341.18030 
 
 
(4-(prop-1-en-2-yl)phenyl)boronic acid MIDA ester (3.5i). The general procedure was 
followed using 199.4 mg (1.01 mmol) aryl MIDA boronate 3.2i and 104.2 mg (0.334 mmol) 
bifunctional MIDA boronate 3.4. The conversion for the deprotection step was 99% and the 
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conversion for the cross-coupling step was 98%. The desired aryl MIDA boronate 3.5i was 
obtained as a colorless solid of >90% purity (64.9 mg, 0.238 mmol, 71% yield).  
 
TLC (20% MeCN in Et2O) 
Rf = 0.36, visualized by UV and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O, 95:5) 
! 7.49 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 8 Hz, 2H), 5.45 (s, 1H), 5.10 (t, J = 1.5 Hz, 1H),  
4.33 (d, J = 17 Hz, 2H), 4.10 (d, J = 17 Hz, 2H), 2.50 (s, 3H), 2.10 (s, 3H). 
 
13C-NMR (125 MHz, DMSO-d6:D2O, 95:5) 
 ! 169.7, 142.7, 141.0, 132.7, 124.8, 112.9, 61.9, 47.8, 21.6. 
 
HRMS (EI+) 
Calculated for C14H16BNO4:   273.11724 
Found:      273.11679 
 
III. AUTOMATED SYNTHESIS OF SMALL MOLECULES VIA MULTIPLE ICC CYCLES 
 
General Automated Procedure for Multiple ICC Cycles 
The general procedure for one ICC cycle is followed with the following additions: 
 
If three building blocks are being assembled, the Second Deprotection Cartridge contains NaOH 
(1.0 mmol, 40 mg) and the Second Reaction Cartridge contains the second bifunctional MIDA 
boronate or the capping building block (0.11 mmol), XPhos 2nd generation palladacycle (0.0056 
mmol, 4.4 mg, 5 mol%), and K3PO4 (1.0 mmol, 212 mg). This cartridge is identical to a First 
Reaction Cartridge, but is not tethered to a Reaction Filtration Cartridge.  
 
If four building blocks are being assembled, the Third Deprotection Cartridge contains NaOH 
(0.33 mmol, 13.3 mg) and no Drying Cartridge is used for the third reaction. The Third Reaction 
Cartridge is a 7-mL glass vial containing a PTFE-coated magnetic stir, the capping building 
block (0.037 mmol), XPhos 2nd generation palladacycle (0.00185 mmol, 1.5 mg, 5 mol%), and 
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K3PO4 (0.33 mmol, 71 mg). The vial is sealed under argon with a septum-top screw cap. At the 
end of the synthesis, the crude reaction is purified by silica gel chromatography or preparative 
HPLC as noted. 
 
 
Oligothiophene (3.9). The general procedure was followed. Crude 3.9 as purified via silica gel 
chromatography (100% hexanes ! 20% EtOAc in hexanes) to afford 3.9 as a red/orange solid 
(7.5 mg, 0.0194 mmol, 50% yield).  
 
3.6
3.8
3.9
3.7
3.7
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TLC (20% EtOAc in hexanes) 
Rf = 0.29, visualized by longwave UV 
 
1H-NMR (500 MHz, CDCl3) 
! 9.81 (s, 1H), 7.54 (s, 1H), 7.24 (d, J = 3.5 Hz, 1H), 7.17 (m, 3H), 7.06 (d, J = 3.5 Hz, 
1H), 6.90 (d, J = 5.0 Hz, 1H), 2.48 (s, 3H), 2.43 (s, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 182.6, 141.6, 140.6, 139.7, 139.2, 136.7, 135.8, 134.8, 134.5, 134.2, 131.7, 130.7, 128.2, 
126.2, 124.8, 124.2, 123.8, 16.1, 15.7. 
 
HRMS (EI+)  
Calculated for C19H14OS4: 385.99277 
Found:    385.99217 
 
 
3.10
3.11
3.12
3.13
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Protected oligophenylene (3.13). The general procedure was followed with the following 
modifications: In the second cross-coupling reaction, the concentration was 0.03 M with respect 
to 3.12, the addition of the boronic acid was performed over 1 minute, and the coupling was run 
in a 7-mL glass vial. 3.13 was afforded as a yellow solid (44.1 mg, 0.0945 mmol, 84% yield).  
 
TLC (40% DCM in hexanes) 
Rf = 0.31, visualized by UV 
 
1H-NMR (500 MHz, CDCl3) 
! 8.06 (d, J = 8 Hz, 2H), 7.59-7.54 (m, 6H), 7.41-7.39 (m, 3H), 7.23 (d, J = 16.5 Hz, 1H),  
7.22 (d, J = 16 Hz, 1H), 7.15 (d, J = 15.5 Hz, 1H), 7.12 (d, J = 16 Hz, 1H), 4.40 (q, J = 7  
Hz, 2H), 1.42 (t, J = 7.5 Hz, 3H), 1.40 (s, 18H). 
 
13C-NMR (125 MHz, CDCl3) 
! 166.5, 151.2, 141.9, 137.8, 136.5, 136.0, 130.9, 130.2, 130.1, 129.3, 127.5, 127.4, 127.3,  
127.0, 126.4, 122.4, 121.0, 61.0, 35.0, 31.6, 14.5. 
 
HRMS (ESI+) 
Calculated for C33H39O2: 467.2950 
Found:    467.2943  
 
 
Oligophenylene (3.14). To a solution of ethyl ester 3.13 (44.1 mg, 0.0945 mmol) in MeOH/THF 
1:1 (2 mL) was added LiOH solution (18 mg, 0.752 mmol in 0.4 mL H2O) in one portion. The 
mixture was stirred vigorously at 45 °C for 3.5 h. The reaction was cooled briefly in an ice-water 
bath and 0.2 mL of 2 N HCl was added. The mixture was diluted with 5 mL H2O and extracted 
O
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with EtOAc (10 mL, then 2 ! 5 mL). The combined organic layers were washed with brine, dried 
over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by 
recrystallization from hot toluene. A second crop was obtained by precipitation from 
toluene/hexanes and combined with the first crop to afford 3.14 as a bright yellow solid (20.5 mg, 
0.047 mmol, 50% yield).  
 
1H-NMR (500 MHz, DMSO-d6) 
" 12.88 (s, 1H), 7.92 (d, J = 8 Hz, 2H), 7.70 (d, J = 8.5 Hz, 2H), 7.64 (s, 3H), 7.43 (d, J = 
1.5 Hz, 2H), 7.40 (d, J = 16.5 Hz, 1H), 7.34 (d, J = 16.5 Hz, 1H), 7.32 (d, J = 17 Hz, 1H), 
7.30 (s, 2H), 7.26 (d, J = 16.5 Hz, 1H), 1.31 (s, 18 H). 
 
13C-NMR (125 MHz, DMSO-d6) 
" 167.0, 150.5, 141.5, 137.2, 136.2, 135.7, 130.6, 129.7 (2C), 129.4, 127.2, 127.1, 126.8, 
126.4, 121.6, 120.8, 34.5, 31.2. 
 
HRMS (EI+)  
Calculated for C31H34O2: 438.25588 
Found:    438.25538 
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PDE472 (3.18). The general procedure was followed with the following modifications: In the 
second cross-coupling reaction, the concentration was 0.03 M with respect to 3.17, 1.11 mmol of 
K3PO4 were used, the addition of the boronic acid was performed over 1 minute, and the 
coupling was run in a 7-mL glass vial. 3.18 was afforded as a colorless solid (6.6 mg, 0.0218 
mmol, 20% yield).  
 
TLC (EtOAc) 
Rf = 0.30, visualized by UV 
 
HPLC 
tR = 17.5 min; flow rate = 25 mL/min, gradient: 5% ! 95% MeCN in H2O over 20 min. 
 
 
 
 
3.15
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3.18
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1H-NMR (500 MHz, acetone-d6) 
! 8.63 (br s, 2H), 8.12 (t, J = 1 Hz, 1H), 7.97 (dd, J = 9.5, 1 Hz, 1H), 7.96 (d, J = 2.5 Hz, 
1H), 7.93 (dd, J = 9, 2.5 Hz, 1H), 7.87 (dd, J = 9.5, 1.5 Hz, 1H), 7.74 (app d, J = 6 Hz, 
2H), 7.35 (d, J = 9 Hz, 1H), 3.98 (s, 3H). 
 
13C-NMR (125 MHz, DMSO-d6) 
! 157.3, 150.1, 149.3, 148.1, 146.1, 142.2, 135.8, 129.8, 129.1, 129.0, 128.2, 120.9, 114.9 
(2C), 112.7, 56.1. 
 
HRMS (ESI+) 
Calculated for C18H14N3O2:  304.1086 
Found:     304.1081 
 
 
(+)-Crocacin C (3.22). The general procedure was followed with the following modifications: In 
the first cross-coupling reaction, P(o-tol)3 was used as the ligand and K2CO3 and Ag2O were 
3.19
3.20
3.21
3.22
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used as the base and the reaction was run for 8 hours. Both deprotection reactions were run for 
10 minutes. The second cross-coupling reaction was run for 18 hours in a 7-mL glass vial. Crude 
3.22 was purified via silica gel chromatography (40% EtOAc in hexanes to 50% EtOAc in 
hexanes) to afford 3.22 as an off-white solid (14.5 mg, 0.0406 mmol, 61% yield).  
 
TLC (20% EtOAc in hexanes) 
Rf = 0.08, visualized by UV 
 
1H-NMR (500 MHz, CDCl3) 
! 7.39 (d, J = 7.5 Hz, 2H), 7.32 (t, J = 7 Hz, 2H), 7.23 (t, J = 7 Hz, 1H), 6.56 (d, J = 16.5 
Hz, 1H), 6.17-6.01 (m, 3H), 5.63 (s, 1H), 5.38 (br s, 2H), 4.08 (dd, J = 7.5, 1 Hz, 1H), 
3.54 (s, 3H), 3.32 (s, 3H), 3.19 (dd, J = 10, 2 Hz, 1H), 2.56-2.53 (m, 1H), 2.25 (d, J = 1 
Hz, 3H), 1.56-1.52 (m, 1H), 1.19 (d, J = 7 Hz, 3H), 0.84 (d, J = 7 Hz, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 169.4, 149.7, 137.2, 136.8, 134.1, 132.1, 129.3, 128.7, 127.7, 126.5, 119.7, 86.5, 81.1, 
61.6, 56.6, 42.7, 40.2, 18.9, 13.9, 9.8. 
 
HRMS (ESI+)  
Calculated for C22H32NO3:  358.2382 
Found:     358.2392 
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!-parinaric acid (3.26). The general procedure was followed with the following modifications:  
The first cross-coupling reaction was run at room temperature for 24 h. The second deprotection 
reaction was run for 10 minutes, and the second cross-coupling reaction was run in a 20-mL 
glass vial at room temperature using aqueous NaOH as the base for 40 minutes. The procedure 
was also conducted under subdued light conditions to protect against isomerization of the 
polyene framework. 3.26 was afforded as a fluorescent solid (18.3 mg, 0.0662 mmol, 56% yield). 
1H NMR indicated a 10:1 mixture of the desired !-parinaric acid (3.26):9-(Z)-parinaric acid 
(arising from 10:1 E:Z mixture of starting material vinyl iodide 3.25). 
 
TLC (50% Et2O in hexanes) 
Rf = 0.13, visualized by UV 
 
HPLC 
tR = 23.7 min; flow rate = 25 mL/min, gradient of 5% " 95% MeCN in H2O over 15 
min followed by 100% MeCN for 30 min. Detected at #= 254 nm. 
3.23
3.24
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1H-NMR (500 MHz, CDCl3) 
! 6.21-6.05 (m, 6H), 5.76-5.63 (m, 2H), 2.34 (t, J = 7 Hz, 2H), 2.15-2.07 (m, 4H), 1.66-
1.60 (m, 2H), 1.43-1.26 (m, 8H), 1.01 (t, J = 7.5 Hz, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 179.2, 136.7, 135.1, 132.6, 132.6, 131.0, 131.0, 130.8, 129.8, 34.0, 33.0, 29.4, 29.2, 
29.1, 29.1, 26.0, 24.8, 13.7. 
 
HRMS (ESI+)  
Calculated for C18H29O2:  277.2168 
Found:    277.2175 
 
 
Protected all-trans-retinal (3.30). The general procedure was followed with the following 
modifications: In the first cross-coupling reaction, SPhos was used as the ligand and the reaction 
was run for 14 hours at room temperature. Both deprotection reactions were run for 10 minutes. 
 
3.27
3.28
3.29
3.30
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The second cross-coupling reaction was run in a 7-mL glass vial at 40 °C for 6 h using Cs2CO3 
as the base. The procedure was also conducted under subdued light conditions to protect against 
isomerization of the polyene framework. Crude 3.30 was purified via silica gel chromatography 
(100% hexanes to 30% EtOAc in hexanes) to afford 3.30 as a single stereoisomer and a yellow 
oil (18.2 mg, 0.0491 mmol, 74% yield).  
 
TLC (petroleum ether:ether 4:1) 
Rf = 0.86, stained by KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
! 6.66 (dd, J = 14.8, 11.2 Hz, 1H), 6.27 (d, J = 15.2 Hz, 1H), 6.19-6.08 (m, 3H), 5.54 (d, 
J = 6 Hz, 1H), 5.21 (d, J = 6.4 Hz, 1H), 3.66 (d, J = 11.2 Hz, 2H), 3.53 (d, J = 10.8 Hz, 
2H), 2.01 (t, J = 6.4 Hz, 2H), 1.95 (s, 3H), 1.91 (s, 3H), 1.70 (s, 3H), 1.62-1.59 (m, 2H), 
1.47-1.44 (m, 2H), 1.23 (s, 3H), 1.01 (s, 6H), 0.75 (s, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 139.3, 137.8, 137.6, 136.6, 135.8, 130.0, 129.3, 127.2, 127.0, 126.2, 109.8, 98.8, 39.6, 
34.2, 33.0, 30.0, 28.9, 23.0, 22.0, 21.7, 19.2, 13.4, 12.7. 
 
HRMS (ESI+) 
Calculated for C25H39O2:   371.2950 
Found:     371.2950 
 
 
All-trans-retinal (3.31). A 7-mL vial charged with 3.30 (18.2 mg, 0.049 mmol, 1.0 equiv.) was 
sealed with a PTFE-lined cap and purged with N2 and THF (1.0 mL, 0.05M) was added to afford 
a clear yellow solution. The vial was cooled to 0 °C in an ice bath for 5 minutes. Aqueous HCl 
(1M, 0.5 mL) was added dropwise to the reaction vial and the reaction mixture was allowed to 
warm to 23 °C with stirring over 30 minutes. After 30 minutes, the reaction mixture was 
3.30
Me
Me
Me Me Me H
O
O
Me
Me
Me
Me
Me Me Me H
O
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transferred to a separatory funnel containing aqueous saturated NaHCO3 (5 mL), rinsing with 
diethyl ether (10 mL) and the phases were separated. The aqueous layer was back-extracted with 
diethyl ether (5 mL) and the combined organic layers were dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo to afford a yellow-orange oil. The resulting crude material (4:1 ratio 
of all-trans retinal (3.31):13-cis-retinal) was adsorbed onto Celite™ from an acetone solution 
and purified by silica gel chromatography (32:1 hexanes:EtOAc) to afford 3.31 as an orange 
solid (8.9 mg, 0.0313 mmol, 64% yield).  
 
1H-NMR (500 MHz, CDCl3) 
! 10.11 (d, J = 8 Hz, 1H), 7.14 (dd, J = 15, 11.5 Hz, 1H), 6.37 (d, J =15 Hz, 1H), 6.34 (d, 
J = 15 Hz, 1H), 6.19 (d, J = 9.5 Hz, 1H), 6.16 (d, J = 16 Hz, 1H), 5.97 (d, J = 8.5 Hz, 1H), 
2.33 (d, J = 1 Hz, 3H), 2.04-2.02 (m, 2H), 2.03 (s, 3H), 1.72 (s, 3H), 1.63-1.60 (m, 2H), 
1.49-1.46 (m, 2H), 1.03 (s, 6H). 
 
IV. AUTOMATED SYNTHESIS OF RATANHINE LIBRARY MEMBERS 
 
General Scheme for Automated Synthesis of Trimer Library Members 
 
 
The general procedure was executed with the conditions stated above for all of the trimer library 
members. 
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Protected ratanhiaphenol III (3.36). TLC (50% DCM in hexanes): Rf = 0.51, stained by 
KMnO4; 1H-NMR (500 MHz, acetone-d6): ! 7.82 (d, J = 8.5 Hz, 1H), 7.74-7.71 (m, 4H), 7.53 (d, 
J = 1.5 Hz, 1H), 7.47-7.42 (m, 6H), 7.39 (d, J = 8.5 Hz, 1H), 7.29 (dd, J = 8.5, 1.5 Hz, 1H), 7.17 
(d, J = 1 Hz, 1H), 6.52-6.46 (m, 3H), 6.24 (dq, J = 15.5, 6.5 Hz, 1H), 4.14-4.11 (m, 2H), 3.93 (s, 
3H), 1.88-1.84 (m, 5H), 1.09 (s, 9H); 13C-NMR (125 MHz, acetone-d6): ! 161.3, 158.8, 153.8 
(2C), 136.7, 134.8, 134.0, 132.2, 131.2, 130.3, 128.7, 128.3, 124.5, 122.8, 118.7, 112.8, 111.2, 
106.6, 105.0, 100.0, 66.2, 55.9, 28.1, 18.6, 18.5, 12.6; HRMS (ESI+) calculated for C36H39O3Si 
[M+H]+ m/z 547.2668, found 547.2673.   
 
 
Library member (3.54). TLC (50% DCM in hexanes): Rf = 0.23, visualized by UV; 1H-NMR 
(500 MHz, acetone-d6): ! 7.84 (dd, J = 8, 0.5 Hz, 1H), 7.74-7.72 (m, 4H), 7.47-7.43 (m, 6H), 
7.14 (s, 1H), 7.10 (d, J = 1.5 Hz, 1H), 6.93 (d, J = 1.5 Hz, 1H), 6.50-6.45 (m, 3H), 6.24 (dq, J = 
15.5, 6.5 Hz, 1H), 4.14-4.10 (m, 2H), 4.01 (s, 3H), 3.93 (s, 3H), 1.87-1.84 (m, 5H), 1.09 (s, 9H); 
13C-NMR (125 MHz, acetone-d6): ! 161.3, 158.7, 153.7, 145.9, 143.0, 136.7, 135.0, 134.8, 132.6, 
132.5, 130.3, 128.7, 128.3, 124.6, 112.8, 111.6, 106.6, 105.2 (2C), 100.0, 66.2, 56.3, 56.0, 28.1, 
18.5 (2C) 12.6; HRMS (ESI+) calculated for C37H41O4Si [M+H]+ m/z 577.2774, found 577.2767. 
 
 
Library member (3.55). TLC (50% DCM in hexanes): Rf = 0.49, stained by KMnO4; 1H-NMR 
(500 MHz, acetone-d6): ! 7.83 (d, J = 8.5 Hz, 1H), 7.74-7.72 (m, 4H), 7.61 (d, J = 1.5 Hz, 1H), 
protected 
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7.47-7.42 (m, 7H), 7.35 (dd, J = 8.5, 2 Hz, 1H), 7.19 (d, J = 0.5 Hz, 1H), 6.77 (dt, J = 16, 1.5 Hz, 
1H), 6.51-6.47 (m, 2H), 6.35 (dt, J = 15.5, 5 Hz, 1H), 4.47 (dd, J = 4.5, 1.5 Hz, 2H), 4.14-4.11 
(m, 2H), 3.94 (s, 3H), 1.88-1.84 (m, 2H), 1.22-1.08 (m, 30H); 13C-NMR (125 MHz, acetone-
d6):! 161.4, 158.8, 154.1, 154.0, 136.7, 134.8, 133.2, 131.3, 130.3, 130.2, 128.8, 128.7, 128.3, 
123.3, 119.3, 112.8, 111.3, 106.7, 105.0, 100.0, 66.2, 64.8, 56.0, 28.1, 18.6, 18.4, 12.8, 12.6; 
HRMS (ESI+) calculated for C45H59O4Si2 [M+H]+ m/z 719.3952, found 719.3925. 
 
 
Library member (3.50). TLC (50% DCM in hexanes): Rf = 0.40, visualized by UV; 1H-NMR 
(500 MHz, acetone-d6):! 7.84 (app d, J = 9 Hz, 1H), 7.74-7.71 (m, 4H), 7.48-7.43 (m, 6H), 7.17 
(d, J = 1 Hz, 1H), 7.16 (s, 1H), 7.00 (d, J = 1.5 Hz, 1H), 6.73 (dt, J = 15.5, 1.5 Hz, 1H), 6.50 (s, 
1H), 6.50--6.48 (m, 1H), 6.36 (dt, J = 16, 4.5 Hz, 1H), 4.47 (dd, J = 5, 1.5 Hz, 2H), 4.14-4.11 (m, 
2H), 4.02 (s, 3H), 3.93 (s, 3H), 1.88-1.84 (m, 2H), 1.20-1.09 (m, 30H); 13C-NMR (125 MHz, 
acetone-d6): ! 161.3, 158.7, 153.8, 146.0, 143.2, 136.7, 143.7, 134.2, 132.7, 130.5, 130.3, 128.8, 
128.7, 128.3, 112.8, 112.3, 106.6, 105.5, 105.2, 100.0, 66.2, 64.8, 56.3, 55.9, 28.1, 18.6, 18.4, 
12.8, 12.6; HRMS (ESI+) calculated for C46H61O5Si2: [M+H]+ m/z 749.4058, found 749.4056.  
 
 
Library member (3.56). TLC (20% EtOAc in hexanes): Rf = 0.28, stained by KMnO4; 1H-NMR 
(500 MHz, acetone-d6): ! 8.37 (dd, J = 3, 0.5 Hz, 1H), 7.89 (dd, J = 8.5, 0.5 Hz, 1H), 7.63 (dd, J 
= 2 Hz, 1H), 7.50 – 7.48 (m, 2H), 7.39 (dd, J = 8.5, 2 Hz, 1H), 7.31 (d, J = 1 Hz, 1H), 6.53 (dd, J 
= 16, 1.5 Hz, 1H), 6.29 (dq, 15.5, 6.5 Hz, 1H), 3.95 (s, 3H), 1.87 (dd, J = 6.5, 1.5 Hz, 3H); 13C-
NMR (125 MHz, acetone-d6):! 157.0, 156.6, 155.2, 142.5, 139.2, 134.5, 132.0, 130.4, 125.1, 
123.7, 121.2, 120.9, 119.3, 111.9, 103.6, 56.2, 18.6; HRMS (ESI+) calculated for C17H16NO2 
[M+H]+ m/z 266.1181, found 266.1180. 
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Library member (3.57). TLC (20% EtOAc in hexanes): Rf = 0.23, stained by KMnO4; 1H-NMR 
(500 MHz, acetone-d6): ! 8.36 (dd, J = 3, 0.5 Hz, 1H), 7.89 (dd, J = 8.5, 0.5 Hz, 1H), 7.49 (dd, J 
= 8.5, 3.0 Hz, 1H), 7.28 (s, 1H), 7.19 (d, J = 1.5 Hz, 1H), 7.01 (d, J = 1.5 Hz, 1H), 6.50 (d, J = 
15.5, 1.5 Hz, 1H), 6.29 (dq, J = 16, 6.5 Hz, 1H), 4.05 (s, 3H), 3.95 (s, 3H), 1.87 (dd, J = 6.5, 1.5 
Hz, 3H); 13C-NMR (125 MHz, acetone-d6): ! 156.9, 156.6, 146.3, 144.5, 142.5, 139.2, 135.5, 
132.3, 131.8, 125.1, 121.2, 120.8, 112.0, 105.8, 103.9, 56.3, 56.2, 18.5; HRMS (ESI+) calculated 
for C18H18NO3 [M+H]+ m/z 296.1287, found 296.1282. 
 
 
Library member (3.58). Library member 3.58 was isolated as an off-white solid containing 3.58 
(5.6 mg, 19% yield) and a small amount of a byproduct and was carried on to the manual 
deprotection without further purification. TLC (20% EtOAc in hexanes): Rf = 0.33, visualized by 
UV; 1H-NMR (500 MHz, acetone-d6): ! 8.37 (dd, J = 3, 1 Hz, 1H), 7.89 (dd, J = 9, 1 Hz, 1H), 
7.71 (d, J = 1.5 Hz, 1H), 7.52 (d, J = 8.5, 1H), 7.49 (dd, J = 8.5, 3 Hz, 1H), 7.46 (dd, J = 8.5, 1H), 
7.34 (d, J = 1 Hz, 1H), 6.80 (dt, J = 15.5, 2 Hz, 1H), 6.40 (dt, J = 15.5, 5 Hz, 1H), 4.50 (dd, J = 
4.5, 2 Hz, 2H), 3.96 (s, 3H), 1.22-1.10 (m, 21H); HRMS (ESI+) calculated for C26H36NO3Si 
[M+H]+ m/z 438.2464, found 438.2468. 
 
 
Library member (3.59). TLC (20% EtOAc in hexanes): Rf = 0.26, visualized by UV; 1H-NMR 
(500 MHz, acetone-d6): ! 8.36 (dd, J= 3, 0.5 Hz, 1H), 7.90 (dd, J = 9, 0.5 Hz, 1H), 7.49 (dd, J = 
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8.5, 3 Hz, 1H), 7.30 (s, 1H), 7.26 (d, J = 1.5 Hz, 1H), 7.08 (d, J = 1.5 Hz, 1H), 6.76 (dt, J = 15.5, 
2 Hz, 1H), 6.41 (dt, J = 16, 4.5 Hz, 1H), 4.49 (dd, J = 5, 2 Hz, 2H), 4.06 (s, 3H), 3.95 (s, 3H), 
1.21-1.11 (m, 21H); 13C-NMR (125 MHz, acetone-d6):! 157.0, 156.6, 146.4, 144.7, 142.5, 139.2, 
134.8, 131.9, 130.2, 129.3, 121.2, 120.8, 112.8, 106.0, 103.9, 64.7, 56.4, 56.2, 18.4, 12.8; HRMS 
(ESI+) calculated for C27H38NO4Si [M+H]+ m/z 468.2570, found 468.2572. 
 
 
Library member (3.60). TLC (20% DCM in hexanes): Rf = 0.27, visualized by UV; 1H-NMR 
(500 MHz, acetone-d6): ! 7.94 (d, J = 9 Hz, 1H), 7.74-7.72 (m, 4H), 7.62 (d, J = 1.5 Hz, 1H), 
7.48-7.42 (m, 7H), 7.37 (dd, J = 8.5, 1.5 Hz, 1H), 7.10 (d, J = 0.5 Hz, 1H), 6.91 (dd, J = 9, 2.5 
Hz, 1H), 6.82 (quint, J = 1.5 Hz, 1H), 6.51 (dd, J = 16, 2 Hz, 1H), 6.27 (dq, J = 16, 7 Hz, 1H), 
4.17-4.14 (m, 2H), 1.90-1.87 (m, 2H), 1.86 (dd, J = 6.5, 1.5 Hz, 3H), 1.10 (s, 9H); 13C-NMR 
(125 MHz, acetone-d6): ! 160.7, 154.2, 151.7, 147.0, 136.7, 134.6, 134.5, 132.0, 130.4, 130.3, 
129.8, 128.7, 125.1, 123.8, 121.5 (JC-F = 257 Hz), 119.2, 116.8, 114.2, 111.6, 109.0, 105.7, 67.0, 
28.1, 18.6 (2C), 12.4; HRMS (ESI+) calculated for C36H36F3O3Si [M+H]+ m/z 601.2386, found 
601.2386. 
   
 
Library member (3.61). TLC (20% DCM in hexanes): Rf = 0.09, visualized by UV; 1H-NMR 
(500 MHz, acetone-d6): ! 7.94 (d, J = 9 Hz, 1H), 7.74-7.72 (m, 4H), 7.48-7.42 (m, 6H), 7.18 (d, 
J = 1.5 Hz, 1H), 7.07 (s, 1H), 7.00 (d, J = 1.5 Hz, 1H), 6.92 (dd, J = 9, 2.5 Hz, 1H), 6.81 (quint, J 
= 2 Hz, 1H), 6.48 (dd, J = 16, 2 Hz, 1H), 6.27 (dq, J = 16, 6.5 Hz, 1H), 4.17-4.14 (m, 2H), 4.03 
(s, 3H), 1.90-1.86 (m, 2H), 1.86 (dd, J = 6.5, 1.5 Hz, 3H), 1.09 (s, 9H); 13C-NMR (125 MHz, 
acetone-d6): ! 160.7, 151.5, 146.9, 146.1, 143.6, 136.7, 135.5, 134.6, 132.3, 131.9, 130.3, 129.7, 
128.7, 125.1, 121.5 (JC-F = 257 Hz), 116.8, 114.2, 111.8, 109.0, 105.9 (2C), 67.0, 56.4, 28.1, 18.6, 
18.5, 12.4; HRMS (ESI+) calculated for C37H38O4F3Si [M+H]+ m/z 631.2491, found 631.2488. 
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Library member (3.62). Library member 3.62 was isolated as a colorless oil containing 3.62 
(21.6 mg, 42% yield) and a small amount of a byproduct and was carried on to the manual 
deprotection without further purification. TLC (10% DCM in hexanes): Rf = 0.11, visualized by 
UV; 1H-NMR (500 MHz, acetone-d6): ! 7.95 (d, J = 9 Hz, 1H), 7.74-7.70 (m, 5H), 7.50-7.41 (m, 
8H), 7.13 (d, J = 0.5 Hz, 1H), 6.92 (dd, J = 9, 2.5 Hz, 1H), 6.82 (quint, J = 1.5 Hz, 1H), 6.79 (dt, 
J = 16, 1.5 Hz, 1H), 6.39 (dt, J = 16, 4.5 Hz, 1H), 4.48 (dd, J = 5, 2 Hz, 2H), 4.18-4.14 (m, 2H), 
1.90-1.87 (m, 2H), 1.21-1.08 (m, 30H); HRMS (ESI+) calculated for C45H54F3O4Si2 [M+H]+ m/z 
771.3513, found 771.3550. 
  
 
Library member (3.63). TLC (20% DCM in hexanes): Rf = 0.11, visualized by UV; 1H-NMR 
(500 MHz, acetone-d6): ! 7.95 (d, J = 8.5 Hz, 1H), 7.74-7.72 (m, 4H), 7.46-7.42 (m, 6H), 7.26 (d, 
J = 1.5 Hz, 1H), 7.09 (s, 1H), 7.06 (d, J = 1 Hz, 1H), 6.93 (dd, J = 8.5, 2.5 Hz, 1H), 6.81 (quint, J 
= 1.5 Hz, 1H), 6.79 (dt, J = 15.5, 2 Hz, 1H), 6.39 (dq, J = 16, 4.5 Hz, 1H), 4.47 (dd, J = 4.5, 1.5 
Hz, 2H), 4.17-4.14 (m, 2H), 4.04 (s, 3H), 1.90-1.86 (m, 2H), 1.20-1.09 (m, 30H); 13C-NMR (125 
MHz, acetone-d6): ! 160.7, 151.6, 146.9, 146.2, 143.8, 136.7, 134.8, 134.6, 132.0, 130.3, 130.2, 
129.8, 129.3, 128.7, 121.5 (JC-F = 257 Hz), 116.8, 114.2, 112.6, 109.0, 106.2, 106.0, 67.0, 64.7, 
56.4, 28.1, 18.5, 18.4, 12.8, 12.4; HRMS (ESI+) calculated for C46H57F3O5Si2Na [M+H]+ m/z 
825.3594, found 825.3600. 
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General Scheme for Automated Synthesis of Tetramer Library Members 
 
 
The general procedure was executed with the conditions stated above for all of the tetramer 
library members. 
 
 
Protected ratanhine (P3.37). HPLC [tR = 13.4, flow rate = 25 mL/min, gradient: 20% ! 100% 
THF:MeCN (1:4) in H2O over 50 min]. 1H-NMR (500 MHz, acetone-d6): " 7.67 (s, 1H), 7.64-
7.62 (m, 4H), 7.54 (d, J = 9 Hz, 2H), 7.50 (s, 1H), 7.45-7.43 (m, 8H), 7.25 (d, J = 2 Hz, 1H), 
7.21 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 6.95 (d, J = 1 Hz, 1H), 6.56 (dd, J = 16, 2 Hz, 
1H), 6.51-6.46 (m, 3H), 6.38 (dq, J = 15.5, 6.5 Hz, 1H), 6.35 (s, 1H), 6.26 (dq, J = 15.5, 6.5 Hz, 
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1H), 5.46 (s, 2H), 3.86-3.83 (m, 2H), 3.81 (s, 3H), 3.57-3.54 (m, 2H), 1.91 (dd, J = 6.5, 1.5 Hz, 
3H), 1.88 (dd, J = 5, 1.5 Hz, 3H), 1.20-1.17 (m, 2H), 0.99 (s, 9H), 0.89-0.86 (m, 2H), 0.02 (s, 
9H); HRMS (ESI+) calculated for C59H65O6Si2 [M+H]+ m/z 925.4320, found 925.4316. 
 
 
Library member (3.64). HPLC [25 mL/min, gradient: A = water, B = 10% THF in MeCN, 0 
min: 80% A, 20% B; 5 min: 0% A, 100% B; 50 min: 0% A, 100% B): 17.1 min; 1H-NMR (500 
MHz, acetone-d6): ! 7.71 (s, 1H), 7.68-7.61 (m, 6H), 7.60 (d, J = 2.5 Hz, 1H), 7.50 (d, J = 1.5 Hz, 
1H), 7.47-7.41 (m, 7H), 7.36 (d, J = 8.5 Hz, 1H), 7.29 (dd, J = 8.5, 1.5 Hz, 1H), 7.17-7.13 (m, 
2H), 7.10-7.06 (m, 2H), 6.95 (d, J = 1 Hz, 1H), 6.56 (dd, J = 16, 2 Hz, 1H), 6.51 (dd, J = 16, 1.5 
Hz, 1H), 6.38 (dq, J = 16, 6.5 Hz, 1H), 6.34 (s, 1H), 6.25 (dq, J = 15.5, 7 Hz, 1H), 5.50 (d, J = 
1.5 Hz, 1H), 5.49 (d, J = 2 Hz, 1H), 3.88-3.86 (m, 2H), 3.79 (s, 3H), 1.90 (dd, J = 6.5, 1.5 Hz, 
3H), 1.87 (dd, J = 6.5, 1.5 Hz, 3H), 1.27-1.23 (m, 2H), 0.99 (s, 9H); HRMS (ESI+) calculated for 
C54H53O5Si [M+H]+ m/z 809.3662, found 809.3658. 
 
 
Library member (3.65). HPLC (25 mL/min, gradient: A = water, B = 10% THF in MeCN, 0 
min: 80% A, 20% B; 5 min: 0% A, 100% B; 50 min: 0% A, 100% B): 14.3 min; TLC (70% 
DCM in hexanes): Rf = 0.5, visualized by UV; 1H-NMR (500 MHz, acetone-d6): ! 7.75 (s, 1H), 
7.68-7.63 (m, 6H), 7.59 (d, J = 2.5 Hz, 1H), 7.47-7.41 (m, 8H), 7.17-7.14 (m, 2H), 7.10-7.07 (m, 
3H), 6.93 (s, 1H), 6.55 (dd, J = 16, 1.5 Hz, 1H), 6.48 (dd, J = 16, 1.5 Hz, 1H), 6.38 (dq, J = 16, 
6.5 Hz, 1H), 6.34 (s, 1H), 6.26 (dq, J = 15.5, 6.5 Hz, 1H), 5.51 (d, J = 2 Hz, 1H), 5.50 (d, J = 2 
Hz, 1H), 4.00 (s, 3H), 3.88-3.85 (m, 2H), 3.78 (s, 3H), 1.90 (dd, J = 6.5, 1.5 Hz, 3H), 1.87 (dd, J 
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= 6.5, 1.5 Hz, 3H), 1.27-1.23 (m, 2H), 0.99 (s, 9H); HRMS (ESI+) calculated for C55H55O6Si 
[M+H]+ m/z 839.3768, found 839.3772. 
 
 
Library member (3.66). HPLC (25 mL/min, gradient: A = water, B = 10% THF in MeCN, 0 
min: 80% A, 20% B; 5 min: 0% A, 100% B; 50 min: 0% A, 100% B): 48.3 min; 1H-NMR (500 
MHz, acetone-d6): ! 7.71 (s, 1H), 7.67-7.58 (m, 7H), 7.47-7.37 (m, 10H), 7.16-7.14 (m, 2H), 
7.10-7.07 (m, 2H), 6.97 (s, 1H), 6.78 (app d, J = 16 Hz, 1H), 6.56 (dd, J = 15.5, 1.5 Hz, 1H), 
6.41-6.36 (m, 2H), 6.35 (s, 1H), 5.51 (d, J = 1.5 Hz, 1H), 5.50 (d, J = 1.5 Hz, 1H), 4.50 (dd, J = 5, 
2 Hz, 2H), 3.88-3.85 (m, 2H), 3.79 (s, 3H), 1.91 (dd, J = 6.5, 1.5 Hz, 3H), 1.29-1.07 (m, 23H), 
0.94 (s, 9H); HRMS (ESI+) calculated for C63H73O6Si2 [M+H]+ m/z 981.4946, found 981.4949. 
 
 
Library member (3.67). HPLC (25 mL/min, gradient: A = water, B = 10% THF in MeCN, 0 
min: 80% A, 20% B; 5 min: 0% A, 100% B; 50 min: 0% A, 100% B): 33.4 min; TLC (50% 
DCM in hexanes): Rf = 0.18, visualized by UV; 1H-NMR (500 MHz, acetone-d6):! 7.75 (s, 1H), 
7.69-7.62 (m, 6H), 7.60 (d, J = 2.5 Hz, 1H), 7.47-7.40 (m, 7H), 7.17-7.13 (m, 3H), 7.10-7.06 (m, 
2H), 7.00 (d, J = 1.5 Hz, 1H), 6.95 (s, 1H), 6.76 (dt, J = 15.5, 1.5 Hz, 1H), 6.56 (dd, J = 15.5, 1.5 
Hz, 1H), 6.40-6.35 (m, 2H), 6.34 (s, 1H), 5.52 (d, J = 1.5 Hz, 1H), 5.50 (d, J = 1.5 Hz, 1H), 4.49 
(dd, J = 5, 2 Hz, 2H), 4.02 (s, 3H), 3.88-3.85 (m, 2H), 3.78 (s, 3H), 1.90 (dd, J = 6.5, 2.5 Hz, 3H), 
1.29-1.23 (m, 2H), 1.23-1.08 (m, 21H), 0.99 (s, 9H); HRMS (ESI+) calculated for 
C64H74O7Si2Na [M+Na]+ m/z 1033.4871, found 1033.4895. 
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Library member (3.68). HPLC (25 mL/min, gradient: A = water, B = 20% THF in MeCN, 0 
min: 80% A, 20% B; 5 min: 0% A, 100% B; 50 min: 0% A, 100% B): 12.2 min; 1H-NMR (500 
MHz, acetone-d6): ! 7.71 (s, 1H), 7.64-7.62 (m, 4H), 7.56-7.53 (m, 2H), 7.46-7.41 (m, 8H), 7.10 
(d, J = 8 Hz, 1H), 7.08 (d, J = 1 Hz, 1H), 6.94 (d, J = 1.5 Hz, 1H), 6.93 (s, 1H), 6.56 (dd, J = 
15.5, 1.5 Hz, 1H), 6.51-6.47 (m, 3H), 6.38 (dq, J = 15.5, 6.5 Hz, 1H), 6.34 (s, 1H), 6.27 (dq, J = 
15.5, 6.5 Hz, 1H), 5.46 (s, 2H), 4.02 (s, 3H), 3.87-3.84 (m, 2H), 3.80 (s, 3H), 3.56 (app t, J = 8 
Hz, 2H), 1.90 (dd, J = 6.5, 1.5 Hz, 3H), 1.88 (dd, J = 6.5, 1.5 Hz, 3H), 1.23-1.20 (m, 2H), 0.98 (s, 
9H), 0.91-0.88 (m, 2H), 0.03 (s, 9H); HRMS (ESI+) calculated for C60H67O7Si2 [M+H]+ m/z 
955.4425, found 955.4437. 
 
 
Library member (3.69). HPLC (25 mL/min, gradient: A = water, B = 20% THF in MeCN, 0 
min: 80% A, 20% B; 5 min: 0% A, 100% B; 50 min: 0% A, 100% B): 26.8 min; 1H-NMR (500 
MHz, acetone-d6): ! 7.69 (s, 1H), 7.64-7.61 (m, 5H), 7.57 (s, 1H), 7.55 (d, J = 9 Hz, 2H), 7.46-
7.34 (m, 9H), 7.10 (d, J = 8.5 Hz, 1H), 6.97 (s, 1H), 6.80 (dt, J = 16, 1.5 Hz, 1H), 6.56 (dd, J = 
15.5, 1.5 Hz, 1H), 6.49 (d, J = 7 Hz, 2H), 6.41-6.34 (m, 3H), 5.46 (s, 2H), 4.51 (dd, J = 5, 2 Hz, 
2H), 3.90-3.85 (m, 2H), 3.81 (s, 3H), 3.58 (app t, J = 8 Hz, 2H), 1.91 (dd, J = 6.5, 1 Hz, 3H), 
1.24-1.17 (m, 5H), 1.15-1.12 (m, 18H), 0.99 (s, 9H), 0.88 (m, 2H), 0.03 (s, 9H); HRMS (ESI+) 
calculated for C68H85O7Si3 [M+H]+ m/z 1097.5603, found 1097.5591. 
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Library member (3.53). HPLC (25 mL/min, gradient: A = water, B = 20% THF in MeCN, 0 
min: 80% A, 20% B; 5 min: 0% A, 100% B; 50 min: 0% A, 100% B): 22.3 min; 1H-NMR (500 
MHz, acetone-d6): ! 7.72 (s, 1H), 7.64-7.62 (m, 5H), 7.55 (d, J = 8.5 Hz, 2H), 7.46-7.41 (m, 7H), 
7.14 (d, J = 1 Hz, 1H), 7.10 (d, J = 8 Hz, 1H), 7.00 (d, J = 1.5 Hz, 1H), 6.95 (s, 1H), 6.76 (dt, J = 
15.5, 1.5 Hz, 1H), 6.56 (dd, J = 16, 2 Hz, 1H), 6.49 (d, J = 8.5 Hz, 2H), 6.42-6.34 (m, 3H), 5.44 
(d, J = 2 Hz, 1H), 5.43 (d, J = 2 Hz, 1H), 4.50 (dd, J = 5, 2 Hz, 2H), 4.03 (s, 3H), 3.88-3.82 (m, 
2H), 3.80 (s, 3H), 3.59 (app t, J = 8 Hz, 2H), 1.91 (dd, J = 6.5, 1.5 Hz, 3H), 1.24-1.17 (m, 5H), 
1.15-1.13 (m, 18H), 0.99 (s, 9H), 0.91-0.88 (m, 2H), 0.03 (s, 9H); HRMS (ESI+) calculated for 
C69H86O8Si3Na [M+Na]+ m/z 1149.5528, found 1149.5552. 
 
V. MANUAL DEPROTECTION OF LIBRARY MEMBERS 
 
Deprotection Condition 1 
To a 7-mL vial containing the protected library member and a PTFE-coated magnetic stir bar 
was added TBAF•3H2O (2.2–15 equiv) followed by 1:1 DMSO/DMPU under ambient 
atmosphere. The vial was sealed with a Teflon-lined cap and stirred at 50 °C for 30 minutes–6 
hours. The reaction was then cooled to room temperature and diluted with a solution of 1:1 
saturated NH4Cl/H2O (1.5–2 mL). The layers were mixed and the aqueous layer was removed. 
The organic layer was washed with H2O (2 " 1.5 mL). The combined aqueous phase was 
extracted with EtOAc (3 mL). The organic phase was dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by silica gel chromatography to give the 
pure product as a white or off-white solid. 
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Ratanhiaphenol III (3.36). Deprotection condition 1 was followed to give 3.36 (7.1 mg, 50% 
yield). TLC (20% EtOAc/hexanes): Rf = 0.14, visualized by shortwave UV; 1H-NMR (500 MHz, 
acetone-d6): ! 8.77 (br s, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 8.5 
Hz, 1H), 7.29 (dd, J = 8.5, 2.0 Hz, 1H), 7.16 (d, J = 1.0 Hz, 1H), 6.64 (d, J = 2.0 Hz, 1H), 6.60 
(dd, J = 8.0, 2.0 Hz, 1H), 6.51 (d, J = 16, 1.5 Hz, 1H), 6.25 (dq, J = 15.5, 7 Hz, 1H), 3.99 (s, 3H), 
1.86 (dd, J = 7.0, 2.0 Hz, 3H); 13C-NMR (125 MHz, acetone-d6): ! 160.2, 159.2, 154.2, 153.8, 
134.0, 132.3, 131.3, 128.5, 124.5, 122.7, 118.7, 111.9, 111.2, 108.5, 104.6, 100.2, 55.9, 18.6; 
HRMS (ESI+) calculated for C18H17O3 [M+H]+ m/z 281.1178, found 281.1181.  
 
 
Deprotected 3.54. Deprotection condition 1 was followed to give deprotected 3.54 (11.7 mg, 
78% yield). TLC (30% EtOAc/hexanes): Rf = 0.3, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 8.73 (br s, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.13 (s, 1H), 7.11 (d, J = 1.0 Hz, 
1H), 6.93 (d, J = 1.0 Hz, 1H), 6.64 (d, J = 2.0 Hz, 1H), 6.60 (dd, J = 8.5, 2.0 Hz, 1H), 6.48 (dd, J 
= 16, 1.5 Hz, 1H), 6.25 (dq, J = 16, 6.5 Hz, 1H), 4.03 (s, 3H), 3.98 (s, 3H), 1.86 (dd, J = 6.5, 1.5 
Hz, 3H); 13C-NMR (125 MHz, acetone-d6): ! 160.2, 159.1, 154.0, 145.9, 142.9, 135.0, 132.7, 
132.6, 128.5, 124.6, 111.9, 111.6, 108.5, 105.1, 104.8, 100.2, 56.4, 55.9, 18.6; HRMS (ESI+) 
calculated for C19H19O4 [M+H]+ m/z 311.1283, found 311.1277. 
 
 
Deprotected 3.55. Deprotection condition 1 was followed to give deprotected 3.55 (6.0 mg, 
56% yield). TLC (50% EtOAc/hexanes): Rf = 0.27, visualized by shortwave UV; 1H-NMR (500 
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MHz, acetone-d6): ! 8.78 (br s, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.43 (d, J 
= 8.5 Hz, 1H), 7.36 (dd, J = 9.0, 2.0 Hz, 1H), 7.18 (d, J = 0.5 Hz, 1H), 6.70 (d, J = 16.0 Hz, 1H), 
6.64 (d, J = 2.5 Hz, 1H), 6.60 (dd, J = 8.5, 2.5 Hz, 1H), 6.38 (dt, J = 16, 5.5 Hz, 1H), 4.25 (t, J = 
5.5 Hz, 2H), 3.99 (s, 3H), 3.84 (t, J = 5.5 Hz, 1H); 13C-NMR (125 MHz, acetone-d6): ! 160.2, 
159.1, 154.2, 153.9, 133.3, 131.3, 130.5, 129.6, 128.5, 123.0, 119.2, 111.8, 111.2, 108.4, 104.5, 
100.2, 63.4, 55.8; HRMS (ESI+) calculated for C18H17O4 [M+H]+ m/z 297.1127, found 297.1128. 
 
 
3.48. Deprotection condition 1 was followed to give 3.48 (7.4 mg, 35% yield). TLC (60% 
EtOAc/hexanes): Rf = 0.22, visualized by shortwave UV; 1H-NMR (500 MHz, acetone-d6): ! 
8.75 (br s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.15 (s, 1H), 6.99 (d, J = 1.0 
Hz, 1H), 6.66 (dt, J = 17, 1.5 Hz, 1H), 6.64 (d, J = 2.0 Hz, 1H), 6.60 (dd, J = 8.5, 2.5 Hz, 1H), 
6.38 (dt, J = 16, 5.5 Hz, 1H), 4.25 – 4.24 (m, 2H), 4.04 (s, 3H), 3.99 (s, 3H), 3.84 (br s, 1H); 13C-
NMR (125 MHz, acetone-d6): ! 160.2, 159.1, 154.2, 146.0, 143.2, 134.4, 132.8, 130.9, 129.7, 
128.5, 112.3, 111.9, 108.5, 105.4, 104.8, 100.2, 63.4, 56.4, 55.9; HRMS (ESI+) calculated for 
C19H19O5 [M+H]+ m/z 327.1232, found 327.1223.  
 
 
Deprotected 3.58. Deprotection condition 1 was followed to give deprotected 3.58 (3.1 mg, 
63% yield). TLC (60% EtOAc/hexanes): Rf = 0.36, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 8.37 (dd, J = 2.5, 0.5 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 1.5 Hz, 
1H), 7.52 (d, J = 8.5 Hz, 1H), 7.50 (dd, J = 9.0, 3.0 Hz, 1H), 7.45 (dd, J = 8.5, 1.5 Hz, 1H), 7.33 
(d, J = 1 Hz, 1H), 6.72 (dt, J = 15.5, 1.5 Hz, 1H), 6.41 (dt, J = 16.0, 5.5 Hz, 1H), 4.26 (t, J = 8.0 
Hz, 2H), 3.96 (s, 3H), 3.87 (br t, J = 5.0 Hz, 1H); 13C-NMR (125 MHz, acetone-d6): ! 157.1, 
O
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156.6, 155.4, 142.4, 139.2, 133.8, 130.4, 130.2, 130.1, 124.1, 121.2, 120.9, 119.8, 111.9, 103.5, 
63.3, 56.2; HRMS (ESI+) calculated for C17H16NO3 [M+H]+ m/z 282.1130, found 282.1132. 
 
 
Deprotected 3.59. Deprotection condition 1 was followed to give deprotected 3.59 (3.9 mg, 
67% yield). TLC (60% EtOAc/hexanes): Rf = 0.27, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 8.36 (dd, J = 2.5, 0.5 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.49 (dd, J = 9.0, 
3.0 Hz, 1H), 7.30 (s, 1H), 7.25 (d, J = 1.0 Hz, 1H), 7.08 (d, J = 1.5 Hz, 1H), 6.68 (app d, J = 15.5 
Hz, 1H), 6.41 (dt, J = 16, 5.5 Hz, 1H), 4.25 (t, J = 5.5 Hz, 2H), 4.06 (s, 3H), 3.95 (s, 3H), 3.86 
(br t, J = 5.5 Hz, 1H); 13C-NMR (125 MHz, acetone-d6): ! 159.9, 156.5, 146.3, 144.6, 142.4, 
139.2, 134.8, 131.8, 130.4, 130.2, 121.2, 120.8, 112.6, 105.9, 103.8, 63.3, 56.3, 56.2; HRMS 
(ESI+) calculated for C18H18NO4 [M+H]+ m/z 312.1236, found 312.1239.  
  
 
Deprotected 3.60. Deprotection condition 1 was followed to give deprotected 3.60 (12.6 mg, 
81% yield). TLC (20% EtOAc/hexanes): Rf = 0.36, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 9.30 (br s, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 1.0 Hz, 1H), 7.47 (d, J 
= 8.5 Hz, 1H), 7.38 (dd, J = 8.5, 1.5 Hz, 1H), 7.10 (s, 1H), 7.03 (dd, J = 8.5, 2.0 Hz, 1H), 6.98 
(m, 1H), 6.52 (dd, J = 15.5, 1.5 Hz, 1H), 6.28 (dq, J = 15.5, 6.5 Hz, 1H), 1.87 (dd, J = 6.5, 1.5 
Hz, 3H); 13C-NMR (125 MHz, acetone-d6): ! 159.7, 154.2, 152.0, 147.2, 134.4, 131.9, 130.5, 
130.0, 125.0, 123.7, 121.5 (JC-F = 257 Hz), 119.1, 115.9, 115.7, 111.5, 109.3, 105.3, 18.5; HRMS 
(ESI+) calculated for C18H14O3F3 [M+H]+ m/z 335.0895, found 335.0889. 
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Deprotected 3.61. Deprotection condition 1 was followed to give deprotected 3.61 (14.3 mg, 
77% yield). TLC (20% EtOAc/hexanes): Rf = 0.27, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 9.33 (br s, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.19 (d, J = 0.5 Hz, 1H), 7.07 (s, 
1H), 7.03 (dd, J = 8.5, 2.0 Hz, 1H), 7.00 (d, J = 1.5 Hz, 1H), 6.97 (m, 1H), 6.49 (dd, J = 15.5, 1.5 
Hz, 1H), 6.28 (dq, J = 16.0, 6.5 Hz, 1H), 4.04 (s, 3H), 1.86 (dd, J = 6.5, 3.0 Hz, 3H); 13C-NMR 
(125 MHz, acetone-d6): ! 159.7, 151.7, 147.1, 146.0, 143.5, 135.4, 132.2, 131.9, 129.9, 125.0, 
121.5 (JC-F = 256 Hz), 115.9, 115.7, 111.8, 109.2, 105.8, 105.6, 56.3, 18.5; HRMS (ESI+) 
calculated for C19H16O4F3 [M+H]+ m/z 365.1001, found 365.0997. 
 
 
Deprotected 3.62. Deprotection condition 1 was followed to give deprotected 3.62 (7.1 mg, 
73% yield). TLC (40% EtOAc/hexanes): Rf = 0.21, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 9.30 (br s, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 1.5 Hz, 1H), 7.50 (d, J 
= 8.5 Hz, 1H), 7.44 (dd, J = 8.5, 2.0 Hz, 1H), 7.12 (d, J = 0.5 Hz, 1H), 7.04 (dd, J = 8.5, 2.5 Hz, 
1H), 6.98 (quint, J = 2 Hz, 1H), 6.72 (d, J = 16 Hz, 1H), 6.41 (dt, J = 16.0, 5.0 Hz, 1H), 4.26 (d, 
J = 5.0 Hz, 2H), 3.84 (br s, 1H); 13C-NMR (125 MHz, acetone-d6): ! 159.8, 154.4, 152.1, 147.2, 
133.8, 130.6, 130.1, 130.0 (2C), 124.0, 121.5 (JC-F = 256 Hz), 119.7, 115.9, 115.7, 111.6, 109.3, 
105.3, 63.3; HRMS (ESI+) calculated for C18H14O4F3 [M+H]+ m/z 351.0844, found 351.0849. 
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Deprotected 3.63. Deprotection condition 1 was followed to give deprotected 3.63 (11.4 mg, 
67% yield). TLC (40% EtOAc/hexanes): Rf = 0.13, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 9.30 (br s, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.26 (d, J = 0.5 Hz, 1H), 7.09 (s, 
1H), 7.06 (d, J = 1.0 Hz, 1H), 7.04 (dd, J = 8.5, 2.5 Hz, 1H), 6.97 (m, 1H), 6.68 (d, J = 15.5 Hz, 
1H), 6.41 (dt, J = 16.0, 5.0 Hz, 1H), 4.26 (d, J = 5.0 Hz, 2H), 4.06 (s, 3H), 3.85 (br s, 1H); 13C-
NMR (125 MHz, acetone-d6): ! 159.7, 151.8, 147.1, 146.1, 143.7, 134.8, 131.9, 130.4, 130.1, 
129.9, 121.5 (JC-F = 256 Hz), 115.9, 115.7, 112.4, 109.2, 106.0, 105.6, 63.3, 56.4; HRMS (ESI+) 
calculated for C19H16O5F3 [M+H]+ m/z 381.0950, found 381.0946. 
 
 
Deprotection Condition 2  
To a 1-mL Reacti-vial™ containing the protected tetramer library member and a PTFE-coated 
magnetic stir bar was added TBAF•3H2O (15-20 equiv) followed by DMSO under ambient 
atmosphere. The vial was sealed with a cap and stirred at 50 °C for 5 hours. The reaction was 
then cooled to room temperature, diluted with 8 mL Et2O and washed with a solution of 1:1 
saturated NH4Cl/H2O (4 mL). The aqueous layer was extracted with 4 mL Et2O. The combined 
organic layers were washed with H2O (2 " 4 mL), then with brine (4 mL). The organic phase was 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified by silica gel chromatography. 
 
 
Deprotected 3.64. Deprotection condition 2 was followed to give deprotected 3.64 (1.0 mg, 
48% yield). TLC (40% EtOAc/pentane): Rf = 0.49, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 7.77 (s, 1H), 7.53 (d, J = 1.5 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.27 (dd, J = 
O
F3CO
OH
OMe
OH
deprotected 3.63
(11.4 mg, 67% yield)
MeO
OH
Me
HO
Me
O
deprotected 3.64
(1.0 mg, 48% yield)
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8.5, 2.0 Hz, 1H), 7.18-7.17 (m, 3H), 6.82 (dd, J = 6.5, 3.0 Hz, 1H), 6.68 (s, 1H), 6.50 (dd, J = 
16.0, 1.5 Hz, 1H), 6.31 (dd, J = 15.5, 1.5 Hz, 1H), 6.24 (dq, J = 16.0, 6.5 Hz, 1H), 6.05 (dq, J = 
15.5, 7.0 Hz, 1H), 5.69 (d, J = 2.5 Hz, 1H), 5.66 (d, J = 2.5 Hz, 1H), 3.99 (s, 3H), 1.85 (dd, J = 
6.5, 1.5 Hz, 1H), 1.78 (dd, J = 6.5, 1.5 Hz, 1H); HRMS (ESI+) calculated for C29H27O4 [M+H]+ 
m/z 439.1909, found 439.1904. 
 
 
Deprotected 3.65. Deprotection condition 2 was followed to give deprotected 3.65 (1.1 mg, 
38% yield). TLC (40% EtOAc/pentane): Rf = 0.46, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 7.81 (s, 1H), 7.18-7.14 (m, 3H), 7.10 (d, J = 1.0 Hz, 1H), 6.90 (d, J = 1.0 Hz, 
1H), 6.82 (dd, J = 7.5, 1.5 Hz, 1H), 6.67 (s, 1H), 6.46 (dd, J = 16, 1.5 Hz, 1H), 6.30 (dd, J = 15.5, 
1.0 Hz, 1H), 6.24 (dq, J = 15.5, 6.5 Hz, 1H), 6.04 (dq, J = 15.5, 6.5 Hz, 1H), 5.70 (d, J = 1.5 Hz, 
1H), 5.67 (d, J = 2.0 Hz, 1H), 3.98 (s, 3H), 3.96 (s, 3H), 1.85 (dd, J = 7.0. 2.0 Hz, 3H), 1.78 (dd, 
J = 6.5, 1.5 Hz, 3H); HRMS (ESI+) calculated for C30H29O5[M+H]+ m/z 469.2015, found 
469.2014. 
 
 
Deprotected 3.66. Deprotection condition 2 was followed to give deprotected 3.66 (0.039 mg, 
14% yield). The yield of the deprotection of 3.66 was determined by 1H-NMR using an internal 
standard. 1H-NMR (500 MHz, acetone-d6): ! 7.78 (s, 1H), 7.60 (d, J = 1 Hz, 1H), 7.40 (d, J = 8 
Hz, 1H), 7.33 (dd, J = 8.5, 1.5 Hz, 1H), 7.19-7.17 (m, 3H), 6.82 (d, J = 9 Hz, 1H), 6.70-6.68 (m, 
2H), 6.37 (dt, J = 16, 5.5 Hz, 1H), 6.31 (dd, J = 15.5, 1 Hz, 1H), 6.05 (dq, J = 15.5, 6.5 Hz, 1H), 
5.69 (d, J = 2 Hz, 1H), 5.66 (d, J = 2 Hz, 1H), 4.24 (dd, J = 5, 2 Hz, 2H), 3.99 (s, 3H), 1.78 (dd, J 
MeO
OH
Me
HO
Me
O
MeO
deprotected 3.65
(1.1 mg, 38% yield)
MeO
OH
Me
HO
O
OH
deprotected 3.66
(0.038 mg, 14% yield)
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= 6.5, 1.5 Hz, 3H); HRMS (ESI+) calculated for C29H27O5 [M+H]+ m/z 455.1858, found 
455.1866. 
 
 
Deprotected 3.67. Deprotection condition 2 was followed to give deprotected 3.67 (0.3 mg, 
21% yield). TLC (40% EtOAc/pentane): Rf = 0.48, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 7.81 (s, 1H), 7.18 – 7.14 (m, 4H), 6.97 (d, J = 1.0 Hz, 1H), 6.82 (dd, J = 7.0, 
1.5 Hz, 1H), 6.67 – 6.63 (m, 2H), 6.37 (dt, J = 16, 5.5 Hz, 1H), 6.30 (dd, J = 15.5, 1.5 Hz, 1H), 
6.04 (dq, J = 16.0, 7.0 Hz, 1H), 5.69 (d, J = 2.0 Hz, 1H), 5.66 (d, J = 2.0 Hz, 1H), 4.23 (d, J = 
4.5 Hz, 2H), 3.98 (s, 3H), 3.98 (s, 3H), 1.78 (dd, J = 6.5, 2.0 Hz, 3H); HRMS (ESI+) calculated 
for C30H29O6 [M+H]+ m/z 485.1964, found 485.1952. 
 
 
Deprotection Condition 3  
To a 1-mL Reacti-vial™ containing the protected library member and a PTFE-coated magnetic 
stir bar was added CsF (25-30 equiv) and 18-crown-6 (2 equiv) followed by DMSO in a 
glovebox. The vial was sealed with a cap and stirred at 50 °C for 14 hours. The reaction was then 
cooled to room temperature, diluted with 8 mL EtOAc and washed with a solution of 1:1 
saturated NH4Cl/H2O (8 mL). The aqueous layer was extracted with 4 mL EtOAc. The combined 
organic layers were washed with H2O (2 " 4 mL), then with brine (8 mL). The organic phase was 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified by silica gel chromatography. 
 
 
MeO
OH
Me
HO
O
MeO
OH
deprotected 3.67
(0.3 mg, 21% yield)
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Ratanhine (3.37). TLC (40% EtOAc/pentane): Rf = 0.44, visualized by shortwave UV; 1H-NMR 
(500 MHz, acetone-d6): ! 7.83 (dt, J = 9.0, 2.0 H, 2H), 7.77 (s, 1H), 7.53 (s, 1H), 7.43 (dd, J = 
8.5, 2.0 Hz, 1H), 7.37 (d, J = 8.5 Hz, 1H), 7.34 (d, J = 2.5 Hz, 1H), 7.28 (d, J = 8.0, 1.0 Hz, 1H), 
7.17 (d, J = 8.5 Hz, 1H), 7.14 (s, 1H), 6.83 (dt, J = 8.5, 2.0 Hz, 2H), 6.55 (s, 1H), 6.50 (dd, J = 
15.5, 1.5 Hz, 1H), 6.44 (dd, J = 16.0, 1.5 Hz, 1H), 6.31-6.21 (m, 2H), 5.61 (d, J = 1.5 Hz, 1H), 
5.57 (d, J = 2.0 Hz, 1H), 3.96 (s, 3H), 1.87 (dd, J = 6.5, 1.5 Hz, 3H), 1.84 (dd, J = 6.5, 1.5 Hz, 
3H). HRMS (ESI+) Calculated for C36H31O6 : 559.2121, found : 559.2128. 
 
 
Deprotected 3.68. Deprotection condition 3 was followed to give deprotected 3.68 (1.1 mg, 
52% yield). TLC (40% EtOAc/pentane): Rf = 0.39, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 7.85 (app d, J = 9.0 Hz, 2H), 7.81 (s, 1H), 7.43 (dd, J = 8.5, 2.5 Hz, 1H), 
7.33 (d, J = 2.5 Hz, 1H), 7.18 (d, J = 8.5 Hz, 1H), 7.12 – 7.10 (m, 2H), 6.92 (d, J = 1.5 Hz, 1H), 
6.84 (app d, J = 9.0 Hz, 2H), 6.55 (s, 1H), 6.49 – 6.42 (m, 2H), 6.30 – 6.21 (m, 2H), 5.62 (d, J = 
2.0 Hz, 1H), 5.58 (d, J = 1.5 Hz, 1H), 3.97 (s, 3H), 3.96 (s, 3H), 1.86 (dd, J = 6.5, 1.5 Hz, 3H), 
1.83 (dd, J = 7.0, 2.0 Hz, 3H); HRMS (ESI+) calculated for C37H33O7 [M+H]+ m/z 589.2226, 
found 589.2224. 
 
 
MeO
OH
Me
O
Me
O
O
OH
protected 
ratanhine (3.37)
(4.7 mg, 36%)
MeO
OH
Me
O
Me
O
MeO
O
OH
deprotected 3.68
(1.1 mg, 52% yield)
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Deprotected 3.69. Deprotection condition 3 was followed to give deprotected 3.69 (0.15 mg, 
22% yield). TLC (60% EtOAc/pentane): Rf = 0.24, visualized by shortwave UV; 1H-NMR (500 
MHz, acetone-d6): ! 7.82 (app d, J = 8.5 Hz, 2H), 7.77 (s, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.43 (dd, 
J = 8.0, 2.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.35-7.33 (m, 2H), 7.17 (d, J = 8.5 Hz, 1H), 7.15 
(d, J = 1.0 Hz, 1H), 6.83 (app d, J = 9.0 Hz, 2H), 6.69 (app d, J = 16.0 Hz, 1H), 6.56 (s, 1H), 
6.44 (d, J = 16 Hz, 1H), 6.38 (dt, J = 16.0, 5.5 Hz, 1H), 6.27 (dq, J = 16, 6.5 Hz, 1H), 5.61 (d, J 
= 1.5 Hz, 1H), 5.58 (d, J = 2.0 Hz, 1H), 4.25-4.24 (m, 2H), 3.97 (s, 3H), 1.84 (dd, J = 6.5, 1.5 Hz, 
3H); HRMS (ESI+) calculated for C36H31O7 [M+H]+ m/z 575.2070, found 575.2070. 
 
 
3.51. Deprotection condition 3 was followed to give 3.51 (0.3 mg, 14% yield). TLC (60% 
EtOAc/pentane): Rf = 0.23, visualized by shortwave UV; 1H-NMR (500 MHz, acetone-d6): ! 
7.85 (dt, J = 8.5, 2.0 Hz, 2H), 7.81 (s, 1H), 7.43 (dd, J = 8.0, 2.0 Hz, 1H), 7.33 (d, J = 2.0 Hz, 
1H), 7.18-7.17 (m, 2H), 7.13 (s, 1H), 6.98 (s, 1H), 6.84 (dt, J = 9.0, 2.0 Hz, 2H), 6.66 (app d, J = 
16.0 Hz, 1H), 6.55 (s, 1H), 6.44 (dd, J = 16.5, 1.5 Hz, 1H), 6.37 (dt, J = 16.0, 5.5 Hz, 1H), 6.27 
(dq, J = 16.0, 6.5 Hz, 1H), 5.62 (d, J = 1.5 Hz, 1H), 5.58 (d, J = 1.5 Hz, 1H), 4.25-4.24 (m, 2H), 
3.99 (s, 3H), 3.96 (s, 3H), 1.83 (dd, J = 6.5, 1.5 Hz, 3H); HRMS (ESI+) calculated for C37H33O8 
[M+H]+ m/z 605.2175, found 605.2167. 
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VI. AUTOMATED SYNTHESIS OF PHARMACEUTICALS 
 
 
Pharmaceutical (3.74). The general procedure was followed (see EXPERIMENTAL SECTION 
III). Crude 3.74 was purified via silica gel chromatography (50% hexanes in EtOAc to 100% 
EtOAc) to afford 3.74 as a tan-orange solid (12.9 mg, 0.0318 mmol, 28% yield).  
 
TLC (EtOAc) 
Rf = 0.25, visualized by UV 
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N
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N
N
MeMe
Me
N
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N
N
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D C
K3PO4 
(1 mmol), 
2nd gen. XPhos 
palladacycle 
(5 mol%),
THF (0.011 M), 
55 °C, 16 h;
NaOH 
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THF,
H2O, 
20 min, rt
0.33 mmol
K3PO4 
(3 mmol), 
2nd gen. XPhos 
palladacycle 
(5 mol%),
THF (0.028 M), 
55 °C, 16 h;
NaOH 
(3 mmol), 
THF 
(0.1 M),
H2O
(0.33 M), 
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1H-NMR (500 MHz, CDCl3) 
! 9.31 (br s, 1H), 9.19 (s, 2H), 8.58 (d, J = 5 Hz, 1H), 8.16 (d, J = 8 Hz, 1H), 8.10 (s, 1H), 
8.05 (s, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.87-7.81 (m, 2H), 7.74 (d, J = 5.5 Hz, 1H), 7.68-
7.60 (m, 2H), 7.56 (br s, 1H), 1.44 (s, 9H). 
 
13C-NMR (125 MHz, CDCl3) 
! 171.2, 152.5, 151.6, 148.5, 143.2, 140.9, 136.9, 135.9, 135.2, 133.2, 132.7, 130.8, 128.9, 
128.6, 127.2, 126.8, 126.3, 125.6, 121.9, 120.6, 118.2, 39.0, 29.9. 
 
HRMS (ESI+) 
Calculated for C26H24N5:  406.2032  
Found:     406.2031 
 
 
BTP2 (3.78). The general procedure was followed (see EXPERIMENTAL SECTION III) with 
the following modifications: In the first cross-coupling reaction, N,N’-dicyclohexylcarbodiimide 
(DCC) was used as a coupling agent. The DCC, carboxylic acid 3.75, and amine MIDA boronate 
3.76 all began in the First Reaction Cartridge and the coupling was run at room temperature for 4 
h. In the second cross-coupling reaction, the concentration was 0.05 M with respect to 3.77, 0.33 
3.75
3.76
3.77
3.78
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mmol of pyridine, 0.25 mmol of Cu(OAc)2, and 125 mg of activated 4 Å powdered molecular 
sieves were used, the addition of the boronic acid was performed over 1 minute, and the coupling 
was run at room temperature for 48 hours in a 7-mL glass vial. 3.78 was afforded a colorless 
solid (6.7 mg, 0.0159 mmol, 9% yield).  
 
TLC (20% EtOAc in hexanes) 
Rf = 0.22, visualized by UV 
 
HPLC  
tR = 11.6 min; flow rate = 25 mL/min, gradient: 5% MeCN in H2O over 10 min followed 
by 5% ! 95% MeCN in H2O over 15 min. 
 
1H-NMR (500 MHz, acetone-d6):  
" 10.15 (br s, 1H), 8.01 (d, J = 9.0 Hz, 2H), 7.66 (d, J = 8.5 Hz, 2H), 7.52 (s, 1H), 2.92 (s, 
3H). 
 
13C-NMR (125 MHz, acetone-d6) 
" 160.8, 159.0, 144.5, 143.1 (JC-F = 39.2 Hz), 141.1, 135.2, 135.1 (JC-F = 40.1 Hz), 127.7, 
121.7, (JC-F = 268.6 Hz), 121.5, 120.1 (JC-F = 269.6 Hz), 108.3, 13.6. 
 
HRMS (ESI+) 
Calculated for C15H10N5OSF6 :  422.0510 
Found:     422.0504 
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VII. BUILDING BLOCK SYNTHESIS FOR SMALL MOLECULE TARGETS  
 
Building block 3.30 for crocacin C was synthesized according to Scheme 3-16: 
 
 
 
Scheme 3-16.4 Conditions: (a) 3-(trimethylsilyl)propiolaldehyde, Sn(OTf)2, NEt3, CH2Cl2, -78 
oC, 2 h; (b) Me4NBH(OAc)3, MeCN:AcOH 2:1, -25 oC, 16 h; (c) Me3OBF4, proton sponge, 
CH2Cl2, 23 oC, 2.5 h; (d) (NH4)2Ce(NO3)6, MeCN:H2O, 10:1, 23 oC, 1 h; (e) Dess-Martin 
periodinane, CH2Cl2, 0 oC to 23 oC, 1.5 h; (f) CHI3, CrCl2, THF, 0 oC to 23 oC, 3 h; (g) n-BuLi, 
THF, B(OMe)3, -78 oC; 1N HCl; (h) N-methyliminodiacetic acid, benzene:DMSO 10:1, 80 oC, 2 
h; (i) AgNO3, 2,6-lutidine, acetone:H2O 1:1, 0 oC, 2.5 h; (j) HSnBu3, Pd2dba3, RuPhos, CH2Cl2, 
23 oC; (k) I2, CH2Cl2, 23 oC. 
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Synthesis of Building Blocks for All-Trans Retinal 
 
Synthesis of Building block 3.27 
 
 
 
MIDA boronate building block 3.27. The following reaction was run in duplicate. In a 
glovebox, to a 40-mL vial charged with vinyl iodide 3.335 (914 mg, 3.66 mmol, 1.2 equiv.) and 
bisborylated diene 3.1r6 (1064 mg, 3.05 mmol, 1.0 equiv.) was added PdCl2(dppf)•CH2Cl2 (125 
mg, 0.153 mmol, 5 mol%), K3PO4 (3884 mg, 18.3 mmol, 6.0 equiv.), and DMSO (20 mL, 0.15 
M). The vial was sealed with a PTFE-lined cap and removed from the glovebox. The vial was 
placed in a 45 °C aluminum heat block and maintained at that temperature with stirring for 24 
hours. The reaction was cooled to 23 °C and transferred to a separatory funnel, diluting with 
EtOAc (50 mL). The organic layer was washed with brine:H2O (1:1, 2 x 50 mL) to remove 
DMSO, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude material 
was adsorbed onto Celite™ from an acetone solution and purified by silica gel chromatography 
(hexanes:EtOAc 1:1 ! EtOAc) to afford 3.27 as a pale yellow solid (1.0 g, 48%).  
 
TLC (EtOAc) 
Rf = 0.45, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 6.17 (d, J = 16.5 Hz, 1H), 6.11 (d, J = 16.5 Hz, 1H), 5.34 (s, 1H), 4.21 (d, J = 16.5 Hz, 
2H), 4.04 (d, J = 17.0 Hz, 2H), 3.03 (s, 3H), 1.98 (s, 3H), 1.98-2.01 (m, 2H), 1.67 (s, 3H), 
1.58-1.62 (m, 2H), 1.45-1.47 (m, 2H), 1.00 (s, 6H). 
 
11B-NMR (128 MHz, acetone-d6) 
" 15.8. 
Me Me
Me
I
+
PdCl2dppf DCM
K3PO4
DMSO
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MeN
O
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Me Me
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13C-NMR (125 MHz, acetone-d6) 
! 169.0, 148.7, 141.2, 138.3, 129.3, 127.1, 62.3, 47.3, 40.2, 34.7, 33.4, 29.2, 21.8, 19.8, 
15.4. 
 
HRMS (ESI+) 
Calculated for C19H29O4NB:   346.2190 
Found:      346.2192 
 
Building block 3.29 
 
Aldehyde S2. Crotyl alcohol S17 (1.08 g, 5.54 mmol, 1.0 equiv.) and activated MnO2 (14 g, 30 
equiv.) was charged in a 100-mL round-bottom flask equipped with a PTFE-coated magnetic stir 
bar and topped with a rubber septum and purged with N2. Dichloromethane (50 mL, 0.11 M) was 
added to the round-bottom flask and the resulting reaction mixture was stirred at 23 °C for 45 
minutes. After 45 minutes, the reaction mixture was filtered through a plug of silica gel and 
Celite™ and concentrated in vacuo to afford S2 as a yellow oil (500 mg, 46% yield).  
 
TLC (petroleum ether:diethyl ether 4:1) 
Rf = 0.51, stained by KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
! 9.79 (d, J = 6.5 Hz, 1H), 6.84-6.86 (m, 1H), 3.00 (s, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 185.9, 141.8, 126.1, 29.9. 
 
HRMS (ESI+)  
Calculated for C4H6OI:  196.9463 
Found:     196.9468 
Me
I O
HMe
I OH
MnO2, THF
S1 S2
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Building block 3.29. Aldehyde S2 (150 mg, 0.77 mmol, 1.0 equiv.), neopentyl glycol (797 mg, 
7.7 mmol, 10.0 equiv.), and p-toluene sulfonic acid (15 mg, 0.08 mmol, 0.1 equiv.) was charged 
in a 40-mL vial equipped with a PTFE-coated magnetic stir bar. The vial was sealed with a 
PTFE-lined cap and purged with N2. Dichloromethane (15 mL, 0.05 M) was added to the vial 
and the resulting mixture was stirred for 1 minute until homogeneous. Activated 4 Å powdered 
molecular sieves (300 mg, 2:1 weight ratio to aldehyde) were added to the vial to afford a cloudy 
white solution. The resulting reaction mixture was stirred at 40 °C for 24 hours. After 24 hours, 
the reaction mixture was filtered through a filter funnel and concentrated in vacuo. The resulting 
white solid was adsorbed onto Celite™ from an acetone solution and purified by silica gel 
chromatography (4:1 petroleum ether:ether) to afford 3.29 as a pale yellow oil (150 mg, 69%). 
 
TLC (petroleum ether:diethyl ether 4:1) 
Rf = 0.71, stained by KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
! 6.27 (d, J = 6.0 Hz, 1H), 5.02 (d, J = 6.0 Hz, 1H), 3.64 (d, J = 11.5 Hz, 2H), 3.88 (d, J 
= 11.0 Hz, 2H), 2.51 (s, 3H), 1.20 (s, 3H), 0.74 (s, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 138.0, 102.0, 97.9, 30.0, 29.1, 22.9, 21.9. 
 
HRMS (ESI+)  
Calculated for C9H16O2I:  283.0195 
Found:     283.0200 
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I O
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 197 
Synthesis of Library Building Block 3.45 
 
 
 
4-bromo-2-iodo-5-methoxyphenol (S4). A 100-mL round-bottom flask charged with 4-bromo-
3-methoxyphenol (S3) (5000 mg, 24.63 mmol, 1.0 equiv.) was sealed with a septum and purged 
with N2 and diethyl ether (25 mL, 1.0 M) was added to afford a clear solution. The flask was 
cooled to 0 °C in an ice bath for 10 minutes. Iodine monochloride (1.3 mL, 1.05 equiv.) was 
added dropwise to the reaction flask and the reaction mixture was allowed to warm to 23 °C with 
stirring over 1.5 hours. After 1.5 hours, the reaction mixture was transferred to a separatory 
funnel containing aqueous saturated Na2S2O3 (50 mL), rinsing with diethyl ether (50 mL) and the 
phases were separated. The aqueous layer was back-extracted with diethyl ether (50 mL ! 3) and 
the combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo to afford crude S4 as a yellow-brown oil (7.86 g, 97% crude yield). This oil was used for 
the next step without further purification.  
 
TLC (hexanes:diethyl ether 2:3) 
Rf = 0.32, stained by KMnO4 
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1H-NMR (500 MHz, CDCl3) 
! 7.73 (s, 1H), 6.62 (s, 1H), 5.23 (s, 1H), 3.86 (s, 3H). 
 
HRMS (EI+)  
Calculated for C7H6O2IBr:  327.85961 
Found:     327.85939 
 
 
Aryl iodide S6. Triphenylphosphine (PPh3, 5054 mg, 19.3 mmol, 1.8 equiv.) was charged in a 
100-mL Schlenk flask equipped with a PTFE-coated magnetic stir bar and back-filled with N2. 
THF (57 mL) was added and the reaction mixture was cooled to 0 °C for 10 minutes. 
Diisopropyl azodicarboxylate (DIAD, 3.8 mL, 1.8 equiv.) was added dropwise to the reaction 
flask affording a white precipitate. This heterogeneous mixture was stirred at 0 °C for 10 minutes. 
Alcohol S5 (5482 mg, 19.3 mmol, 1.8 equiv.) was added to the reaction flask and THF (4 mL) 
was added to dissolve all reagents and the resulting mixture was stirred at 0 °C for 10 minutes. 
Separately, S4 (3511 mg, 10.7 mmol, 1.0 equiv.) was charged in a 20-mL vial, back-filled with 
N2, and THF (6 mL) was added. This solution was added to the reaction flask at 0 °C and stirred 
at that temperature for 10 minutes. After 10 minutes, the reaction mixture was warmed to 23 °C 
with stirring for 16 hours. After 16 hours, the reaction mixture was transferred to a 200-mL 
round-bottom flask, rinsing with diethyl ether (20 mL), and concentrated in vacuo to afford an 
orange oil. The crude material was adsorbed onto Celite™ from an acetone solution and purified 
by SiO2 chromatography (20% DCM:hexanes " 30% DCM:hexanes) to afford S6 as a white 
solid (5.23 g, 82%).  
 
TLC (hexanes:diethyl ether 2:3) 
Rf = 0.68, stained by KMnO4 
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1H-NMR (500 MHz, CDCl3) 
! 7.81 (s, 1H), 7.65 (d, J = 7.0 Hz, 4H), 7.43 – 1.38 (m, 6H), 6.09 (s, 1H), 4.02 – 3.98 (m, 
2H), 3.68 (s, 3H), 1.86 – 1.83 (m, 2H), 1.07 (s, 9H). 
 
13C-NMR (125 MHz, CDCl3) 
 ! 157.8, 156.8, 141.2, 135.8, 133.5, 129.5, 127.9, 103.0, 98.0, 75.6, 67.6, 56.2, 27.6, 18.0,  
11.7. 
 
HRMS (ESI+) 
Calculated for C25H28O2SiBrINa:  616.9984 
Found:      616.9979 
 
 
Building block 3.45. In a glove box, to a 100-mL round-bottom flask equipped with a PTFE-
coated magnetic stir bar and containing S6 (3572 mg, 6.0 mmol, 1.0 equiv.) was added 
potassium acetate (1767 mg, 18.0 mmol, 3.0 equiv.), bis(neopentylglycolato)diboron (1355 mg, 
6.0 mmol, 1.0 equiv.) and PdCl2dppf•CH2Cl2 (147 mg, 0.18 mmol, 3 mol%). The flask was 
sealed with a septum cap and removed from the glove box. Outside the glovebox, DMSO (50 mL, 
0.12 M) was added to the reaction flask under N2 atmosphere and the reaction mixture was 
placed in an 80 °C oil bath and stirred at that temperature for 18 hours. After 18 hours, the 
reaction mixture was cooled to 23 °C and 1 M aqueous NaOH (18.0 mL, 3.0 equiv) was added 
dropwise and the resulting heterogeneous mixture was stirred vigorously for 30 minutes at 23 °C. 
The reaction mixture was transferred to a separatory funnel with EtOAc (100 mL) and water 
(100 mL). The layers were separated and the aqueous phase was extracted with water (3 x 100 
mL). Combined organic layers were dried over anhydrous MgSO4, and concentrated in vacuo to 
afford a crude sample of S7 as a brown oil. This crude boronic acid was concentrated in a 40-mL 
I-Chem vial and charged with N-methyliminodiacetic acid (MIDA) anhydride S88 (3873 mg, 30 
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mmol, 5.0 equiv.) and equipped with a PTFE-coated magnetic stir bar. The vial was flushed with 
N2 and THF (20 mL, 0.3 M) was added and the reaction mixture was placed in a 70 °C 
aluminum heat block and stirred at that temperature for 24 hours. After 24 hours, the reaction 
mixture was cooled to 23 °C and transferred to a separatory funnel with EtOAc (100 mL) 
followed by deionized water (100 mL). The phases were separated and the aqueous layer was 
extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 
mL), dried over anhydrous MgSO4, and concentrated in vacuo to afford an off-white solid. The 
crude material was adsorbed onto Celite™ from an acetone solution and purified by SiO2 
chromatography (hexanes:EtOAc 1:1 ! EtOAc) and recrystallized from DCM/hexanes to afford 
3.45 as a white solid (1.707 g, 46% over three steps).  
 
TLC (EtOAc) 
Rf = 0.66, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 7.70 (d, J = 8.0 Hz, 2H), 7.63 (s, 1H), 7.42-7.45 (m, 6H), 6.45 (s, 1H), 4.35 (d, J = 17.0 
Hz, 2H), 4.20 (d, J = 17.0 Hz, 2H), 4.11-4.14 (m, 2H), 3.72 (s, 3H), 2.84 (s, 3H), 1.91 – 
1.88 (m, 2H), 1.05 (s, 9H). 
 
13C-NMR (125 MHz, acetone-d6) 
" 169.3, 163.1, 158.5, 138.9, 136.5, 134.5, 130.3, 128.7, 98.5, 70.1, 67.2, 64.5, 56.3, 48.2,  
27.9, 21.7, 18.5, 11.8. 
 
HRMS (ESI+)  
Calculated for C30H36O6BNSiBr: 624.1588 
Found:     624.1602 
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Synthesis of Building Block 3.42 
 
 
 
Building block 3.42. To a stirred solution of triphenylphosphine (1.10 g, 4.2 mmol, 1.2 equiv) in 
THF (10 mL) at 0 °C was added dropwise diisopropylazodicarboxylate (DIAD; 830 µL, 4.2 
mmol, 1.2 equiv) to generate a yellow suspension. In one portion, 4-bromo-3-methoxyphenol 
(S9) (711 mg, 3.5 mmol, 1 equiv) and S5 (1.19 g, 4.2 mmol, 1.2 equiv) were added. The mixture 
was stirred for 15 minutes, after which the ice bath was then removed and the reaction warmed to 
ambient temperature. After stirring for 1 hour, the reaction was diluted with diethyl ether and 
adsorbed onto Celite™ in vacuo. The Celite™ pad was loaded onto a silica gel column and 
eluted with hexanes/DCM gradient (4:1 to 3:7).  Fractions containing a minor impurity were re-
adsorbed on Celite™ and eluted from a silica gel column using a hexanes/DCM gradient (4:1 to 
3:1).  Purified fractions were combined to afford 3.42 as a colorless amorphous solid (1.19g, 
72%). 
 
1H-NMR (500 MHz, acetone-d6) 
! 7.74 – 7.72 (m, 4H), 7.50 – 7.44 (m, 6H), 7.34 (d, J = 8.5 Hz, 1H), 6.43 (d, J = 2.5 Hz, 
1H), 6.27 (dd, J = 9.0, 3.0 Hz, 1H), 4.08 – 4.05 (m, 2H), 3.81 (s, 3H) 1.86 – 1.83 (m, 2H), 
1.11 (s, 9H). 
 
13C-NMR (125 MHz, acetone-d6) 
! 160.5, 157.5, 136.6, 134.7, 133.8, 130.3, 128.7, 107.7, 102.4, 101.3, 66.3, 56.4, 28.1, 
18.5, 12.5. 
 
HRMS (EI+) 
Calculated for C25H29O2SiBr:  468.11202 
Found:     468.11118 
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Synthesis of Building Block 3.44 
 
 
 
Building block 3.44. To a stirred solution of triphenylphosphine (765 mg, 3.0 mmol, 1.5 equiv) 
in THF (7.5 mL) at 0 °C was added dropwise diisopropylazodicarboxylate (DIAD; 570 µL, 3.0 
mmol, 1.5 equiv) to generate a yellow suspension. In one portion, 4-bromo-3-
(trifluoromethoxy)phenol (S10) (500 mg, 2.0 mmol, 1 equiv) and S5 (830 mg, 3.0 mmol, 1.5 
equiv) were added. The mixture was stirred for 15 minutes, after which the ice bath was then 
removed and the reaction warmed to ambient temperature. After stirring for 16 hours, the 
reaction was diluted with diethyl ether and adsorbed onto Celite™ in vacuo. The Celite™ pad 
was loaded onto a silica gel column and eluted with 4:1 hexanes/DCM.  The colorless oil from 
this column was re-adsorbed onto Celite™, loaded onto silica gel, and eluted with a 
hexanes/DCM gradient (hexanes to 9:1 hexanes/DCM) to afford 3.44 as a colorless oil (785 mg, 
77%). 
 
1H-NMR (500 MHz, acetone-d6) 
! 7.71 – 7.69 (m, 4H), 7.55 (d, J = 8.5 Hz, 1H), 7.47 – 7.41 (m, 6H), 6.82 – 6.81 (m, 1H), 
6.75 (dd, J = 8.5, 2.5 Hz, 1H), 4.11 – 4.07 (m, 2H), 1.86 – 1.83 (m, 2H), 1.08 (s, 9H). 
 
13C-NMR (125 MHz, acetone-d6) 
! 160.5, 157.5, 136.6, 134.7, 133.8, 130.3, 128.7, 107.7, 102.4, 101.3, 66.3, 56.4, 28.1, 
18.5, 12.5. 
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Synthesis of Building Block 3.47 
 
 
 
 
Methyl benzoate S13. Triphenylphosphine (PPh3, 7450 mg, 28.4 mmol, 1.8 equiv.) was charged 
in a 250-mL round-bottom flask equipped with a PTFE-coated magnetic stir bar and back-filled 
with N2. THF (70 mL) was added and the reaction mixture was cooled to 0 °C for 10 minutes. 
Diisopropyl azodicarboxylate (DIAD, 5.6 mL, 28.4 mmol, 1.8 equiv.) was added dropwise to the 
reaction flask affording a white precipitate. This heterogeneous mixture was stirred at 0 °C for 10 
minutes. TMS ethanol S12 (4.1 mL, 28.4 mmol, 1.8 equiv.) was added to the reaction flask and 
the resulting mixture was stirred at 0 °C for 10 minutes. Phenol S11 (2400 mg, 15.8 mmol, 1.0 
equiv.) was added to the flask in one portion followed by THF (10 mL) and the resulting reaction 
mixture was and stirred at 0 °C for 10 minutes. After 10 min, the reaction mixture was warmed 
to 23 °C with stirring for 16 hours. After 16 hours, the reaction mixture was concentrated in 
vacuo to afford a clear oil. This crude oil was dissolved in minimum amount of diethyl ether (5 
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mL). Hexanes (100 mL) were added and the solution was stirred at 23 °C for 5 minutes until 
white solid precipitated. The solid was filtered through a fritted filter funnel rinsing with hexanes. 
The filtrate was concentrated in vacuo to afford a clear oil, which was adsorbed onto Celite™ 
from an acetone solution and purified by SiO2 chromatography (20% DCM:hexanes ! 50% 
DCM:hexanes) to afford S13 as a clear oil (434 mg, 11%). 
 
TLC (dichloromethane:hexanes 1:1) 
Rf = 0.28, shortwave UV 
 
1H-NMR (500 MHz, CDCl3) 
" 7.97 (d, J = 9.5 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 4.13 (t, J = 7.5 Hz, 2H), 3.88 (s, 3H), 
1.15 (t, J = 8.0 Hz, 2H), 0.09 (s, 9H). 
 
13C-NMR (125 MHz, CDCl3) 
" 216.4, 172.1, 163.5, 132.3, 121.4, 114.2, 65.8, 17.6, -1.35.   
 
HRMS (ESI+) 
 Calculated for C13H20O3SiNa: 275.1079 
 Found:     275.1084 
 
Benzoic acid S14. A 40-mL vial equipped with a PTFE-coated magnetic stir bar was charged 
with LiOH.H2O (722 mg, 17.2 mmol, 10 equiv.) and deionized H2O (4 mL). The vial was placed 
in a 60 °C aluminum heating block and stirred at that temperature for 5 minutes until a clear 
solution was afforded. The vial was removed from the heating block and a solution of S13 (434 
mg, 1.72 mmol, 1.0 equiv.) in THF (9 mL, 0.2 M) was added to the reaction vial. The vial was 
sealed with a PTFE-lined cap and placed in a 60 °C aluminum heating block and stirred at that 
temperature for 14 hours. The reaction mixture was cooled to 23 °C, then to 0 °C for 10 minutes. 
6 N HCl was added dropwise to the crude reaction mixture with stirring until pH # 1. The 
reaction mixture was transferred to a separatory funnel with H2O (20 mL) and EtOAc (40 mL). 
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The phases were separated and the aqueous layer was extracted with EtOAc (40 mL x 2). The 
combined organic layers were washed with brine (50 mL), dried over anhydrous MgSO4, and 
concentrated in vacuo to afford a white solid. The crude solid was adsorbed onto Celite™ from 
an acetone solution and purified by SiO2 chromatography (1:4 EtOAc:hexanes ! 2:1:7 
EtOAc:EtOH:hexanes) to afford S14 as a white solid (361 mg, 88%).  
 
TLC (EtOAc:hexanes 1:4) 
Rf = 0.22, shortwave UV 
 
1H-NMR (500 MHz, CDCl3) 
" 8.03 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 4.15 (t, J = 7.5 Hz, 2H), 1.16 (t, J = 
8.0 Hz, 2H), 0.09 (s, 9H). 
 
13C-NMR (125 MHz, CDCl3) 
" 172.2, 163.5, 132.3, 121.4, 114.2, 65.8, 17.6, -1.35.   
 
HRMS (ESI+) 
 Calculated for C12H18O3SiNa: 261.0923 
 Found:     261.0934 
 
 
Aryl iodide S16. A 100-mL flask equipped with a PTFE-coated magnetic stir bar was charged 
with S14 (361 mg, 1.51 mmol, 1.0 equiv.) and back-filled with N2. S15 (447 mg, 1.82 mmol, 1.2 
equiv.), DMAP (222 mg, 1.82 mmol, 1.2 equiv.), and dichloromethane (20 mL, 0.08 M) were 
added to the reaction flask. The clear, colorless solution was cooled to 0 °C and stirred at that 
temperature for 10 minutes. DCC (375 mg, 1.82 mmol, 1.2 equiv.) was added in one portion at 
0 °C under N2 and stirred at that temperature for 10 minutes. The ice bath was removed after 10 
minutes and the reaction flask was allowed to warm to 23 °C with stirring over 15 hours. After 
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15 hours, the reaction mixture was concentrated in vacuo to afford a yellow sludge. The crude 
material was adsorbed onto Celite™ from an acetone solution and purified by SiO2 
chromatography (30% DCM:hexanes ! 40% DCM:hexanes) to afford S16 as a clear oil (575 
mg, 81%).  
 
TLC (30% DCM:hexanes) 
Rf = 0.21, shortwave UV 
 
1H-NMR (500 MHz, CDCl3) 
" 8.14 (d, J = 8.5 Hz, 2H), 7.92 (s, 1H), 7.61 (d, J = 8.5 Hz, 1H), 6.96 (d, J = 9.0 Hz, 
2H), 6.92 (d, J = 8.5 Hz, 1H), 6.70 (dd, J = 11.0 Hz, J = 14.5 Hz, 1H), 5.78 (s, 1H), 5.74 
(s, 1H), 5.32 (d, J = 11.0 Hz, 1H), 4.17 (t, J = 8.0 Hz, 2H), 1.18 (t, J = 7.5 Hz, 2H), 0.10 
(s, 9H). 
 
13C-NMR (125 MHz, CDCl3) 
" 164.4, 163.6, 148.2, 137.5, 135.3, 132.8, 132.4, 129.2, 124.9, 120.8, 117.5, 114.4, 90.4, 
   65.9,17.5, -1.33.   
 
HRMS (ESI+) 
 Calculated for C20H24O3SiI: 467.0540 
 Found:    467.0534 
 
 
Vinyl bromide S18. A 50-mL flask equipped with a PTFE-coated magnetic stir bar was charged 
with S16 (575 mg, 1.23 mmol, 1.0 equiv.), sealed with a septum, and back-filled with N2. 
Dichloromethane (12 mL, 0.1 M) was added to afford a clear, colorless solution. This solution 
was cooled to 0 °C and stirred at that temperature for 10 minutes. Bromine (0.14 mL, 2.71 mmol, 
2.2 equiv.) was added dropwise to the reaction mixture at 0 °C over the course of 20 minutes 
O
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until a bright red color persisted. The crude reaction mixture was concentrated in vacuo and 
azeotroped with DCM (3 x 15 mL) to afford dibromide S17 as a yellow foamy solid (721 mg, 
93% crude yield). S17 (721 mg, 1.15 mmol, 1.0 equiv.) was concentrated in a 50-mL round-
bottom flask. The flask was equipped with a PTFE-coated magnetic stir bar, sealed with a 
septum, and back-filled with N2. Acetonitrile (11.5 mL, 0.1 M) was added and the reaction 
mixture was stirred at 23 °C for 5 minutes. DBU (0.2 mL, 1.34 mmol, 1.2 equiv.) was added 
dropwise and the resulting mixture was stirred for 10 minutes. After 10 minutes, incomplete 
conversion was observed by TLC analysis, so another 0.3 mL of DBU was added dropwise. 
After 20 minutes of stirring at 23 °C, the reaction mixture was cooled to 0 °C and 1 N HCl (10 
mL) was added. The reaction mixture was transferred to a separatory funnel with EtOAc (15 mL) 
and H2O (15 mL) and the layers were separated. The phases were separated and the aqueous 
layer was extracted with EtOAc (10 mL x 2). The combined organic layers were dried over 
anhydrous MgSO4 and concentrated in vacuo to afford a clear oil. The crude material was 
adsorbed onto Celite™ from an acetone solution and purified by SiO2 chromatography (40% 
DCM:hexanes) to afford S18 as a pale yellow oil (503 mg, 75% over two steps). 
 
TLC (1:3 DCM:hexanes) 
Rf = 0.25, shortwave UV 
 
1H-NMR (500 MHz, CDCl3) 
! 8.13 (d, J = 9.0 Hz, 2H), 7.78 (s, 1H), 7.70 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 8.5 Hz, 
1H), 6.96 (d, J = 9.0 Hz, 2H), 5.91 (d, J = 1.5 Hz, 1H), 5.84 (d, J = 2.0 Hz, 1H), 4.17 (t, 
J = 8.0 Hz, 2H), 1.17 (t, J = 8.0 Hz, 2H), 0.10 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
! 164.1, 163.6, 147.8, 138.9, 138.9, 135.4, 132.5, 125.3, 123.0, 122.7, 120.7, 114.4, 89.4, 
65.9,17.5, -1.34. 
 
HRMS (ESI+) 
 Calculated for C20H24O3SiI: 467.0540 
 Found:    467.0534 
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Building block 3.47. In a glove box, to a 7-mL vial equipped with a PTFE-coated magnetic stir 
bar and containing S18 (20 mg, 0.037 mmol, 1.0 equiv.) and trans-propenyl boronic acid (S19) 
(4.73 mg, 0.055 mmol, 1.5 equiv.) was added ground potassium phosphate (23 mg, 0.11 mmol, 
3.0 equiv.) and PdCl2dppf•CH2Cl2 (1.5 mg, 0.002 mmol, 5 mol%) followed by THF (0.7 mL, 
0.05 M). The vial was sealed with a cap and removed from the glove box. The vial was placed in 
a 45 °C aluminum heating block and stirred at that temperature for 24 hours. After 24 hours, the 
reaction mixture was cooled to 23 °C, filtered through a pad of Celite™, and concentrated in 
vacuo. The crude material was adsorbed onto Celite™ from an acetone solution and purified by 
SiO2 chromatography (30% DCM;hexanes) to afford 3.47 as a pale yellow oil (13.5 mg, 80% 
yield).  
 
TLC (1:1 DCM:hexanes)  
Rf = 0.31, shortwave UV 
 
1H-NMR (500 MHz, CDCl3) 
! 8.15 (d, J = 8.5 Hz, 2H), 7.40 (s, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 8.5 Hz, 
1H), 6.96 (d, J = 9.0 Hz, 2H), 6.39 (d, J = 16.0 Hz, 1H), (dq, J = 15.5 Hz, J = 6.5 Hz, 
1H),  5.89 (d, J = 1.5 Hz, 1H), 5.82 (d, J = 1.5 Hz, 1H), 4.17 (t, J = 8.0 Hz, 2H), 1.90 (d, 
J = 7.0 Hz, 3H), 1.17 (t, J = 8.0 Hz, 2H), 0.10 (s, 9H). 
 
13C-NMR (125 MHz, CDCl3) 
! 164.6, 163.4, 146.4, 135.8, 133.2, 132.4, 129.6, 127.6, 127.2, 126.8, 124.6, 123.2,   
122.1, 121.2, 114.3, 65.9, 18.5, 17.5, -1.33.   
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HRMS (ESI+) 
 Calculated for C23H28O3SiBr:  459.0991 
 Found:     459.0987 
 
Synthesis of Building Block 3.46 
 
 
 
 
4-iodo-2-vinylphenyl benzoate (S21). A dry 25-mL Schlenk flask equipped with a PTFE-coated 
magnetic stir bar was charged with S20 (738 mg, 3 mmol) and DMAP (73.3 mg, 0.6 mmol) 
under N2. The flask was sealed with a rubber septum and CH2Cl2 (15 mL) was added via syringe. 
To this solution was added DIPEA (2.1 mL, 12.1 mmol) in one portion. Benzoyl chloride (0.7 
mL, 6.03 mmol) was then added neat dropwise over 5 minutes. The reaction was stirred for 
another 19 hours at room temperature, then transferred into a separatory funnel containing 1 N 
HCl (10 mL). After mixing and phase separation, the organic layer was washed with another 
portion of 1 N HCl (10 mL) and then with H2O (20 mL). The combined aqueous layer was 
extracted with CH2Cl2 (20 mL). The organic phase was washed with brine (20 mL), dried over 
anhydrous MgSO4, filtered and concentrated. The crude product was purified by silica gel 
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chromatography (30 - 35% CH2Cl2/hexanes) to afford S21 as a colorless viscous oil (643 mg, 
61%).  
 
TLC (50% DCM/hexanes) 
Rf = 0.44, visualized by shortwave UV. 
 
1H-NMR (500 MHz, CDCl3) 
! 8.21 (d, J = 7 Hz, 2H), 7.94 (d, J = 2 Hz, 1H), 7.66 (tt, J = 7.5, 1.5 Hz, 1H), 7.63 (dd, J 
= 8, 1.5 Hz, 1H), 7.56 (t, J = 7.5 Hz, 2H), 6.94 (d, J = 8.5 Hz, 1H), 6.71 (dd, J = 17.5, 11 
Hz, 1H), 5.77 (dd, J = 18, 1 Hz, 1H), 5.34 (d, J = 11 Hz, 1H). 
 
13C-NMR (125 MHz, CDCl3) 
! 164.6, 148.0, 137.5, 135.4, 133.9, 132.7, 130.2, 129.0, 128.9, 128.7, 124.7, 117.7, 90.6. 
 
HRMS (ESI+) 
 Calculated for C15H12O2I:  350.9882 
 Found:   350.9890 
 
 
2-(1-bromovinyl)-4-iodophenyl benzoate (S23). A solution of S21 (3.37 g, 9.62 mmol) in 
CH2Cl2 (120 mL) in a 200-mL round-bottom flask was cooled to 0 °C under N2. Bromine (0.49 
mL, 9.62 mmol) was added neat dropwise over 15 minutes. After the addition was complete, the 
reaction was stirred for a further 5 minutes. The reaction was concentrated in vacuo to give an 
orange solid (S22). Residual bromine was removed by azeotroping the residue with CH2Cl2 (15 
mL " 2). The round bottom flask containing the crude product and equipped with a PTFE-coated 
magnetic stir bar was sealed with a rubber septum and back-filled with N2 twice. MeCN (120 
mL) was added to dissolve most of the solid. DBU (1.4 mL, 9.5 mmol) was then added neat 
dropwise via syringe over 15 minutes. The reaction was stirred for 15 minutes before being 
I
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charged with another portion of DBU (0.2 mL, 1.34 mmol) added neat dropwise into the reaction. 
After another 15 minutes, another portion of DBU (0.2 mL, 1.34 mmol) was added. The reaction 
was poured slowly into 2 N HCl solution (100 mL) cooled to 0 °C with vigorous stirring. EtOAc 
(50 mL) was added and the mixture stirred. After phase separation, the aqueous layer was 
extracted with EtOAc (50 mL). The combined organic phase was washed with brine (100 mL), 
then dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by silica gel chromatography (30-35% CH2Cl2/hexanes) to afford S23 as an off-white 
solid (2.67g, 66% over 2 steps).  
 
TLC (40% CH2Cl2/hexanes) 
Rf = 0.47, visualized by shortwave UV. 
 
1H-NMR (500 MHz, CDCl3) 
! 8.20 (d, J = 7.5 Hz, 2H), 7.79 (d, J = 2 Hz, 1H), 7.72 (dd, J = 8.5, 2 Hz, 1H), 7.66 (tt, J 
= 7.5, 1H), 7.52 (tt, J = 8, 1.5 Hz, 2H), 6.99 (d, J = 8.5 Hz, 1H), 5.92 (d, J = 2 Hz, 1H), 
5.85 (d, J = 1.5 Hz, 1H). 
 
13C-NMR (125 MHz, CDCl3) 
! 164.4, 147.6, 138.9 (2C), 135.4, 133.9, 130.3, 128.8, 128.6, 125.1, 123.1, 122.5, 89.7. 
 
HRMS (ESI+) 
 Calculated for C15H10O2BrINa : 450.8807  
 Found:   450.8809 
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Building block 3.46. A dry 40-mL vial equipped with a PTFE-coated magnetic stir bar was 
charged with S23 (858 mg, 2.0 mmol) and propenyl boronic acid (223 mg, 2.6 mmol). The vial 
was brought into a glovebox and charged with K3PO4 (1.27 g, 3 equiv.), PdCl2dppf.CH2Cl2 (849 
mg, 4 mmol) and THF (20 mL, 0.1 M). The vial was sealed with a Teflon-lined cap and stirred at 
60 °C for 18 hours. The reaction was cooled to 23 °C and filtered through a pad of Celite™ and 
concentrated in vacuo. The crude product was purified by silica gel chromatography (30-40% 
CH2Cl2/hexanes) to give 3.46 as an off-white solid (268 mg, 39%).  
 
TLC (40% CH2Cl2/hexanes) 
Rf = 0.43, visualized by shortwave UV 
 
1H-NMR (500 MHz, CDCl3) 
! 8.22 (dd, J = 8.0, 1.0 Hz, 2H), 7.65 (t, J = 7.5 Hz, 1H), 7.52 (app t, J = 8.0 Hz, 2H), 
7.41 (d, J = 2.0 Hz, 1H), 7.36 (dd, J = 8.5, 2.0 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H), 6.40 
(dd, J = 16.0, 1.5 Hz, 1H), 6.26 (dq, J = 15.5, 6.5 Hz, 1H), 5.90 (d, J = 1.5 Hz, 1H), 5.83 
(d, J = 2.0 Hz, 1H), 1.90 (dd, J = 7.0, 1.5 Hz, 3H). 
 
13C-NMR (125 MHz, CDCl3) 
! 164.8, 146.2, 136.0, 133.6, 133.3, 130.3, 129.5, 129.3, 128.6, 127.6, 127.2, 127.0, 124.5, 
123.1, 122.2, 18.5. 
 
HRMS (ESI+) 
 Calculated for C18H16O2Br : 343.0334 
 Found:   343.0336 
 
Br
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VIII. BUILDING BLOCK SYNTHESIS AND MANUAL EXPERIMENTS FOR 
POLYTERPENE 3.83 AND ALKALOID 3.82 TARGETS 
 
Synthesis of Bifunctional Building Block 3.98 
 
 
 
Alkyl iodide 3.107.  To a flame-dried 250 mL round bottom flask was added triphenylphosphine 
(4.81 g, 18.35 mmol, 1.1 equiv.) and imidazole (1.71 g, 25 mmol, 1.5 equiv.). The reaction flask 
was fitted with a septum, purged with N2, and charged with MeCN (16.8 mL, 1 M) and Et2O 
(28.0 mL, 0.6 M).  After stirring at room temperature for 5 min as a clear solution, the reaction 
was cooled to 0 ºC and iodine was added portionwise (4.24 g, 16.7 mmol, 1.0 equiv.). The 
reaction mixture was allowed to stir at 0 ºC for 15 minutes as a bright yellow, clear solution. 
Meanwhile, a flame-dried 20 mL vial was charged with alcohol 3.106 (3.70 g, 16.8 mmol; 1.0 
equiv.). The vial was sealed with a PTFE-lined cap, purged with N2 and charged with Et2O (7 
mL, 2.5 M). The solution of alcohol in diethyl ether was added to the reaction flask dropwise via 
syringe. The reaction mixture was allowed to stir at 0 ºC for 15 minutes as a pale yellow solution 
at which point the reaction was warmed to room temperature and stirred for 1 h. The reaction 
was diluted with hexanes (100 mL), filtered through a short silica plug eluting with hexanes, and 
concentrated in vacuo to afford a yellow oil. The crude material was purified by SiO2 column 
chromatography on silica gel (hexanes) to afford 3.107 as a yellow oil (4.61 g, 85%). 
Characterization matched what is reported in the literature.9 
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TLC (hexanes) 
 Rf = 0.19, visualized with UV, stained with KMnO4  
 
1H-NMR (500 MHz, CDCl3)  
! 7.59 – 7.57 (m, 2H), 7.42 – 7.41 (m, 3H), 5.80 (tq, J = 6.8 Hz, J = 2.0 Hz, 1H), 3.22 (t, 
J = 7.4 Hz, 2H), 2.79 (q, J = 7.4 Hz, 2H), 1.74-1.73 (m, 3H), 0.43 (s, 6H). 
 
13C-NMR (125 MHz, CDCl3)  
! 139.1, 138.1, 137.5, 134.1, 129.0, 127.8, 32.6, 15.2, 5.1, -3.4. 
 
 
Alkyl pinacol ester 3.107. In a glovebox, to a 100 mL recovery equipped with magnetic stir bar 
and charged with alkyl ioidide 3.106 (4.61 g, 13.97 mmol, 1.0 equiv.) and triphenylphosphine 
(478 mg, 1.82 mmol, 0.13 equiv.) was added bis(pinacolato)diboron (5.32 g, 20.96 mmol, 1.5 
equiv.), lithium methoxide (1.06 g, 27.99 mmol, 2.0 equiv.), and copper(I) iodide (287 mg, 1.51 
mmol, 0.1 equiv.) The reaction flask was fitted with a septum, removed from the glovebox, and 
was charged with DMF (28 mL, 0.50 M). The resulting reaction mixture was allowed to stir at 
room temperature for 18 h, and the reaction mixture was diluted with EtOAc (50 mL), filtered 
through a short silica plug eluting with EtOAc, and concentrated in vacuo to afford a slurry in 
residual DMF. Crude mixture was transferred to a separatory funnel and washed with H2O (slow, 
dropwise, 200 mL). The aqueous layer was back-extracted with EtOAc (2 x 50 mL). Combined 
organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to afford a pale 
yellow oil. The crude material was adsorbed onto Celite from an acetone solution and purified by 
SiO2 chromatography (hexanes:EtOAc 4:1 to afford 3.107 as a yellow oil (4.13 g, 89%). 
 
TLC (4:1 hexanes:EtOAc) 
 Rf = 0.69, visualized by UV, stained with KMnO4 
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1H-NMR (500 MHz, CDCl3) 
 ! 7.51-7.49 (m, 2H), 7.36-7.32 (m, 3H), 5.83 (tq, J = 6.5 Hz, 2.0 Hz, 1H), 2.25 (q, J 
= 7.5 Hz, 2H), 1.67 (s, 3H), 1.23 (s, 12H), 0.89 (t, J = 7.5 Hz, 2H), 0.32 (s, 6H) 
 
13C-NMR (125 MHz, CDCl3) 
 ! 143.7, 139.0, 134.1, 133.0, 128.8, 127.7, 83.1, 29.8, 24.9, 23.0, 14.8, -3.3. 
 
HRMS (EI+) 
 Calculated for C19H31O2BSi:  330.2186 
 Found:    330.2186 
 
 
MIDA boronate 3.108. To a 1 L recovery flask was added pinacol ester 3.107 (7.26 g, 22.0 
mmol, 1.0 equiv.) and N-methyliminodiacetic acid (30.0 g, 204 mmol, 9.3 equiv.). The reaction 
flask was fitted with a septum, purged with N2, and charged with DMSO (220 mL, 0.1 M). The 
vial was placed in a 77 oC oil bath and maintained at that temperature with stirring for 15 h. The 
reaction mixture was diluted with EtOAc (100 mL) and transferred to a separatory funnel rinsing 
with EtOAc (50 mL). The layers were separated and the aqueous layer was extracted with EtOAc 
(3 x 75 mL). The combined organic layers were washed with H2O (slowly dropwise, 600 mL), 
dried over Na2SO4, filtered, and concentrated in vacuo to afford a yellow oil/off-white solid 
precipitate. The crude material was adsorbed onto Celite from an acetone solution and purified 
by SiO2 chromatography (hexanes:EtOAc 1:1 " EtOAc) to recover 3.107 as a yellow oil (2.62 g, 
36% recovery) and afford 3.108 as a white solid (4.29 g, 54%). 
 
TLC (EtOAc) 
 Rf = 0.26, visualized by UV, stained with KMnO4 
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1H-NMR (500 MHz, acetone-d6)  
! 7.53 – 7.51 (m, 2H), 7.37 – 7.31 (m, 3H), 5.94 (tq, J = 7.0, 1.5 Hz, 1H), 4.19 (d, J = 
16.5 Hz, 2H), 4.03 (d, J = 16.5 Hz, 2H), 3.10 (s, 3H), 2.23 – 2.17 (m, 2H), 1.17 (s, 3H), 
0.75 – 0.69 (m, 2H), 0.31 (s, 6H). 
 
13C-NMR (125 MHz, acetone-d6)  
! 168.8, 145.6, 139.4, 134.7, 132.6, 129.6, 128.5, 62.6, 46.2, 25.2, 23.9, 14.8, -3.2. 
 
HRMS (ESI+) 
 Calculated for C18H27BNO4Si:  360.1802 
 Found:     360.1802 
 
 
Building block 3.98. To a 100 mL recovery flask equipped with magnetic stir bar was added 
MIDA boronate 3.108 (1.141 g; 3.18 mmol, 1.0 equiv.), 2,6-lutidine (0.26 mL, 2.22 mmol, 0.7 
equiv.) and hexafluoroisopropanol (12.8 mL, 0.25 M). After stirring at room temperature for 5 
min as an off-white/pale yellow solution, the reaction was cooled to 0 ºC and NIS (637 mg, 4.76 
mmol, 1.5 equiv.) was added in one portion. The reaction mixture was allowed to stir at 0 ºC for 
15 minutes as a deep red, clear solution at which point the reaction was warmed to room 
temperature and stirred for 15 minutes. The reaction was quenched with saturated aqueous 
Na2S2O3 (13 mL) and transferred to a separatory funnel as a pale yellow solution rinsing with 
EtOAc (20 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (2 x 
15 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated in 
vacuo to afford an off-white solid. The crude material was adsorbed onto Celite from an acetone 
solution and purified by SiO2 chromatography (hexanes:acetone 4:1 " hexanes:acetone 3:1 " 
hexanes:acetone 2:1 " hexanes:acetone 1:1) to afford 3.98 as a off-white solid. Solid was 
dissolved in a minimal amount of DCM and layered with hexanes causing a white precipitated to 
form. Precipitate isolated by vacuum filtration (1.01 g, 91%). 
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TLC (EtOAc) 
 Rf = 0.30, visualized by UV, stained with KMnO4 
 
1H-NMR (500 MHz, acetone-d6)  
! 6.24 (tq, J = 7.5, 1.5 Hz, 1H), 4.19 (d, J = 17.0 Hz, 2H), 4.02 (d, J = 17.0 Hz, 2H), 3.10 
(s, 3H), 2.36 (s, 3H), 2.13 – 2.07 (m, 2H), 0.74 – 0.71 (m, 2H). 
 
13C-NMR (125 MHz, acetone-d6)  
 ! 168.7, 145.0, 92.7, 62.6, 46.3, 27.6, 26.1. 
 
HRMS (ESI+) 
 Calculated for C10H16BNO4I:  352.0217 
 Found:    352.0218 
 
Manual Synthesis of Polyterpene Linear Precursor 3.100 
 
 
 
MIDA boronate 3.120.  
To a flame-dried 20 mL vial equipped was added zinc dust (981 mg, 15 mmol, 1.5 equiv.) and 
iodine (127 mg, 0.5 mmol, 0.5 equiv.). The vial was sealed with a PTFE-lined cap, purged twice 
with argon, and charged with DMF (4.0 mL, 2.5 M). After stirring at room temperature for 1 min, 
homoallylic bromide 3.97 (1.63 g, 1.43 mmol, 1.0 equiv.) was added to the reaction vial via 
syringe under a positive pressure of argon. The gas inlet needle was removed, and the vial was 
placed in an 80 oC aluminum heat block and maintained at that temperature with stirring for 4 h.  
 
In a glovebox, to a flame-dried 40 mL vial charged with vinyl iodide 3.98 (351 mg, 1.0 mmol, 
1.0 equiv.) was added PdCl2(PPh3)2 (21 mg, 0.31 mmol, 0.03 equiv.), THF (18 mL, 0.05 M), 
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followed by alkyl zinc 3.97 solution in DMF (1.0 mL, 2.5 M, 2.5 equiv.). The vial was sealed 
with a PTFE-lined cap and removed from the glovebox. The vial was placed in a 45 oC 
aluminum heat block and maintained at that temperature with stirring for 14 h. After 14 h, the 
reaction mixture was cooled to RT and quenched with saturated aqueous NH4Cl (20 mL) 
affording a white precipitate. This crude mixture was transferred into a separatory funnel rinsing 
with EtOAc (30 mL) and brine (30 mL) was added. The layers were separated and the aqueous 
layer was extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with 
brine:H2O (1:1, 50 mL), dried over MgSO4, filtered, and concentrated in vacuo to afford an 
orange brown oil. The crude material was adsorbed onto Celite from an acetone solution and 
purified by SiO2 chromatography (hexanes:EtOAc 1:1 ! EtOAc) to afford 3.98 as a pale yellow 
solid (190 mg, 60%). 
 
TLC (EtOAc) 
 Rf = 0.22, visualized by UV, stained with KMnO4 
 
1H-NMR (500 MHz, CDCl3)  
" 5.16 (t, J = 6.5 Hz, 1H), 5.08 (t, J = 7.0 Hz, 1H), 4.04 (d, J = 16.5 Hz, 2H), 3.71 (d, J = 
16.5 Hz, 2H), 2.91 (s, 3H), 2.09 – 1.98 (m, 4H), 1.96 -1.93 (m, 2H), 1.66 (s, 3H), 1.59 (s, 
3H), 1.58 (s, 3H), 0.66 – 0.63 (m, 2H). 
 
13C-NMR (125 MHz, CDCl3)  
" 168.3, 134.3, 131.4, 126.9, 124.4, 62.0, 46.0, 39.8, 26.9, 25.8, 22.4, 17.8, 16.1. 
 
HRMS (ESI+) 
 Calculated for C16H27BNO4Na:  308.2033 
 Found:     308.2035 
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Boronic acid 3.121. To a 40 mL vial was added MIDA boronate 3.120 (163 mg, 0.53 mmol, 1.0 
equiv.). The vial was sealed with a PTFE-lined cap, purged with N2, charged with THF (5.3 mL, 
0.1 M), and allowed to stir at room temperature. After 2 minutes, 1M NaOH (1.6 mL, 1.59 mmol, 
3.0 equiv.) was added to the reaction vial. The reaction mixture was stirred vigorously at ambient 
temperature for 20 minutes. The reaction was quenched with pH 6 phosphate buffer (7 mL) and 
transferred to a separatory funnel rinsing with Et2O (10 mL) and the layers were separated. The 
aqueous layer was extracted with Et2O (15 mL). The combined organic layers were dried over 
Na2SO4, filtered, and concentrated in vacuo into a 20 mL vial to afford a pale yellow oil (112 mg, 
>100% crude yield). This material was used directly in the following reaction. 
 
TLC (EtOAc) 
 Rf = 0.59, stained with KMnO4 
 
1H-NMR (acetone-d6) 
! 6.50 (s, 2H), 5.17 (t, J = 6.5 Hz, 1H), 5.10 (t, J = 6.5 Hz, 1H), 2.11 - 2.04 (m, 4H), 1.96 
- 1.93 (m, 2H), 1.64 (s, 3H), 1.58 (s, 3H), 1.58 (s, 3H), 0.75 (t, J = 7.5 Hz, 2H). 
 
 
Linear precursor 3.100. In a glovebox, to a flame dried 20 mL vial charged with aryl bromide 
3.99 (36 mg, 0.17 mmol, 1.0 equiv.) and Ag2O (113 mg, 0.49 mmol, 3.0 equiv.) was added 
K2CO3 (134 mg, 0.97 mmol, 6.0 equiv.) and Pd[P(o-tol)3]2 (29 mg, 0.04 mmol, 0.25 equiv.). To 
the 20 mL vial containing boronic acid 3.121 was added THF (1.0 mL) and the boronic acid 
solution was transferred to the reaction vial rinsing with THF (2.4 mL). The vial was sealed with 
a PTFE-lined cap and removed from the glove box. The vial was placed in a 60 oC aluminum 
heat block and maintained at that temperature with stirring for 16 h. After 16 h, the reaction 
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mixture was cooled to 23 oC and diluted with Et2O (10 mL), filtered through a short silica gel 
plug eluting with Et2O, and concentrated in vacuo to afford a yellow oil. Crude material was 
purified by preparatory HPLC (50% MeCN ! 95% MeCN) to afford 3.100 as a pale yellow oil 
(28.5 mg, 60%).  
 
TLC (hexanes) 
 Rf = 0.31, visualized by UV, stained with KMnO4 
 
HPLC 
 tR = 19.89 min; flow rate = 25 mL/min, gradient of 50% ! 95% MeCN in H2O over 15 
min followed by 95% MeCN in H2O for 10 min. Detected at "= 254 nm. 
 
1H-NMR (500 MHz, CDCl3)  
# 6.38 (d, J = 2.3 Hz, 2H), 6.32 (t, J = 2.3 Hz, 1H), 5.20 (tq, J = 7.0, 1.3 Hz, 1H), 5.15 – 
5.08 (m, 1H), 3.80 (s, 6H), 2.60 (dd, J = 9.0, 6.7 Hz, 2H), 2.35 – 2.28 (m, 2H), 2.11 – 
2.04 (m, 2H), 2.00 (dd, J = 9.1, 5.9 Hz, 2H), 1.70 (d, J = 1.5 Hz, 3H), 1.63 – 1.59 (m, 6H). 
 
13C-NMR (125 MHz, CDCl3)  
# 160.8, 145.0, 135.9, 131.5, 124.4, 123.7, 106.6, 97.8, 55.4, 39.9, 36.6, 29.9, 26.9, 25.8, 
17.8, 16.2. 
 
HRMS (ESI+) 
 Calculated for C19H29O2:  289.2168 
 Found:    289.2175 
 
 
 
 
 
 
 
 
 
 221 
Synthesis of Alkaloid Building Block 3.101 
 
 
 
 
Phosphonoacetate 3.111. To a 500 mL flask was charged with potassium tert-butoxide (6.3420 
g, 56.5 mmol, 1.2 equiv.), fitted with a septum, and back-filled with nitrogen was added DMF (x 
mL). The flask was cooled to 0 °C and phosphonoacetate S26 (15.0 g, 47.2 mmol, 1.0 equiv.) 
was added dropwise over 10 min. After 40 min of stirring, methyl iodide (4.4 mL, 70.7 mmol, 
1.5 equiv.) was added dropwise over 10 minutes at 0 oC. The reaction was slowly warmed to RT 
with stirring, then heated to 45 °C and the reaction was allowed to stir at that temperature for 24 
h. After 24 h, the reaction mixture was cooled to RT, quenched with saturated NH4Cl (100 mL), 
and transferred to a separatory funnel with water (50 mL) and diethyl ether (150 mL). The layers 
were shaken and separated. The aqueous layer was extracted with diethyl ether (3 x 150 mL).  
Combined organic layers were washed with brine (200 mL), dried over MgSO4, filtered, and 
concentrated to yield a yellow oil that contained a mixture of starting material, product, and 
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bismethylated byproduct in a ratio of 0.08 : 1 : 0.28.  The crude material was dissolved in 4:1 
hexanes:ethyl acetate and purified by SiO2 chromatography to afford 3.111 as a colorless oil 
(4.16 g, 27% yield). 1H-NMR identical to literature.10 
 
 
!-"-unsaturated ester 3.112. A 300 mL round bottom flask was charged with 18-crown-6 (6.13 
g, 23 mmol, 5.0 equiv.) and the flask was sealed with rubber septa and back-filled with N2. THF 
(80 mL) was added to afford a clear, colorless solution. To a 20 mL vial containing 
phosphonoacetate # (1.54 g, 4.64 mmol, 1.0 equiv.) was added THF (10 mL). This solution was 
transferred to the reaction flask via syringe. Additional THF (10 mL) was used for quantitative 
transfer. The reaction mixture was cooled to -78 oC in an IPA/dry ice bath for 5 min, KHMDS 
(0.5M in toluene, 9.3 mL, 10 equiv.) was added dropwise to the reaction flask over 5 min, and 
the resulting off-white cloudy solution was stirred at -78 oC for 30 min. To a 20 mL vial charged 
with aldehyde 3.110 (874 mg, 4.64 mmol, 1.0 equiv.) was added THF (5 mL). After 30 min of 
stirring, this solution was added to the reaction mixture at -78 oC, and additional THF (10 mL) 
was used for quantitative transfer. The resulting reaction mixture was stirred at -78 oC for 50 min. 
After 50 min, the IPA/dry ice bath was removed, and the reaction mixture was quenched with 
saturated aqueous NH4Cl (100 mL) in which formation of a white precipitate was observed. The 
resulting biphasic mixture was transferred to a 500 mL separatory funnel, rinsing with diethyl 
ether (100 mL) for quantitative transfer. The layers were separated and the aqueous layer was 
extracted with diethyl ether (50 mL). The combined organic layers were washed with brine (100 
mL), dried over MgSO4, and concentrated in vacuo to afford a crude mixture. The crude material 
was dissolved in 10% diethyl ether in hexanes and purified by SiO2 chromatography (10% 
diethyl ether in hexanes) to afford 3.112 as a clear, colorless oil (1.03 g, 86%). 
 
TLC (10% diethyl ether in hexanes) 
Rf = 0.57, stained by KMnO4 
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1H-NMR (500 MHz, CDCl3) 
! 6.02 (t, J = 7.0 Hz, 1H), 3.72 (s, 3H), 3.67 (t, J = 6.5 Hz, 2H), 2.69 (q, J = 7.0 Hz, 2H), 
1.90 (d, J = 1.5 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H). 
  
13C-NMR (125 MHz, CDCl3) 
! 168.5, 140.0, 128.3, 62.6, 51.4, 33.3, 26.1, 20.8, 18.5, -5.16. 
 
HRMS (ESI+) 
 Calculated for C13H27O3Si: 259.1729 
 Found:    259.1731 
 
 
Allylic alcohol 3.113. A 100 mL Schlenk flask was sealed with a rubber septum and back-filled 
with N2 and THF (20 mL) was added. To a 50 mL recovery flask charged with ester 3.112 (1.03 
g, 4 mmol, 1.0 equiv.) was dissolved in THF (10 mL) and this solution was added to the reaction 
flask followed by quantitative transfer using THF (10 mL). The flask was placed in a -40 oC 
ethylene glycol/dry ice bath and stirred until the temperature stabilized to -45 oC. DIBAL-H (1.0 
M in hexanes, 12.0 mL, 3.0 equiv.) was added dropwise to the reaction flask over 10 min, and 
the resulting reaction mixture was allowed to slowly warm to -15 oC with stirring over 4 h. After 
4 h, saturated Rochelle’s salt (15 mL) was added and the reaction mixture was vigorously stirred 
for 5 min followed by addition of glycerol (2.4 mL) to afford a biphasic mixture. The crude 
mixture was transferred to a 250 mL separatory funnel. The layers were separated and to the 
aqueous layer was added ethyl acetate (20 mL) and glycerol (1.0 mL) and layers were separated. 
The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, 
filtered, and concentrated in vacuo to afford 3.113 as a cloudy oil (758.2 mg, 83%). This crude 
mixture was used in the next step without further purification. 
 
TLC (33% diethyl ether in hexanes) 
Rf = 0.34, stained by KMnO4 
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1H-NMR (500 MHz, CDCl3) 
! 5.28 (td, J = 8.0 Hz, J = 1.5 Hz, 1H), 4.04 (s, 2H), 3.61 (t, J = 6.0 Hz, 2H), 2.45 (br s, 
1H), 2.29 (q, J = 7.0 Hz, 2H), 1.80 (d, J = 1.0 Hz, 3H), 0.88 (s, 9H), 0.05 (s, 6H). 
  
13C-NMR (125 MHz, CDCl3) 
! 138.1, 124.8, 62.7, 61.6, 31.2, 26.1, 22.4, 18.6, -5.29. 
 
HRMS (ESI+) 
 Calculated for C12H27O2Si: 231.1780 
 Found:    231.1781 
 
 
Benzoate 3.70. A 50 mL Schlenk flask was charged with DMAP (45 mg, 0.37 mmol, 11 mol%), 
sealed with a rubber septum, and back-filled with N2. DCM (6 mL) was added to afford a clear, 
colorless solution. Benzoyl chloride (0.6 mL, 4.95 mmol, 1.5 equiv.) was added dropwise over 1 
min and stirred for 5 min at RT. The reaction was then cooled to 0 oC in an ice bath. To a 50 mL 
pear flask charged with alcohol 3.113 (758 mg, 3.3 mmol, 1.0 equiv.) and sealed with a rubber 
septum was added DCM (3 mL) and the flask was cooled to 0 oC under positive pressure of N2. 
Triethyl amine (0.7 mL, 4.95 mmol, 1.5 equiv.) was added dropwise to the alcohol solution 
turning the reaction pale yellow. After stirring for 5 min at 0 oC, this solution was cannulated to 
the reaction flask under positive N2 pressure over 5 min. The resulting reaction mixture was 
allowed to stir at 0 oC for 30 min, turning bright yellow over time. After 30 min, H2O (20 mL) 
was added to the reaction mixture at 0 oC. The crude mixture was transferred to a 125 mL 
separatory funnel using DCM (20 mL). The layers were separated and to the aqueous layer was 
extracted with DCM (20 mL). The combined organic layers were washed with brine (30 mL), 
dried over sodium sulfate, filtered, and concentrated in vacuo. The crude oil was dissolved in 5% 
diethyl ether in hexanes and purified by SiO2 chromatography (5% diethyl ether in hexanes) to 
afford 3.70 as a clear, colorless oil (999 mg, 90%). 
Me
OTBS
OBz
3.70
 
 
 225 
 
TLC (10% diethyl ether in hexanes) 
Rf = 0.53, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
! 8.05-8.02 (m, 2H), 7.64 (tt, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.52 (t, J = 7.5 Hz, 2H), 5.53 
(td, J = 7.5 Hz, J = 1.0 Hz, 1H), 4.88 (s, 2H), 3.68 (t, J = 6.5 Hz, 2H), 2.40 (q, J = 6.5 
Hz, 2H), 1.86 (d, J = 1.5 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 6H). 
  
13C-NMR (125 MHz, acetone-d6) 
! 166.6, 133.9, 132.7, 131.3, 130.2, 129.4, 128.0, 64.1, 63.4, 32.2, 26.3, 21.8, 18.8, -5.15. 
 
HRMS (ESI+) 
 Calculated for C19H31O3Si: 335.2042 
 Found:    335.2043 
 
 
Alcohol 3.114. A 50 mL round bottom flask charged with TBS-protected alcohol 3.70 (999 mg, 
2.99 mmol, 1.0 equiv.) was sealed with a rubber septum and back-filled with N2. 1% HCl in 
EtOH solution (30 mL, 0.1 M) was added at RT to afford a clear, colorless solution and stirred 
for 25 min. After 30 min, reaction flask was cooled to 0 oC and slowly quenched with saturated 
NaHCO3 (10 mL); white precipitate was observed. The crude mixture was transferred to a 125 
mL separatory funnel with diethyl ether (30 mL) and H2O (5 mL). The layers were separated 
with the addition of brine (10 mL). The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo to afford a pale yellow oil. The crude oil was dissolved in 20% EtOAc in 
hexanes and purified by SiO2 chromatography (20% EtOAc in hexanes " 50% EtOAc in 
hexanes) to afford 3.114 as a clear, colorless oil (638 mg, 97%). 
 
 
Me
OH
OBz
3.114
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TLC (20% EtOAc in hexanes) 
Rf = 0.14, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
! 8.04 - 8.02 (m, 2H), 7.63 (tt, J = 7.5 Hz, J = 1.5 Hz, 1H), 7.51 (tt, J = 7.5 Hz, J = 1.5 
Hz, 2H), 5.54 (t, J = 7.5 Hz, 1H), 4.88 (s, 2H), 3.62 (br t, J = 5.5 Hz, 1H), 3.60 - 3.56 (m, 
2H), 2.39 (q, J = 7.0 Hz, 2H), 1.84 (q, J = 1.0 Hz, 3H). 
  
13C-NMR (125 MHz, acetone-d6) 
! 166.7, 133.9, 132.6, 131.3, 130.2, 129.4, 128.2, 64.1, 62.3, 32.4, 21.7. 
 
HRMS (ESI+) 
 Calculated for C13H16O3Na: 243.0997 
 Found:    243.0998 
 
 
Bromide 3.115. A 100 mL Schlenk flask was charged with PPh3 (1805 mg, 6.86 mmol, 1.2 
equiv.), sealed with a rubber septum, and back-filled with N2. MeCN (10 mL) was added to 
afford a heterogeneous solution which was cooled to 0 oC in an ice bath. A 40 mL vial charged 
with alcohol 3.114 (1.26 g, 5.72 mmol, 1.0 equiv.) was back-filled with N2, and MeCN (10 mL) 
was added. This alcohol solution was transferred to the reaction flask with an additional MeCN 
(10 mL) rinse for quantitative transfer. To another 40 mL vial charged with CBr4 (2277 mg, 6.86 
mmol, 1.2 equiv.) and back-filled with N2 was added MeCN (7 mL). This CBr4 solution was 
transferred to the reaction flask with an additional MeCN (10 mL) rinse for quantitative transfer. 
The reaction mixture was stirred at 0 oC for 5 min and then was allowed to slowly warm to RT 
and stirred for 3 h. After 3 h, the crude mixture was transferred to a 200 mL round bottom flask 
with acetone (50 mL) and concentrated in vacuo to afford a heterogeneous mixture of yellow oil 
and white solid. The crude material was adsorbed onto Celite from an acetone solution and 
Me
Br
OBz
3.115
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purified by SiO2 chromatography (hexanes ! 10% EtOAc in hexanes) to afford 3.115 as a clear 
pale yellow oil (1.534 g, 95%). 
 
TLC (30% EtOAc in hexanes) 
Rf = 0.69, stained by KMnO4 
 
1H-NMR (500 MHz, acetone-d6) 
" 8.05 - 8.03 (m, 2H), 7.65-7.62 (m, 1H), 7.54-7.50 (m, 2H), 5.51 (t, J = 7.5 Hz, 1H), 
4.88 (s, 2H), 3.51 (t, J = 7.0 Hz, 2H), 2.77 (q, J = 7.0 Hz, 2H), 1.87 (s, 3H). 
  
13C-NMR (125 MHz, acetone-d6) 
" 166.6, 134.0, 133.9, 131.2, 130.2, 129.4, 127.9, 63.9, 33.6, 31.9, 21.7. 
 
HRMS (ESI+) 
 Calculated for C13H15O2BrNa : 305.0153 
 Found:      305.0157 
 
 
Building block 3.101. To a 20 mL vial was added zinc dust (531.4 mg, 8.13 mmol, 1.5 equiv.) 
and iodine (138 mg, 0.54 mmol, 0.1 equiv.). The vial was sealed with a PTFE-lined cap, purged 
twice with argon, and charged with DMF (1.4 mL). After stirring at RT for 1 min all of the dark 
purple color disappeared. In a separate 20 mL vial containing homoallylic bromide 3.115 (1.53 g, 
5.42 mmol, 1.0 equiv.) was added DMF (2.0 ml). This solution was transferred to the reaction 
via syringe. Additional DMF (2.0 mL) was used for quantitative transfer. The argon inlet was 
removed, and the vial was placed in an 80 oC aluminum heat block and allowed to stir at that 
temperature for 8 h. After 8 h, the reaction mixture containing alkyl zinc bromide S25, now 
orange in color, was cooled to RT and stored in the glove box overnight allowing the zinc dust to 
settle. 
Me
OBz
Br
CO2Et
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In a glovebox, to a 40 mL vial equipped with a magnetic stir bar charged with vinyl iodide 3.116 
(466 mg, 1.81 mmol, 1.0 equiv.) was added PdCl2(PPh3)2 (38 mg, 0.054 mmol, 0.03 equiv.), 
THF (16.4 mL, 0.083 M), and alkyl zinc S25 solution in DMF (5.4 mL, 0.1 M, 3.0 equiv.). The 
vial was sealed with a PTFE-lined cap and removed from the glovebox. The vial was placed in a 
45 oC aluminum heat block and maintained at that temperature with stirring for 6 h. After 6 h, the 
reaction mixture was cooled to ambient temperature, quenched with saturated aqueous NH4Cl 
(20 mL) causing a white precipitate to form, and transferred into a separatory funnel containing 
brine rinsing with diethyl ether (30 mL). The layers were separated and the aqueous layer was 
extracted with diethyl ether (2 x 30 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo to afford a dark brown oil. The crude material was dissolved 
in MeCN and filtered through a short pad of silica gel and Celite and purified by prepatory 
HPLC purification to afford building block 3.101 as a clear yellow oil (250 mg, 45%) in addition 
to ~85% pure material (157 mg, additional 28%). 
 
TLC (5% EtOAc in hexanes) 
Rf = 0.25, stained by KMnO4 
 
HPLC 
tR = 14.3 min; flow rate = 25 mL/min, gradient of 60% ! 95% MeCN:H2O over 10 min 
followed by 95% MeCN:H2O over 7 min. 
 
1H-NMR (500 MHz, CDCl3) 
" 8.04 (d, J = 8.0 Hz, 2H), 7.56 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.29 (d, J = 
7.0 Hz, 1H), 5.45 (t, J = 7.0 Hz, 1H), 4.84 (s, 2H), 4.24 (q, J = 7.0 Hz, 2H), 2.45-2.41 (m, 
2H), 2.39-2.34 (m, 2H), 1.85 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H). 
  
13C-NMR (125 MHz, CDCl3) 
" 166.7, 162.5, 145.0, 133.1, 131.8, 130.3, 129.7, 128.9, 128.5, 117.2, 63.5, 62.6, 32.4,  
26.0, 21.7, 14.3. 
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HRMS (ESI+) 
 Calculated for C18H21O4BrNa : 403.0521 
 Found:      403.0519 
 
Manual Synthesis of Alkaloid Linear Precursor 3.102 
 
 
Linear precursor 3.102. Boronic acid 3.121 was prepared and concentrated in a 7 mL vial. In a 
glovebox, to a flame dried 7 mL vial charged with vinyl bromide 3.101 (38.1 mg, 0.1 mmol, 1.0 
equiv.) was added Pd[P(o-tol)3]2 (17.9 mg, 0.025 mmol, 0.25 equiv.), Ag2O (57.9 mg, 0.25 mmol, 
2.5 equiv.), K2CO3 (69.1 mg, 0.5 mmol, 5.0 equiv.) and THF (1.0 mL). To this vial was added 
P(t-Bu)2Me solution in THF (14 mg/mL, 0.2 mL, 0.25 equiv.) and boronic acid 3.121 solution in 
THF (98 mg/mL, 0.5 mL, 2.5 equiv.) followed by THF (0.3 mL) rinse. The vial was sealed with 
a PTFE-lined cap and removed from the glovebox. The vial was placed in a 60 oC aluminum heat 
block and maintained at that temperature with stirring for 14 h. After 14 h, the reaction mixture 
was cooled to 23 oC and diluted with acetone, filtered through a short silica gel plug eluting with 
acetone, and concentrated in vacuo to afford a yellow oil. Crude material was first purified by 
SiO2 chromatography (hexanes ! 5% EtOAc in hexanes) to afford a clear pale yellow oil (33 
mg, 69% semi-purified yield containing P(o-tol)3 and other minor byproducts). This material was 
further purified by preparatory HPLC (60% MeCN ! 95% MeCN) to afford 3.102 as a pale 
yellow oil (6.6 mg, 15%).  
 
TLC (5% EtOAc in hexanes) 
 Rf = 0.23, visualized by UV, stained with KMnO4 
 
HPLC 
 tR = 20.2 min; flow rate = 25 mL/min, gradient of 60% ! 95% MeCN in H2O over 10 
min followed by 95% MeCN in H2O for 15 min. Detected at "= 254 nm. 
Me
Me Me
B(OH)2
Br
Me
CO2Et
OBz
+
Pd[P(o-tol)3]2
P(t-Bu)2Me
Ag2O, K2CO3
THF
3.1013.121
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Me Me
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1H-NMR (500 MHz, CDCl3)  
! 8.05 (dd, J = 8.0 Hz, J = 1.0 Hz, 2H), 7.56 (tt, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.44 (t, J = 
7.5 Hz, 2H), 6.74 (t, J = 7.5 Hz, 1H), 5.45 (t, J = 7.5, 1H), 5.14 (t, J = 7.0 Hz, 1H), 5.09 
(tt, J = 7.0 Hz, J = 1.0 Hz, 1H), 4.84 (s, 2H), 4.17 (q, J = 7.0 Hz, 2H), 2.33 – 2.25 (m, 
6H), 2.11 – 2.03 (m, 4H), 1.97 – 1.94 (m, 2H), 1.85 (s, 3H), 1.68 (s, 3H), 1.59 (s, 3H), 
1.58 (s, 3H), 1.28 (t, J = 7.0 Hz, 3H). 
 
13C-NMR (125 MHz, CDCl3)  
! 168.0, 166.7, 141.5, 136.0, 133.1, 132.9, 131.5, 131.2, 130.4, 129.7, 129.6, 128.6, 124.5, 
123.6, 63.6, 60.5, 39.9, 29.0, 27.8, 27.23, 27.17, 26.9, 25.8, 21.7, 17.8, 16.1, 14.4.  
 
HRMS (ESI+) 
 Calculated for C29H41O4:  453.3005 
 Found:    453.2999 
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IX. AUTOMATED SYNTHESIS OF LINEAR PRECURSORS   
 
 
Citreofuran linear precursor (3.85). The general procedure was followed with the following 
modifications: In the first deprotection reaction, 4 mmol of NaOH were used and the reaction 
was run for 30 minutes. In the first cross-coupling reaction, the concentration was 0.05 M with 
respect to 3.91, 1 mmol of Ag2O, 2 mmol of K2CO3, and 25 mol% of Pd[P(o-tol)3]2 were used, 
the addition of the boronic acid was performed over 1 minute, and the reaction was run at 60 °C 
for 14 h. In the second deprotection reaction, 0.3 mmol of NaOH were used. In the second cross-
coupling reaction, the concentration was 0.02 M with respect to 3.92, 0.3 mmol of K3PO4 and 10 
mol% of 2nd generation XPhos palladacycle were used, and the reaction was run for 6 hours in a 
7-mL glass vial. This automated cycle was performed 6 times to accumulate 3.85 as a slightly 
yellow residue (88.4 mg total; average of 14.7 mg, 0.020 mmol, 39% yield).   
 
HPLC  
tR = 18.5 min, flow rate = 25 mL/min, gradient: 100% MeCN over 10 min followed by 
90% MeCN in EtOAc over 15 min. 
0.33 mmol
1 mmol
Ag2O (1 mmol),
K2CO3 (2 mmol),
Pd[P(o-tol)3]2
(25 mol%),
THF (0.05 M), 
60 °C, 14 h
NaOH (4 mmol), 
THF (0.1 M),
H2O (0.33 M), 
30 min, rt
D C P
SiO2
MeOH:Et2O;
THF
K3PO4 (0.3 mmol), 
2nd gen. XPhos 
palladacycle 
(10 mol%),
THF (0.02 M), 
55 °C, 6 h
NaOH 
(0.3 mmol), 
THF,
H2O, 
20 min, rt
D C
0.05 mmol
Br O B O
O
O
O
MeN
Me
TIPSO B O
O
O
O
MeN
OBn
OBn
OTMSEO
Br
OBn
OBn
O
O
TIPSO
Me
TMSEO
3.85
3.91
3.92
O
TIPSO
Me
NMe
O O
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1H-NMR (500 MHz, acetone-d6) 
 ! 7.50-7.48 (m, 2H), 7.43-7.39 (m, 4H), 7.37-7.32 (m, 3H), 7.31-7.28 (m, 1H), 6.77 (d, J  
= 2.5 Hz, 1H), 6.68 (d, J = 2.5 Hz, 1H), 6.37 (d, J = 3.0 Hz, 1H), 6.10 (d, J = 3.0 Hz, 1H), 
5.14 (s, 2H), 5.13 (s, 2H), 4.14-4.08 (m, 3H), 3.64 (d, J = 1.5 Hz, 2H), 2.75 (t, J = 8.0 Hz, 
2H), 1.92-1.80 (m, 2H), 1.24 (d, J = 6.5 Hz, 3H), 1.09-1.08 (m, 21H), 0.98-0.95 (m, 2H), 
0.03 (s, 9H). 
 
 
Polyterpene linear precursor 3.100. The general procedure was followed with the following 
modifications: In the first cross-coupling reaction, 0.33 mL of a freshly prepared solution of 3.97 
in DMF (2.5 M) was added manually to the First Reaction Cartridge, the concentration was 0.05 
M with respect to 3.98, 3 mol% of PdCl2(PPh3)2 was used, and the reaction was run at 45 °C for 
14 hours. Furthermore, the Reaction Filtration Cartridge contained only 300 mg of Celite™ and 
after filtration, the crude reaction underwent an automated aqueous quench (6 mL saturated 
aqueous NH4Cl + 1 mL water) followed by an automated drying process before being purified. 
In the second deprotection reaction, 0.84 mmol of NaOH were used and the reaction was run for 
30 minutes. In the second cross-coupling reaction, the concentration was 0.05 M with respect to 
0.33 mmol
0.83 mmol
(2.5 M solution in DMF)
PdCl2(PPh3)2
(3 mol%),
THF:DMF (19:1)
(0.05 M), 
45 °C, 14 h
C P
SiO2
MeOH:Et2O;
THF
Ag2O (0.168 mmol),
K2CO3 (0.336 mmol),
Pd[P(o-tol)3]2
(25 mol%),
THF (0.05 M), 
60 °C, 16 h
NaOH 
(0.84 mmol), 
THF,
H2O, 
30 min, rt
D C
0.056 mmol
ZnBr
Me
Me
MeN
O
O
O
OBI
Me
OMe
OMeBr
Me
Me Me
OMe
OMe
3.97
3.99
3.100
MeN
O
O
O
OB
Me
Me
Me
3.98
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3.99, 0.168 mmol of Ag2O, 0.336 mmol of K2CO3, and 25 mol% of Pd[P(o-tol)3]2 were used, the 
addition of the boronic acid was performed over 1 minute, and the reaction was run at 60 °C in a 
7-mL glass vial. This automated cycle was performed 6 times to accumulate 3.100 as a slightly 
yellow residue (17.7 mg total; average of 3.0 mg, 0.010 mmol, 18% yield).  
 
TLC (hexanes) 
 Rf = 0.31, visualized by UV, stained with KMnO4 
 
HPLC 
 tR = 19.9 min; flow rate = 25 mL/min, gradient of 50% ! 95% MeCN in H2O over 15 
min followed by 95% MeCN in H2O for 10 min. Detected at "= 254 nm. 
 
1H-NMR (500 MHz, CDCl3)  
# 6.38 (d, J = 2.3 Hz, 2H), 6.32 (t, J = 2.3 Hz, 1H), 5.20 (tq, J = 7.0, 1.3 Hz, 1H), 5.15 – 
5.08 (m, 1H), 3.80 (s, 6H), 2.60 (dd, J = 9.0, 6.7 Hz, 2H), 2.35 – 2.28 (m, 2H), 2.11 – 
2.04 (m, 2H), 2.00 (dd, J = 9.1, 5.9 Hz, 2H), 1.70 (d, J = 1.5 Hz, 3H), 1.63 – 1.59 (m, 6H). 
 
13C-NMR (125 MHz, CDCl3)  
# 160.8, 145.0, 135.9, 131.5, 124.4, 123.7, 106.6, 97.8, 55.4, 39.9, 36.6, 29.9, 26.9, 25.8, 
17.8, 16.2. 
 
HRMS (ESI+) 
 Calculated for C19H29O2:  289.2168 
 Found:    289.2175 
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